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PREFACE 
The role of heat shock proteins (hsps) in regulating the activity of heme-regulated 
inhibitor in rabbit reticulocyte lysate of protein synthesis was studied. For these studies, 
biologically active Hsp 70 and hsp90 were purified from different tissues. These hsps 
were used for characterizing the refolding of thermally denatured luciferase. I used 
inhibitors of hsp70 and hsp90 and the classical enzyme inhibition kinetics and Western 
blot analysis to decipher the mechanism that underly refolding of thermally denatured 
luciferase. Moreover, the importance of hsp70 and hsp90 in de nova folding of 
luciferase was also studied. Finally, based on the experimental results, a general model 
for the refolding of denatured luciferase by heat shock proteins in rabbit reticulocyte 
lysate has been proposed. The research presented here greatly enriches our knowledge in 
the function of heat shock proteins and strongly supports the prevailing concept that heat 
shock proteins, working as molecular chaperones, play a fundemental role in living cells. 
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The process by which protein molecules achieve their native conformations is a 
subject of fundamental and practical importance. Recent evidence indicates that misfolding 
of proteins is the molecular basis of a growing list of human diseases (Table 1). 
Fundamental interest in the "protein folding problem" arises because we do not yet 
understand how a complex network of noncovalent interactions can specify one particular 
compact conformation for an intrinsically flexible polypeptide (Dill, 1990), how the 
polypeptide rapidly finds that compact conformation (Baldwin, 1994, Kuszewski et al., 
1994), or why such a purely noncovalent process involves large kinetic barriers (Baker & 
Agard, 1994). In vitro, many unfolded proteins fold to their native conformations 
spontaneously. This observation, first made by Anfinsen approximately three decades ago, 
suggested that all the information necessary to specify the three dimensional structure of a 
protein is contained in its linear amino acid sequence (Anfinsen, 1973). Consequently, it 
has been assumed that the de nova folding of proteins also occurs spontaneously. This 
view has changed profoundly over the past seven years. The correct folding of proteins in 
vivo is believed to be greatly enhanced by interaction with accessory proteins known as 
molecular chaperones. Molecular chaperones occur ubiquitously and many of them are 
classified as heat shock proteins (hsps), although they have essential function under normal 
growth conditions. Molecular chaperones belong to one of three highly conserved families: 
hsp90, hsp70 and hsp 60. Hsp60 is commonly referred to as chaperonins. Hsp70 and 
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Table 1. Some putative protein folding diseases (Thomas et al., 1995). 
Disease Mutant protein/protein Molecular phenotype 
involved 
Inability to fold 
Cystic fibrosis CFfR Misfolding/altered hsp70 & 
calnexin interactions 
Marfan syndrome Fibrillin Misfolding 
Amytotrophic lateral Superoxide dismutase Misfolding 
sclerosis 
Scurvy Collagen Misfolding 
Maple syrup urine disease a.-Ketoacid dehydrogenase Misassembly/misfolding 
Cancer p53 Misfolding/altered hsp70 & 
hsp90 interaction 
Osteogenesis imperfecta Type 1 procollagen pre a Misassembly/altered BiP 
expression 
Toxic folds 
Scrapie/Creutzfeldt- Prion protein Aggregation 
Jakob/familial insomnia 
Alzheimer's disease ~-Amyloid Aggregation 
Familial amyloidosis Transthyretin/lysozyme Aggregation 
Cataracts Crystallins Aggregation 
Mislocalization owing 
to misf olding 
Familial LDL receptor Improper trafficking 
hypercholesterolemia 
a.1-Antitrypsin deficiency a.1-Antitrypsin Improper trafficking 
Tay-Sachs disease ~-Hexosaminidase Improper trafficking 
Retinitis pigmentosa Rhodopsin Improper trafficking 
Leprechaunism Insulin receptor Improper trafficking 
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hsp60 are involved in the early stages of protein biogenesis. Hsp90 may be involved in 
the later stages of protein biogenesis where extensive secondary structure has already 
formed (Melnick et al., 1992, Melnick et al., 1994, Smith, 1993). 
Molecular chaperones appear to facilitate protein folding primarily by reducing the 
number of protein molecules that follow non-productive folding pathways that would lead 
to aggregation of the protein. The chaperone activity is based on the selective affinity of 
chaperones for nonnative proteins. A characteristic of nonnative proteins is the exposure of 
interior hydrophobic residues to the solvent. Chaperones protect these exposed 
hydrophobic residues from nonproductive hydrophobic inter- and intramolecular 
aggregation. Transient binding of nonnative proteins by chaperones destabilizes kinetically 
trapped intermediates that can then resume potentially productive folding pathway. As 
native proteins are not generally recognized, such cycles of binding, unfolding, and release 
favor the accumulation of folded native versus nonnative proteins. 
Previous work suggests that chaperones function as heteromeric chaperone 
machines in an ATP dependent manner. The affinity of chaperones for polypeptide 
substrates is modulated by associated proteins (cohorts) and conformational changes 
induced by the binding and hydrolysis of ATP (Georgopoulos, 1992, Hartl, 1995). 
Chaperone associated cohorts modulate chaperone function by a number of mechanisms: 
they may interact with chaperone-bound substrates directly; they may modulate the 
interactions of hsps with their protein substrates; or they may modulate the rate of ATP 
hydrolysis or nucleotide exchange. 
Disulfide isomerases and PPiases 
Two rate limiting events in the folding of polypeptides are catalyzed by two enzyme 
families: protein disulfide isomerases and peptidylprolyl cis-trans isomerases. In vitro 
protein folding is limited by the sampling and attainment of the proper configuration of 
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disulfide bonds and the cis-trans isomerisation of the polypeptide backbone around the 
peptide bond adjacent to proline residues. Both reactions in vivo are characterized by two 
enzymes families: (i) Protein disulfide isomerases catalyze the making and breaking of 
disulfide bonds. This reaction occurs in the oxidizing environment of the endoplasmic 
reticulum. (ii) Peptidylprolyl cis-trans isomerases (PPlases) catalyses the cis-trans 
isomerization of peptide bonds preceding proline residues. Cis-trans isomerization occurs 
in the cytoplasm and in most subcellular compartments (Stamnes et al., 1991). 
PPiases fall into two structurally unrelated families. These families are named after 
the clinically important immunosuppressive agents that inhibit their isomerase activity. The 
eukaryotic cyclophilins bind cyclosporin A (CsA) with high affinity, whereas the FK506-
binding proteins (FKBPs) bind the structurally distinct compounds FK506 and rapamycin. 
Both CsA and FK506 act as immunosuppressants by preventing the transcription of genes 
involved in activation of T lymphocytes, whereas rapamycin potentially inhibits the 
response of T cells to the lymphokine IL-2 (Schreiber, 1990). These immunosuppressive 
drugs do not act through inhibition of the PPiase activity of T cells as they are effective at 
concentrations far below those of the PPiase enzymes, and they inhibit distinct signalling 
pathway. 
Immunophilins that interact with the hsp90 chaperone machine, display similar 
structural organization with two functional domains: an N-terminal region with overlapping 
isomerase and ligand binding domains; and a conserved C-terminal segment that consists of 
a 3-unit tetratricopeptide repeat (TPR) domain followed by a potential site for calmodulin 
binding (Ratajczak et al., 1993). The immunophilins bind to hsp90 through their TPR 
motifs (Radanyi et al., 1994, Ratajczak & Carrello, 1996). 
TCP-l(t-complex polypeptide 1) ring complex (TRiC) 
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The Chaperonin family of chaperones (Escherichia coli GroEL, mitochondrial 
hsp60, and chloroplast rubisco binding protein) have a characteristic oligomeric structure 
consisting of two stacked heptameric rings (Hendrix, 1979, Hohn et al., 1979, Puskin et 
al., 1982). The bacterial chaperonin GroEL and the eukaryotic homologs in the 
mitochondria and chloroplast are homo-oligomeric, whereas the eukaryotic cytoplasmic 
homolog of GroEL, TRiC, is composed of eight different but homologous subunits 
(Frydman et al., 1992, Lewis et al., 1992). GroES and hsplO are the cohorts of GroEL 
and hsp60, respectively. GroES is a single seven membered ring of 10 kD subunits 
(Chandrashekar et al., 1986). The eukaryotic equivalent of GroES in the cytoplasm has 
not yet been identified. 
GroEL in conjunction with the cochaperonin GroES facilitates the folding of many 
E.coli proteins in a controlled ATP dependent fashion. GroES binds to GroEL and 
coordinates its ATPase activity (Langer et al., 1992, Todd et al., 1993). TRiC was 
analyzed as a potential chaperonin (GroEL/hsp60) equivalent of the eukaryotic cytosol. 
The main function of TRiC appears to be in chaperoning monomeric protein folding. TRiC 
binds unfolded polypeptides, thereby preventing their aggregation, and mediates ATP 
dependent renaturation of small molecular weight proteins. 
Heat shock protein 70 (hsp70) 
Hsp70 has widely different functions in eukaryotic cells, both under normal growth 
conditions and under cellular stress (Craig et al., 1994, Hendrick & Hartl, 1993). In 
cooperation with other chaperones, they stabilize preexistent proteins against aggregation 
and mediate the folding of newly translated polypeptides in the cytosol as well as within 
organelles. The hsp70 in mitochondria and endoplasmic reticulum may play an additional 
role by providing a driving force for protein translocation (Hohfeld & Hartl, 1994, Stuart 
et al., 1994). A link between the function of the hsp70 class of chaperones and cellular 
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proteolysis has also been demonstrated (Craig et al., 1994). Finally, hsp70 is suggested to 
be involved in signal transduction pathways in cooperation with hsp90 (Bohen & 
Yamamoto, 1993, Rutherford & Zuker, 1994). 
Hsp70 participates in all the above mentioned processes through its ability to 
recognize nonnative conformations of other proteins. Hsp70 binds to extended peptide 
segments of seven or eight residues with a net hydrophobic character. Extended 
hydrophobic residues are exposed by polypeptides during translation and membrane 
translocation, or following stress-induced damage (Blond-Elguindi et al., 1993, Flynn et 
al., 1991, Landry et al., 1992, Palleros et al., 1991). Peptide binding is mediated by a 
carboxyl-terminal -25kD domain of hsp70 (Freeman et al., 1995, Wang, 1993) and is 
regulated by the binding of ATP to the -44kD amino-terminal domain (Chappell et al., 
1987, Flaherty et al., 1990). Nucleotide-induced conformational changes of the conserved 
ATPase core are transmitted to the carboxyl-terminal region, modulating its intrinsic peptide 
affinity. The ATP-bound form of hsp70 binds and releases peptide rapidly, whereas the 
ADP-bound form binds and releases slowly (Palleros et al., 1991, Schmid et al., 1994, 
Szabo et al., 1994). Cycling of hsp70 between these nucleotide states depends on its 
interaction with its cohorts such as DnaJ and GrpE of E.coli. GrpE functions as a 
nucleotide exchange factor (Liberek et al., 1991, Szabo et al., 1994), allowing rebinding of 
ATP that in turn promotes substrate dissociation (Palleros et al., 1991, Szabo et al., 1994). 
Another cytosolic cohort of hsc70 called hsc70-interacting protein Hip (also known as 
p48), has been identified in the eukaryotes (Hohfeld et al., 1995). Hip is not a GrpE 
homolog, but stabilizes the ADP state of hsc70 that has a high affinity for substrate. 
DnaJ (hsp40) 
DnaJ activates the ATPase of the bacterial hsp70 homolog DnaK (Langer et al., 
1992, Liberek et al., 1991). Hsp40, an eukaryotic DnaJ homolog have been identified in 
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all compartments of eukaryotic cells that contain hsp70 (Cyr et al., 1994). All DnaJ-like 
proteins contain an N-terminal J-domain, which is proposed to mediate interactions with 
hsp70 that regulate ATPase activity. The C-terminal domain of DnaJ is proposed to 
mediate interactions with polypeptides, but is much less conserved. 
DnaJ-dependent activation of DnaK depends on ATP hydrolysis and the 
conformation of the protein substrates. Unlike hsp70, which recognizes short stretches of 
amino acids that assume an extended conformation, DnaJ prefers protein substrates 
exhibiting secondary andtertiary conformation (Wawrzynow et al., 1995, Wawrzynow & 
Zylicz, 1995). The ability of DnaJ to stimulate DnaK's substrate binding properties 
correlates with DnaJ's affinity for the various protein substrates. Specifically, DnaJ will 
activate DnaK to associate to a substrate for which DnaJ itself has a very low affinity, albeit 
to a lesser extent than for substrates to which DnaJ has a high affinity (Wawrzynow et al., 
1995). However, YDJ-1, the yeast homolog of DnaJ, stimulates the ATP-dependent 
dissociation of complexes between SSAl (the yeast homolog of DnaK) and CMLA, a 
protein for which YDJ-1 has a low binding affinity (Cyr et al., 1994). In contrast, YDJ-1 
was observed to stabilize complexes between SSAl and the substrates for which YDJ-1 
has high affinity (Cyr et al., 1994). This screening by DnaJ for the conformation of 
polypeptides that bind to hsp70 is suggested to be the basis for the ability of DnaJ to 
facilitate both the dissociation and the stablilization of complexes between hsp70 and 
polypeptides. 
P60 is suggested to be the eukaryotic homolog of GrpE. P60 promotes the 
recycling of hsp70 by increasing the rate of dissociation of hsp70-ADP in the presence of 
ATP (Gross & Hessefort, 1996, Gross et al., 1996). P60 plays an important role at an 
intermediate stage of PR assembly (Smith et al., 1995). It binds to the progesterone 
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receptor in conjunction with hsp70 (Smith et al., 1993b). P60 is thought to pass the 
protein substrate from the hsp70 chaperone complex to the hsp90-immunophilin chaperone 
complex (Chen et al., 1996). 
P60 contains six to eight TPR domains (Honore et al., 1992). The N-terminal 
region is necessary for hsp70 binding and a central region containing TPR motifs is 
necessary for binding to both hsp90 and hsp70 (Chen et al., 1996). P60 can bind either 
hsp70 or hsp90 independently and in an ATP independent manner. 
Heat shock protein 90 (hsp90) 
Several lines of evidence indicate that the 90-kDa heat shock proteins (hsp90) 
facilitate the folding of "substrate" proteins. Hsp90 is essential for cell viability, and is 
expressed both constitutively and during cell stress [reviewed in (Craig et al., 1994, 
Gething & Sambrook, 1992, Jacob & Buchner, 1994)]. Hsp90 prevents the aggregation 
of proteins in vitro (Jacob et al., 1995, Miyata & Yahara, 1992, Wiech et al., 1992) and 
stimulates the recovery of activity from denatured or improperly folded proteins (Jacob et 
al., 1995, Miyata & Yahara, 1992, Schumacher et al., 1994, Shaknovich et al., 1992, 
Shue & Kohtz, 1994, Wiech et al., 1992). The activities or conformations of hsp90-bound 
substrate proteins change upon dissociation from cytoplasmic hsp90 (Bresnick et al., 1989, 
Brugge et al., 1983, Courtneidge & Bishop, 1982, Hartson & Matts, 1994, Kost et al., 
1989, Sanchez et al., 1985, Ziemiecki, 1986). Also consistent with a role for hsp90 in 
protein folding, genetic evidence indicates that hsp90 supplies an essential positive function 
for certain signal transduction proteins (Aligue et al., 1994, Carver et al., 1994, Cutforth & 
Rubin, 1994, Picard et al., 1990, Xu & Lindquist, 1993). Recently it has been shown 
that hsp90 is required for the initial de nova folding and the reiterative support of p56lck 
structure in rabbit reticulocyte lysate (Hartson et al., 1996, Hartson & Matts, 1994). 
However, hsp90 does not appear to play a generic role in folding of all nascent 
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polypeptides (Frydman et al., 1994), but rather appears to act on specific target proteins 
(Xu & Lindquist, 1993). Thus, hsp90 may function as a "signal transduction chaperone", 
participating in the folding of certain proteins in concert with regulatory stimuli [reviewed 
in (Bohen et al., 1995, Craig et al., 1994, Rutherford & Zuker, 1994)]. In addition to the 
role of hsp90 in folding, hsp90 is speculated to be involved in protein targeting (Brugge, 
1986, Owens-Grillo et al., 1996, Pratt, 1992). 
Hsp90 functions as a chaperone machine with a number of noncovalently 
associated cohorts-hsc70, p60, p48, p23 and an assortment of immunophilins (Hutchinson 
et al., 1994b, Hutchinson et al., 1995, Jackson et al., 1983, Jacob & Buchner, 1994, 
Schumacher et al., 1994, Smith et al., 1993a, Smith et al., 1990a, Smith et al., 1992, 
Smith et al., 1995). Hsp90 interacts with a variety of proteins such as steroid receptors 
(Bohen & Yamamoto, 1993, Joab et al., 1984, Picard et al., 1990), the aryl hydrocarbon 
receptor (Carver et al., 1994), serine/threonine protein kinases (Matts et al., 1992, Miyata 
& Yahara, 1992), cytoskeletal proteins (Koyasu et al., 1986, Minami et al., 1993).and the 
v-src (Xu & Lindquist, 1993), Wee-1 (Aligue et al., 1994) and sevenless receptor 
(Cutforth & Rubin, 1994) tyrosine kinases. 
Much of what is known about the hsp90 chaperone machine comes from studies 
examining the factors required to reconstitute the hormone binding activity of salt-stripped 
glucocorticoid and progesterone steroid hormone receptors (SHR) in rabbit reticulocyte 
lysate (RRL) (Hutchinson et al., 1994a, Hutchinson et al., 1994b, Hutchinson et al., 
1995, Johnson & Toft, 1995, Smith et al., 1992, Smith et al., 1993b, Smith et al., 1995, 
Smith et al., 1990b). ATP-dependent binding of hsc70 to SHR is required for the 
subsequent interaction of hsp90 and its associated cohorts with SHR (Hutchinson et al., 
1994b, Smith et al., 1993a). Hsp90, hsc70, p60 and p48 are present in chaperone 
complexes at intermediate times during SHR reconstitution, while hsp90, p23 and 
individual immunophilins are present in later complexes formed just prior to or at the point 
of SHR reconstitution (Johnson et al., 1994, Johnson & Toft, 1995, Smith et al., 1993b, 
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Smith et al., 1995). The SHR in this mature complex is competent to bind hormone and is 
maintained in this state via reiterative, ATP-dependent interactions with the RRL chaperone 
machinery. 
Originally it was thought that hsp90 played a passive role in keeping steroid 
receptor inactive. In the inactive form, the steroid receptors are associated with large (9S-
10S) particles composed in part of chaperones and PPiases. Upon activation, the steroid 
receptors dissociate from hsp90 and become competent to bind DNA. The tight relation 
between receptor activity and dissociation from hsp90 led to the initial interpretation that the 
function of hsp90 is purely inhibitory, playing a passive role in keeping receptor inactive. 
However, using the yeast genetic system it was established that an hsp90-dependent 
function is essential for the function of steroid hormone receptors in vivo (Bohen & 
Yamamoto, 1994, Picard et al., 1990). 
Protein 23 (p23) 
The specific function of the hsp90 cohort p23 is unknown. p23 binds to hsp90 in 
an ATP-dependent manner, but this binding does not require ATP hydrolysis (Johnson et 
al., 1994, Johnson & Toft, 1994). Besides hsp90, p23 containing complexes are found to 
have three different immunophilins - cyclophilin40, FKBP52, and FKBP54, in rabbit 
reticulocyte lysate. It is proposed that the p23 complex seen is a collection of different 
complexes, each with hsp90, p23, and one type of immunophilin. 
p23 is present in progesterone receptor (PR) complexes under specific conditions 
and absent under others. Depletion of p23 from lysate prevents the assembly of PR 
complexes, in which the PR is competent to bind hormone. Addition of purified p23 
restores the hormone binding activity, indicating that PR chaperone complexes containing 
p23 are an essential precursor to the formation of active PR (Hutchinson et al., 1995, 
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Johnson & Toft, 1994). ATP hydrolysis is required for the association of p23 with 
PR/hsp90 chaperone machine complexes (Johnson & Toft, 1994). 
Role of chaperones in regulating protein synthesis 
In this dissertation, RRL is used as the model system because of its unique 
capabilities for in vitro protein synthesis. Moreover RRL is a rich source of molecular 
chaperones that are involved in regulating protein synthesis, folding, and renaturation. In 
RRL, protein synthesis is regulated at the initiation level by heme. Ninety percent of the 
protein produced in RRL is hemoglobin. Without heme, newly synthesized globin is 
converted to apohemoglobin, which readily denatures. In heme deficiency, protein 
synthesis in RRL is inhibited at the initiation level due to activation of the heme regulated 
inhibitor (HRI). HRI on activation, phosphorylates the 38kDa a-subunit of eIF-2. 
Phosphporylation of eIF-2 sequesters the factor responsible for eIF2 recycling (eIF-2B). 
eIF-2B is required for catalyzing the exchange of GDP for GTP bound to eIF-2, and hence 
for the formation of the [eIF-2•GTP•met-tRNAi] ternary complex. Thus phosphorylation 
of eIF-2 leads to inhibition of protein synthesis at the initiation level. The physiological 
role of the phosphorylation of eIF-2 in reticulocytes is to coordinate the synthesis of globin 
with the availability of heme. 
In addition to heme deficiency HRI is activated under oxidative stress, heat stress 
and heavy metal ion treatment in heroin supplemented lysates. HRI has been demonstrated 
to interact with the hsps and hsp cohorts, hsp90, hsc70, FKBP52 and p23in situ in RRL 
(Matts & Hurst, 1989, Matts et al., 1992, Xu et al., In preparation). Correlative data 
suggest that hsps regulate the activation of HRI; HRI is less sensitive to activation by heat 
and oxidative stress in lysates containing high levels of hsc70. The notion that the binding 
of hsp70 to HRI inhibits its activation is supported by the observation that denatured 
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proteins bind to hsp70, block the interaction of hsp70 with HRI, activate HRI and inhibit 
protein synthesis (Matts et al., 1993). 
The ability of RRL to renature protein appears to be regulated by the amount of 
hsc70 present. The rate of luciferase renaturation in the reticulocyte lysate is proportional 
to the amount of hsp70 present (Schumacher et al., 1994). Heat shock, which is suggested 
to lower the amount of active pool of hsp70, inhibited the rate of luciferase renaturation. 
From these observations, we propose that activation of HRI is regulated by a competition 
for hsp70 between HRI and nascent or denatured proteins (Matts et al., 1993). 
Physiological conditions that lead to the accumulation of denatured or unfolded nascent 
polypeptides would lead to the activation of HRI and the cessation of protein synthesis. 
Such a mechanism would coordinate the rate of protein synthesis with the ability of the cell 
to properly fold nascent polypeptides or to renature damaged proteins. This dissertation 
addresses the relationship of hsp function between protein folding, protein renaturation and 
regulation of protein synthesis. This is accomplished by using different pharmacological 
drugs directed against hsps. 
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CHAPTER II 
ROLE OF HSP90 IN LUCIFERASE RENATURATION 
Introduction 
Protein folding and renaturation in vivo are facilitated by a group of proteins 
referred to heat shock proteins (hsp) or molecular chaperones [reviewed in (Becker & 
Craig, 1994, Craig et al., 1994, Georgopoulos, 1992, Gething & Sambrook, 1992, Hartl, 
1995). Molecular chaperones appear to function in complexes referred to as chaperone 
machines (Georgopoulos, 1992) Chaperones primarily interact with hydrophobic regions 
of newly synthesized or denatured protein substrates to prevent illicit interactions between 
the bound protein and other cellular components. The affinity of chaperones for 
polypeptide substrates is modulated by associated proteins (cohorts) and conformational 
changes induced by the binding and hydrolysis of ATP (Becker & Craig, 1994, 
Georgopoulos, 1992, Hartl, 1995). Chaperone-associated cohorts modulate chaperone 
function by a number of mechanisms: they may interact with chaperone-bound substrates 
directly; they may modulate the interactions of hsps with their protein substrates; or they 
may modulate the rate of ATP hydrolysis or nucleotide exchange. Chaperones appear to 
facilitate protein folding primarily by reducing the number of molecules that follow non-
productive folding pathways that would lead to aggregation of the protein. 
Hsp90 is an extremely abundant constitutively expressed heat shock protein 
[reviewed in (Jacob & Buchner, 1994)]. Genetic (Bohen & Yamamoto, 1993, Picard et 
al., 1990, Xu & Lindquist, 1993) and biochemical (Jacob et al., 1995, Pratt & Welsh, 
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1994b, Schumacher et al., 1994, Wiech et al., 1993, Wiech et al., 1992) studies indicate 
that members of the hsp90-gene family are involved in protein folding and renaturation 
under normal and adverse physiological conditions. Little is known, however, about the 
mechanism of action of hsp90 in the folding and renaturation of proteins, but it appears to 
act at later stages in protein folding pathways where extensive secondary structure has 
already formed (Melnick et al., 1992, Melnick et al., 1994, Shue & Kohtz, 1994, Smith, 
1993). Hsp90 functions as chaperone machine with a number of noncovalently associated 
cohorts [hsc70, p60; p48; p23; and an assortment of immunophilins (Chang & Lindquist, 
1994, Hutchinson et al., 1994a, Hutchinson et al., 1994b, Hutchinson et al., 1995, Jacob 
& Buchner, 1994, Johnson & Toft, 1995, Schumacher et al., 1994, Smith et al., 1992, 
Smith et al., 1993b, Smith et al., 1995, Smith et al., 1990b)]. Much of what is known 
about the hsp90 chaperone machine comes from studies examining the factors required to 
reconstitute the hormone binding activity.of salt-stripped glucocorticoid and progesterone 
hormone steroid hormone receptors (SHR) in rabbit reticulocyte lysate (RRL) (Hutchinson 
et al., 1994a, Hutchinson et al., 1994b, Hutchinson et al., 1995, Johnson & Toft, 1995, 
Smith, 1993, Smith et al., 1992, Smith et al., 1995, Smith et al., 1990b). ATP-dependent 
binding of hsc70 to SHR is required for the subsequent interaction of hsp90 and its 
associated cohorts with SHR (Hutchinson et al., 1994b, Smith et al., 1992). Hsp90, 
hsc70, p60 and p48 are present in chaperone complexes at intermediate times during SHR 
reconstitution, while hsp90, p23 and individual immunophilins are present in later 
complexes formed just prior to or at the point of SHR reconstitution (Johnson & Toft, 
1994, Johnson & Toft, 1995, Smith, 1993, Smith et al., 1995). These studies indicate that 
these complexes represent dynamic, reiterative, ATP-dependent cycles of association of the 
SHRs with the hsp90 chaperone machine that maintain these SHRs in a conformation 
competent to bind hormone. 
Benzoquinonoid ansamycins are antibiotics of fungal origin that revert cell 
transformation mediated by p6ov-src and several other tyrosine kinases (Uehara et al., 
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1986, Uehara et al., 1988). Benzoquinonoid ansamycins such as geldanamycin (GA) and 
herbimycin A (HbA) were traditionally thought to be direct inhibitors of tyrosine kinases 
(Uehara et al., 1989). However, recent work suggests that benzoquinonoid ansamycins 
inhibit the tyrosine kinase activity of p6ov-src through an indirect mechanism (Whitesell et 
al., 1994). In extracts of cells transformed by p6ov-src, hsp90 was the predominant 
protein bound by immobilized GA (Whitesell et al., 1994). Binding of hsp90 to 
immobilized GA was specifically blocked by soluble HbA and soluble GA. Immobilized 
GA did not bind p6ov-src. GA treatment disrupted the interaction of hsp90 with p6ov-src 
in vivo, concomitant with reversion of p6ov-src transformation. Since genetic studies 
have previously demonstrated that hsp90 function is required for maturation or support of 
p6ov-src function (Xu & Lindquist, 1993), these results strongly argue that the mechanism 
of GA and HbA action involves the disruption of hsp90 function. Consistent with this 
putative mechanism, GA induces loss of function for the erb-B2 gene product (Chavany et 
al., 1996), the progesterone receptor (Johnson & Toft, 1995, Smith et al., 1995), the 
glucocorticoid receptor (Whitesell et al., 1995), and the raf kinase (Schulte et al., 1995) 
and disrupts the normal interaction of these proteins with hsp90 or with the hsp90 homolog 
GRP94. Two studies address the mechanism of GA inhibition of hsp90 chaperone 
machinery (Johnson & Toft, 1995, Smith et al., 1995). These studies indicate that GA 
decreases the recovery of progesterone receptors in complexes with hsp90 that containing 
the p23 and immunophilin cohorts. Instead, receptor accumulates in complexes containing 
hsp90, hsp70, and two hsp cohorts, p60 and p48. 
To characterize further the mechanism of action of BAs, we have examined the 
effects of GA on the steady-state kinetics of the renaturation of denatured luciferase in 
RRL. Previously, we have demonstrated that chaperone-mediated renaturation of thermally 
denatured firefly luciferase requires hsp90, hsc70, and other as yet unidentified 
components present in RRL (Schumacher et al., 1994). The RRL model system was 
selected for these studies because luciferase renaturation mediated by mixing partially 
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purified preparations of hsc70 and hsp90 was previously observed to be noncatalytic, 
requiring the addition of a large excess of the chaperone components relative to amount of 
luciferase present (Schumacher et al., 1994). In this report, we demonstrate that luciferase 
renaturation in RRL obeyed Michaelis-Menten kinetics. The Eadie-Hofstee plot of the rates 
of luciferase renaturation determined while varying both ATP and luciferase concentrations 
was a series of nearly parallel lines that is characteristic of sequential reaction mechanisms. 
Kinetic analysis of inhibition of luciferase renaturation by GA reveals the probable 
mechanism and targets of GA. Our findings also support the notion that BAs are specific 
inhibitors of hsp90, and indicate that the hsp90 chaperone machinery associated with 
denatured luciferase is identical to that described above for the progesterone receptor. 
Similarly, these associations are modulated by GA in a fashion identical to that described 
for the progesterone receptor. These results imply that the action of hsp90 on well 
documented hsp90-bound proteins is related to that occurring during protein renaturation, 
i.e., chaperoning of protein folding. 
Experimental procedures 
Materials 
Bovine Creatine phosphokinase (Type I), serum albumin (acetylated), herbimycin 
A, firefly luciferase and luciferin were purchased from Sigma. Geldanamycin was provided 
by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, 
Division of Cancer Treatment, National Cancer Institute. Geldampicin was provided by 
Dr. Kenneth L. Rinehart (U. of Illinois, Urbana). The F5 anti-p60 and the JJ3 anti-p23 
monoclonal antibodies were provided by Dr. David Smith (U. of Nebraska, Omaha) and 
Dr. David Toft (Mayo Medical School, Rochester, MN), respectively. The 4322 anti-
hsp70/90 and anti-hsp90 (84/86) antiserum was provided by Dr. Stephen Ullrich (NCI) 
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and the anti-hsp40 antiserum was provided by Dr. William Welch (UCSF). Anti-luciferase 
affinity purified polyclonal antibodies was purchased from Promega. 
Buffers and reagents 
The buffers used were as follows: assay buffer (AB) consisting of 25 mM Tricine-
HCl (pH 7.8), 8 mM MgS04, 0.1 mM EDTA, 33 mM dithiothreitol, 470 µM D-luciferin, 
240 µM coenzyme A, and 0.5 mM ATP; stability buffer (SB) consisting of 25 mM 
Tricine-HCl (pH 7.8), 8 mM MgS04, 0.1 mM EDTA, 10 mg/ml bovine serum albumin, 
10% glycerol, and 1 % Triton X-100; dialysis buffer (DB) consisting of 10 mM Tris-HCl 
(pH 7.4), 3 mM Mg(OAc)2, 100 mM KCl, and 2 mM dithiothreitol; tris buffer (TB) 
consisting of 10 mM Tris-HCl (pH 7.4); tris buffered saline (TBS) consisting of TB and 
150 mM NaCl; TB/500 consisting TB and 500 mM NaCl; and TB/50 consisting of TB and 
50mMKCl. 
Luciferase renaturation assay 
Reticulocyte lysate was prepared as described (Matts et al., 1991). Dialyzed RRL 
was prepared by dialysis of 2.5 ml of RRL against 500 ml of DB buffer for six h at 4 °C 
with buffer changes every 1.5 h. The endogenous ATP concentration in undialyzed lysate 
and the ATP and ADP concentrations remaining in the dialyzed lysate were analyzed as 
described (BioOrbit, 1991). 
Firefly luciferase (2 mg/ml) in SB was denatured by incubation at 41 ° C for 10 min 
(Schumacher et al., 1994) unless otherwise specified. After being cooled on ice, aliquots 
were diluted 20-fold into heme-deficient protein synthesis mixes (Matts et al., 1991) 
containing 10 µM edeine or dialyzed reticulocyte lysate containing 10 mM creatine 
phosphate, 20 U/ml creatine phosphokinase and varying concentrations of ATP. Samples 
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were incubated at 28 °C and at various time points (usually 10 min) the luciferase activity 
prese:p.t in 2 µl aliquots (unless otherwise stated) was determined by dilution into 50 µl AB. 
Light production was measured for 10 sin a Lumac (3M) Bioluminometer (model 2010A). 
The rate of luciferase renaturation was determined to be linear over the time period for all 
assays and the rate of luciferase renaturation is expressed in the figures and table as light 
producing units renatured per 10 min interval (light units/10 min). For the kinetic analysis, 
less than 1 % of the denatured luciferase was renatured over the time course of the assay, so 
the concentration of denatured luciferase effectively remained constant. Curve fitting was 
done with the nonlinear least squares program STEPT (Chandler, 1988) using weighting 
factors equal to the reciprocal of the variances of each data point. As described previously 
(Schumacher et al., 1994), (i) luciferase renaturation was ATP-dependent; (ii) no 
significant spontaneous (chaperone-independent) renaturation of the luciferase was 
observed when the denatured luciferase stock was incubated at 28 °C in the absence of 
RRL; and (iii) at very limiting luciferase concentrations (0.03-0.3 nM) 60 to 100% of the 
denatured luciferase could be renatured upon prolonged incubation (75-90 min) in RRL 
Several factors were found to affect the rate of luciferase renaturation in the assay. 
As previously reported, different lysate preparations renatured luciferase at different rates 
because the preparations contain different quantities of hsps (Matts & Hurst, 1992, 
Schumacher et al., 1994). Because of the expense of the enzyme, stock solutions of native 
luciferase were stored at 4 °C and used over the period of a week. Aliquots of the stock 
solution were clarified by centrifugation prior to use. The rate of luciferase renaturation 
was observed to decrease with time of storage of the stock solution. This correlated with 
the accumulation of some insoluble material in the stock solution over the storage period. 
Ongoing protein synthesis in RRL was also observed to inhibit luciferase renaturation. 
Undialyzed lysate was thawed rapidly at 30 °C, followed by the addition of ediene to insure 
that translation was fully inhibited. All data points reported in the figures represent 
19 
measurements determined in a single experiment using a single lysate preparation and 
luciferase stock. All experiments were carried out at least three times. 
Purification of hsps and hsp cohorts 
Hsc70 was purified to apparent homogeneity from the post ribosomal supernatant 
of rabbit reticulocyte lysate as described for the purification of supernatant factor (Gross, 
1976, Gross et al., 1994). The initial steps in the purification of the hsp90 were similar to 
the steps for the purification of supernatant factor: precipitation at pH 5.4; reprecipitation at 
40-80% saturated ammonium sulfate; and chromatography on DEAE-cellulose. These 
steps were followed by chromatography on Superose 12/HR and monoQ columns as 
previously described (Denis, 1988). p60 copurified with hsc70 up to the ATP-agarose 
affinity chromatography step, where p60 was present in the fraction of proteins that did not 
bind to the column in buffer containing 0.1 M KCl (Gross et al., 1994). The p60 was 
approximately 67% pure at this stage with hsc70 being the primary contaminating protein 
(p60:70 -5:1). Chicken p23 (Johnson & Toft, 1994) was generously provided by Dr. 
David Toft (Mayo Medical School). Western blotting with an anti-hsp40 antiserum 
indicated that none of these preparations were contaminated with hsp40. 
Immunoadsor:ptions of proteins 
Goat anti-rabbit IgG was cross-linked to agarose (GaR-agarose) as previously 
described (Matts et al., 1992). Affinity pure anti-luciferase antibody (10 µl) was adsorbed 
to 20 µl of GaR-agarose (diluted 1:1 in TBS) in the presence or absence (control) of 
luciferase ( 40 µg) for 2 hr on ice. In the absence of stability buffer, purified luciferase 
spontaneously denatures. The GaR-agarose was then washed with 500 µl each of TBS, 
TB/500, TBS, and TB/50. RRL (35 µl), diluted 1:1 to contain 10 mM creatine 
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phosphate,20 U/ml creatine phosphokinase, 75 mM KCl and either DMSO or GM (1 
µg/ml), were then added to GaR-agarose. The mixtures were incubated for 5 min at 30 °C 
with periodic mixing to prevent settling of the agarose. The unadsorbed proteins were 
separated from adsorbed proteins (pellets) by centrifugation. Pellets were washed four 
times with TB/50. 
Western blot analysis 
Samples were prepared for SDS-PAGE, separated in 10% gels, and transferred to 
PVDF membrane as previously described (Matts & Hurst, 1992, Matts et al., 1992). 
Hsp70 and hsp90 were detected by western blotting with the 4322 anti-hsp70/hsp90 
antiserum (Ehrhart et al., 1988) or an anti-hsp90 (anti-mouse hsp84/86 antipeptide) 
antiserum provided by Dr. Stephen Ullrich (NCI) as previously described (Matts & Hurst, 
1992, Matts et al., 1992). p60, p48 and p23 were detected by western blotting with the F5 
anti-p60 (Smith et al., 1993b) 3G6 anti-p48 (Smith et al., 1995) and the JJ3 anti-p23 
(Johnson & Toft, 1994)mAb, respectively. 
Results 
GA and HbA inhibit luciferase refolding. 
Recent studies suggest that benzoquinonoid ansamycins bind hsp90 and inhibit its 
function (Whitesell et al., 1994). Since it is previously demonstrated that hsp90 plays a 
role in chaperone mediated renaturation of denatured luciferase in RRL (Schumacher et al., 
1994 ), we examined the effect of GA and HbA on the renaturation of luciferase. While 
neither GA nor HbA had any effect on the activity of native luciferase (not shown), they 
inhibited luciferase renaturation in a dose-dependent manner (Fig. 1). The concentrations 
of GA and HbA that inhibited luciferase renaturation by 50% of the maximally induced 
inhibition (IC50) were estimated to be 0.2 and 1.3 µM, respectively. Maximum inhibition 
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of luciferase renaturation was observed at a GA concentration of 0.7 µM. Addition of the 
DMSO vehicle at concentrations up to 0.2% (v/v) had no effect on the rate of luciferase 
renaturation. The pharmacologically inactive BA, geldampicin (Whitesell et al., 1994) did 
not inhibit luciferase renaturation when added at concentrations up to 15 µM (not shown). 
The extent of GA-induced inhibition of the rate of luciferase renaturation was 
observed to be dependent on the temperature at which the luciferase was denatured (Table 
II). GA decreased the initial velocity of luciferase renaturation by 50% when the luciferase 
was denatured at 38 °C and by 80% when the luciferase was denatured at 41 °C. These 
observations suggest that the more severely luciferase was denatured, the more dependent 
luciferase became on a GA-inhibitable event for rapid renaturation. 
Kinetic analysis of chaperone-mediated luciferase renaturation. 
We next examined the kinetics of luciferase renaturation in reticulocyte lysate to 
determine whether the mechanism by which BAs inhibit the renaturation of luciferase could 
be analyzed using steady state kinetics. At saturating ATP concentrations, the rate of 
luciferase renaturation was saturable with respect to the concentration of denatured 
luciferase present, and followed a rectangular hyperbolic curve that is characteristic of 
enzymes following Michaelis-Menten kinetics (Fig 2A). The Kapp and Vapp for the 
reaction were calculated to be 1.0 ± 0.17 µM and 1.0 ± 0.097 105 Light Units/10 min, 
respectively. The Kapp was calculated assuming that the luciferase preparation was 
homogeneous, and that all the denatured luciferase (MW=65,000) present represented 
soluble monomeric substrate with a single chaperone binding site. Therefore, this 
estimated Kapp represented a maximum value, since some insoluble material was noted to 
be present in the luciferase stock. 
The renaturation of luciferase in RRL requires the presence of an optimum 
concentration of K+, Mg2+ and ATP (Schumacher et al., 1994). To allow the kinetic 
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analysis of the effects of varying ATP concentrations on the rate of luciferase renaturation, 
RRL was dialyzed to remove endogenous ATP. The ATP remaining in the lysate was 
quantified and was found to be 5 µM and 20 µM in the absence and presence of a CP/CPK 
ATP regenerating system, respectively. The rate of luciferase renaturation was determined 
at a near-saturating concentration of denatured luciferase and varying ATP concentrations 
(Fig 2B). The Kapp and Yapp for ATP in the reaction were estimated to be 61 ± 8.0 µM 
and 4.2 ± 0.25 x 104 Light Units/10 min, respectively. Renaturation rate was next 
determined while varying both ATP and luciferase concentrations. An Eadie-Hofstee plot 
of the data generated a series of nearly parallel lines that is characteristic of sequential 
reaction mechanisms (Fig. 3). 
Kinetic analysis of GA-induced inhibition of luciferase renaturation. 
We next examined the kinetics of luciferase renaturation in the presence of GA to 
gain insight into the mechanism by which GA inhibited chaperone-mediated luciferase 
renaturation. Luciferase renaturation rates were determined at saturating ATP and varying 
luciferase and GA concentrations. Eadie-Hofstee plots of the data indicated that GA 
inhibited luciferase renaturation noncompetitively, affecting both the Yapp and the 
Yapp/Kapp (Fig. 4A). Replots of Yapp/Kapp versus [GA] (Fig. 4B) and 1/V app versus 
[GA] were hyperbolic (Fig. 4C), indicating that luciferase renaturation could not be 
completely inhibited even at saturating concentrations of GA. Concentrations of GA up to 
3.5 µM inhibited luciferase renaturation no more than that observed with 0.7 µM GA. 
We next examined the effect of GA on the kinetics of luciferase renaturation at near 
saturating luciferase and varying ATP concentrations in a dialyzed RRL as described above 
(Fig SA). Eadie-Hofstee plots of the data generated a series of straight lines that intersected 
at a single point; a pattern which is characteristic of uncompetitive inhibition. However, the 
lines intersected to the right of the y-axis, indicating that GA should theoretically stimulate 
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luciferase renaturation in a competitive manner with respect to ATP, at very low ATP 
concentrations. The replots of Kapp/Vapp versus [GA] (Fig SB) and lN app versus [GA] 
(Fig. SC) appeared nonlinear. The best-fit of the lN app versus [GA] replot was parabolic, 
but a rigorous exclusion of a linear fit would require more data. While the stimulatory 
effect of GA on luciferase renaturation that is predicted to occur at very low ATP 
concentrations is curious, it is physiologically irrelevant, since the parabolic shape of the 
[GA] versus lN app replot indicates that this phenomenon does not occur at higher ATP 
concentrations where GA inhibits luciferase renaturation. 
Effects of GA on the interaction of components of the hsp90-chaperone machine with 
denatured luciferase. 
To further elucidate the mechanism by which GA inhibits luciferase renaturation, 
the components of the hsp90 chaperone machine that were co-immunoprecipitable with 
denatured luciferase in RRL were characterized. Hsp90, hsc70 and the cohorts p60, p48 
and p23 were observed to interact with luciferase (Fig. 6). The interaction of hsc70 with 
luciferase was indicated by the increase in amount hsc70 present in the immune pellet 
relative to the nonspecific binding apparent in the minus luciferase control (Fig. 6, lane 1 vs 
lanes 2 & 3). GA treatment was found to increase the steady state level of p60, while it 
decreased the steady state level of p23 interacting with luciferase relative to the control (Fig. 
6, lane 2 vs lane 3). 
Hsp90 specifically reverses inhibition of luciferase renaturation induced by geldanamycin. 
To further test the hypothesis that GA binds hsp90 and inhibits its function, we 
examined the effect of purified hsps and hsp cohorts on luciferase renaturation in 
reticulocyte lysate (Fig. 7). In the absence of GA, addition of purified hsp90, p60 or p23 
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to control RRL had no effect on luciferase renaturation (Fig. 7, closed bars: none vs 90, 
23, or 60). Luciferase renaturation was stimulated by 70% upon the addition of purified 
hsc70 (Fig. 7: 70). Addition of both hsp90 and hsc70 stimulated luciferase renaturation by 
80% (Fig 7: 90+ 70). A small ( an additional 5% ), but reproducible stimulation of luciferase 
renaturation was observed when p23 was added in conjunction with hsc70 alone, or with 
hsc70 and hsp90 (Fig. 7: 23+70 & 90+70+23). Addition of other combinations of 
components had no effect on luciferase renaturation. 
The effect of the purified hsps and hsp cohorts on GA-induced inhibition of 
luciferase renaturation was then examined. Luciferase renaturation was inhibited by 60% 
in RRL in the presence of 0.7 µM GA (Fig. 7, closed vs open bars: none). GA inhibited 
luciferase renaturation to a similar degree (60 to 70%) in RRL supplemented with purified 
p23, p60, hsc70 or any combination of these components (Fig. 7) compared to RRL that 
was supplemented with the purified components and incubated in the absence of GA. 
In contrast to the other components, hsp90 was observed to specifically reverse 
GA-induced inhibition of the rate of luciferase renaturation. In the presence of GA, 
addition of hsp90 to RRL stimulated luciferase renaturation by 100% relative to the control 
containing GA but lacking hsp90 (Fig. 7, open bars: none vs 90). In hsp90-supplemented 
RRL containing GA the rate of luciferase renaturation was restored to within 80% of the 
rate observed in hsp90-supplemented RRL incubated in the absence of GA (Fig. 7, closed 
vs open bars: 90}. In RRL supplemented with hsp90 in combination with the other 
purified components, GA-induced inhibition of the rate of luciferase renaturation ranged 
from 7 to 20%. In addition, the extent to which hsp90 reversed the inhibitory effect of GA 
was proportional to the amount of hsp90 added to the lysate (data not shown). The ability 
of hsp90 to protect against GA-induced inhibition of the rate of luciferase renaturation was 
not simply an effect of adding protein to the lysate, since addition of BSA showed no 
protection against GA-induced inhibition of luciferase renaturation. 
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Discussion 
Kinetics of Chaperone Facilitated Protein Renaturation in RRL. 
While the mechanism by which protein renaturation occurs in RRL is undoubtedly 
complex, the data presented here indicate that the problem is at least partially tractable to 
analysis using steady state kinetics. Luciferase renaturation showed substrate saturation 
with respect to both ATP and luciferase concentrations and followed Michaelis-Menten 
kinetics. Eadie-Hofstee plots of the initial velocity data (Fig. 3) were a family of nearly 
parallel lines characteristic of sequential mechanisms. The parallel pattern observed for the 
chaperone-mediated luciferase renaturation of this study could be explained by either of the 
abbreviated alternatives presented in Fig. 8. Specifically, addition of denatured luciferase 
could immediately follow addition of ATP to the chaperone machine (Fig. 8A). In this 
scheme the hsp90 chaperone machine would be a single large complex of proteins [e.g., a 
foldasome (Hutchinson et al. 1995, Hutchinson et al., 1994b ). The data is also consistent 
with models proposed by the laboratories of Smith and Toft (Johnson & Toft, 1995, 
Prapapanich et al., 1996, Smith et al., 1995) in which there is an ATP-dependent assembly 
of an hsp90-p23-immunophilin complex which subsequently binds to 
SHR/hsp90/hsc70/p60/p48 complexes and from which the previously bound chaperones 
dissociate (Fig. 8B). 
The association of hsp90, hsc70, and cohorts p60, p48, and p23 with denatured 
luciferase suggests that renaturation of luciferase occurs by a mechanism similar to that 
involved in restoring the hormone binding activity of SHRs (Hutchinson et al., 1994a, 
Hutchinson et al., 1994b, Hutchinson et al., 1995, Johnson & Toft, 1995, Smith, 1993, 
Somma et al., 1995). This observation implies that the function of the hsp90 chaperone 
machine is not specific to its previously described interactions with signal transduction 
proteins, and that it is capable of carrying out a more generalized protein folding function in 
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vivo. This folding activity appears to target proteins containing partially unfolded 
structure. This notion is consistent with previous reports that indicate hsp90 interacts with 
late folding intermediates of proteins prior to their conversion to the native state (Hartson & 
Matts, 1994, Jacob et al., 1995, Melnick et al., 1992, Melnick et al., 1994, Smith, 1993). 
Effect of geldanamycin on the interactions of hsps and associated cohorts with denatured 
luciferase. 
The data presented here support the hypothesis that GA is a specific inhibitor of 
hsp90 function. GA inhibited luciferase renaturation in RRL, but had no direct effect on 
luciferase activity in vitro or in RRL after its renaturation. The difference observed 
between the IC50 values for GA and HbA-induced inhibition of luciferase renaturation is 
similar to differences observed between the potency of the two drugs in in vivo assays of 
their tumoricidal activity (Whitesell et al., 1992). GA-induced inhibition of luciferase 
renaturation was specifically reversed by the addition of hsp90 to RRL, but not by the 
addition of hsc70, p60, or p23. 
The binding of GA to hsp90 appears to inhibit the normal sequential interaction of 
components of the hsp90-chaperone machinery with luciferase. GA increased the amount 
of p60 and decreased the amount of p23 associated with the hsp90-chaperone machinery 
containing bound luciferase. GA has similar effects on the association of p23 and p60 with 
progesterone receptor/hsp90 complexes reconstituted in RRL (Johnson & Toft, 1995, 
Smith et al., 1995). Recent results indicate that hsp40 also binds to denatured luciferase. 
We have not yet examined whether immunophilins interact with hsp90-p23 bound 
luciferase or whether GA blocks this interaction as has been reported for the progesterone 
receptor. Thus, as for the progesterone receptor, GA appears to prevent the transition of 
hsp90/hsc70/p60/p48 complexes that contain bound substrate to hsp90 complexes 
containing p23 and bound substrate. Previous work indicates that GA does not simply act 
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by stabilizing hsp90/hsc70/p60/p48 complexes containing bound progesterone receptor 
(Smith et al., 1995). Therefore, the binding of GA to hsp90 appears to block the ability of 
p23 or hsp90-p23 complexes to interact stably with luciferase present in 
hsp90/hsc70/p60/p48 complexes. These observations imply that a GA-sensitive event is a 
hsp90-p23 dependent event. 
An alternate pathway for luciferase renaturation exists in RRL. 
Kinetic analyses of GA-induced inhibition of luciferase renaturation at varying 
luciferase concentrations indicate that luciferase can renature by more than one pathway. 
GA inhibited luciferase renaturation noncompetitively with respect to luciferase 
concentration, indicating that at saturating ATP concentrations GA binds to both the hsp90-
chaperone machine/ ATP complex and the hsp90-chaperone machine/ ATP/luciferase 
complex. The hyperbolic replots of GA concentration versus IN app and Kapp/V app 
indicate that GA can not completely inhibit luciferase renaturation even at saturation. This 
indicates that luciferase can renature by a slower alternate reaction pathway in the presence 
of GA. The existence of an alternate pathway is consistent with the observations that: (i) 
folding of newly synthesized luciferase in·RRL requires hsc70, hsp40 and additional lysate 
chaperone components (e.g., TRiC), but does not appear to involve hsp90 (Frydman et al., 
1994); and (ii) refolding of luciferase that has been denatured by treatment with 
guanidinium•HCl can be chaperoned by hsc70, hsp40 and Hip (p48) in vitro (Freeman et 
al., 1995, Hohfeld et al., 1995). 
The observations that the extent to which GA inhibits the rate of luciferase 
renaturation depends on the age of the luciferase stock and the temperature at which it was 
denatured also suggest that denatured luciferase is a mixed population of molecules whose 
rate of renaturation varies in their sensitivity to inhibition by GA. Evidence for the 
existence of multiple unfolding intermediates of thermally denatured citrate synthase that 
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renatured at different rates in the presence of hsp90 in vitro has been previously reported 
(Jacob et al., 1995). 
The alternate pathway that is followed in the presence of GA probably involves 
dissociation of luciferase from the intermediate hsp90-chaperone machine complex 
containing hsc70, p60 and p48 (Prapapanich et al., 1996, Smith et al., 1995), and likely 
involves hsp40 (Hohfeld et al., 1995). The GA-insensitive folding pathway may be 
slower for a number of related reasons. The interaction of the folding intermediate with 
hsp90-p23 might facilitate the acquisition of a folded structure (e.g., the binding of the 
folding intermediate to the hsp90-p23 chaperone machine may increase the rate constant of 
the forward reaction). In addition, more nonproductive folding pathways might be 
accessible to the folding intermediate in the absence of an interaction with hsp90 containing 
bound p23 (e.g., the binding of the folding intermediate to the hsp90-p23 chaperone 
machine may decrease the rate constant for the back reaction). As a result, luciferase would 
require more reiterative cycles of association with the chaperone machinery to fold. 
Furthermore, since denatured luciferase is likely a mixed population of substrate, the 
folding of a portion of the denatured luciferase population may be accelerated to a greater 
extent or completely dependent upon association with the hsp90 chaperone machinery 
containing p23. Reiterative cycles of association of this population of luciferase molecules 
with the hsp90-chaperone machine complex containing hsc70, p60 and p48 would slow the 
rate of folding of the luciferase population capable of following the GA-insensitive folding 
pathway. 
Other observations reported here suggest that the GA-sensitive folding pathway is 
normally preferred. GA inhibited the rate of luciferase renaturation by 70% in RRL lysate 
supplemented with hsc70. However, a 35% inhibition would have been expected if hsc70 
was stimulating luciferase renaturation solely through a GA-insensitive (hsp90-p23 
independent) pathway. In addition, hsp90 reversed GA-induced inhibition of luciferase 
renaturation in hsc70 supplemented lysate nearly completely. Thus, the exogenous hsc70 
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appeared to be preferentially stimulating luciferase renaturation through the GA-sensitive 
(hsp90-p23 dependent) pathway in RRL. 
Mechanism of action of geldanamycin. 
Kinetic analyses of GA-induced inhibition of luciferase renaturation with respect to 
varying ATP concentration suggests a possible mechanism by which the binding of GA to 
hsp90 inhibits hsp90 function. Inhibition of luciferase renaturation by GA was 
uncompetitive with respect to ATP (Fig. 5A). This shows that the inhibition by GA is 
either not reversibly connected with the addition of ATP or that GA inhibits an enzyme 
form downstream from that with which ATP combines. These possiblities are consistent 
with the schemes presented in Fig. 8. The best-fit curve of the replot of [GA] versus 
1/V app was parabolic, suggesting that two molecules of GA are binding to each hsp90-
chaperone machine complex. This is consistent with the notion that hsp90 is present in the 
chaperone complex as a dimer (6), if the conformation of each hsp90 present in the dimer is 
not equivalent. Alternatively, two GA binding sites may be present in each hsp90 
monomer. Since no amount of ATP relieves the inhibitory effect of GA, GA and ATP are 
clearly binding to different sites. 
The data suggest that GA acts by inducing changes in the binding or hydrolysis of 
ATP by the hsp90 chaperone machinery. GA caused a significant reduction in the Kapp of 
the hsp90-chaperone machine for ATP from -60 to -12 µM. This observation indicates 
that the binding of GA to the hsp90 chaperone machine complex either decreases the rate of 
ATP dissociation (e.g., increases the affinity of the hsp90-chaperone machine for ATP), or 
slows the rate at which ATP is converted to product (e.g., inhibits the rate of ATP 
hydrolysis). The effects of GA on the Kapp for ATP and the interaction of p23 with the 
hsp90-chaperone machine containing bound luciferase are consistent with previous reports 
that (a) p23 interacts with hsp90 in the presence of either ATP or nonhydrolyzable ATP 
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analogs; but (b) the presence of hydrolyzable ATP is required for the stable association of 
p23 with hsp90/progesterone receptor complexes (Johnson & Toft, 1995); and (c) the 
hsp90 cohort p23 does not interact with the hsp90 chaperone machinery containing bound 
substrate (SHR) in the presence of GA [(Johnson & Toft, 1995, Smith et al., 1995). & 
Fig. 6]. 
Based on the correlation between GA's effects on p23 binding to the hsp90 
chaperone machinery and GA's effects on ATP affinity or hydrolysis, we speculate that 
p23 plays a role in regulating either ATP hydrolysis or nucleotide exchange during the 
action of the hsp90 chaperone machine. The binding of GA to hsp90 could be directly 
affecting the ATP binding site that has been proposed to be present on hsp90 (Fig. 8A) 
(Csermely et al., 1993, Johnson & Toft, 1995, Nadeau et al., 1993) However, since the 
existence of the hsp90 ATP binding site has recently been questioned (Jacob et al., 1996), 
the binding of GA to hsp90 may affect the ATP binding site present on some other some 
component of the hsp90 chaperone machinery, such as hsc70 through allosteric 
interactions. 
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Figure 1. Concentration dependence for benzoquinonoid ansamycin-induced inhibition 
of luciferase renaturation in RRL. 
Heme-deficient protein synthesis mixes (100 µl) containing 10 µM edeine 
were preincubated for 20 min at 30 °C in the presence of 0.1 µI of DMSO 
(vehicle control), or 0.1µ1 of DMSO containing varying concentrations of 
GA(O) or HbA(D). Five µI of denatured luciferase (10 µg/ml) was then 
diluted into 100 µl oflysate. After 10 min, the amount of luciferase activity 
present in a 20 µl aliquot of each reaction was measured as described under 
"Materials and Methods". Light forming units renatured per 10 min of 
incubation is plotted versus the final concentration of GA or HbA. 
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Figure 2. Luciferase renaturation shows Michaelis-Menten kinetics in RRL. 
(A) The rate of luciferase renaturation was measured at saturating ATP and 
varying luciferase concentrations in heme-deficient protein synthesis mixes 
containing 10 µM edeine as described under "Materials and Methods". 
Light forming units renatured per 10 min of incubation is plotted versus 
luciferase concentration. (B) The rate of luciferase renaturation was 
measured at 2.1 µM luciferase and varying ATP concentrations in a 
dialyzed lysate as described under "Materials and Methods". 
-en 
C .E a 
0 
T"" 



































0 2 4 6 8 
1 0- 2x [ATP] µM 
35 
Figure 3. Eadie-Hofstee plot of kinetics of luciferase renaturation. 
The rate of luciferase renaturation was measured in dialyzed RRL in the 
presence of varying ATP and luciferase concentrations as described under 
"Materials and Methods" and Fig. 2. Concentration of luciferase present in 
the renaturation assay was 1.03 µM (0), 0.77 µM (0), 0.51 µM (e), and 
0.26 µM (+), respectively. ATP concentrations were varied between 0.02 
and 0.1 mM. The experiment was repeated three times with similar results. 
Lines were analyzed as described under "Materials and Methods ". 
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Figure 4. Effect of GA on the rate of luciferase renaturation in the presence of saturating 
ATP and varying luciferase concentrations. 
(A) Eadie-Hofstee plot of the kinetics of luciferase renaturation measured at 
saturating ATP (1.7 mM endogenous) and varying luciferase and GA 
concentrations. The rate of luciferase renaturation was measured in 100 µl 
of heme-deficient protein synthesis mixes containing 10 µM edeine and 0.1 
µl DMSO (0), or 0.17 µM (0), 0.34 µM (e), and 0.67 µM (+) GA as 
described under "Materials and Methods" and Fig. 2 and 3. (B) Replot of 
KappNapp versus [GA]. (C) Replot of 1/Vapp versus [GA]. The 
experiment was repeated five times with similar results. The data were 
analyzed as described under "Material and Methods". The smooth curves (B 
& C) represents the best-fit hyperbola. A linear fit can be excluded by a chi-
square probability > 0.9995 for the Kapp/Yapp curve, and -0.90 for the 
lN app curve. 
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Figure 5. Effect of GA on the rate of luciferase renaturation in the presence of saturating 
luciferase and varying ATP concentrations. 
(A) Eadie-Hofstee plot of the kinetics of luciferase renaturation measured at 
saturating luciferase and varying ATP and GA concentrations. The rate of 
luciferase renaturation was measured in 100 µl of dialyzed lysate containing 
2.1 µM luciferase and varying ATP concentrations in the presence of 0.1 µl 
DMSO (0), or 0.17 µM (0), 0.34 µM (e), and 0.67 µM (+) GA as 
described under "Materials and Methods". (B) Rep lot of KappN app versus 
[GA]. (C) Replot of 1/Vapp versus [GA]. The data were analyzed as 
described under "Material and Methods". The smooth curves (B & C) 
represents the best-fit parabola. 
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Figure 6. Effect of GA on the interaction of denatured luciferase with heat shock 
proteins. 
Luciferase was adsorbed to affinity-purified anti-luciferase antibody bound 
to GaR-agarose as described under "Materials and Methods". The 
immobilized luciferase was incubated for 5 min at 30 °C in heme-deficient 
protein synthesis mixes in the presence or absence of GA (lµg/ml). A 
control incubation containing anti-luciferase antibody adsorbed to GaR-
agarose, but no luciferase. 
C DMSO GA 
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Figure 7. Effects of purified hsps and hsp cohorts on GA-induced inhibition ofluciferase 
renaturation in RRL. 
Rabbit reticulocyte lysate containing 10 mM creatine phosphate, 20 U/ml 
creatine phosphokinase, 75 mM KCl, 1 mM Mg(OAc)2 and 1 µ1/ml DMSO 
(closed bars) or 0.7 µM GA (open bars) was supplemented with: buffer 
(con); 20 µg/ml of p23 (23); 160 µg/ml of hsp90 (90); 80 µg/ml of hsc70 
(70); 25 µg/ml of p60 (60); or combinations of these quantities of proteins. 
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Figure 8. Possible schemes for GA-induced inhibition of luciferase renaturation. 
(A) A possible reaction sequence for the hsp90 chaperone machinery. The 
hsp90 chaperone machinery is assumed to be a large complex (foldasome) 
containing p60, p48, p23 and the immunophilins. Only hsp90 and hsc70 are 
shown. (B). An alternate scheme in which there is an ATP-dependent 
assembly of chaperones X (hsp90, p23 and immunophilins) to form complex 
Y which then adds to the hsp90/hsc70 complex containing p60, p48 and 
bound luciferase. The ? after ATP associated with hsp90 denotes the fact 












































Table II. The degree of GA-induced inhibition of luciferase renaturation depends on the 
temperature of denaturation. 
Luciferase (0.7 µM), denatured at 38 or 41 °c for 10 min, was diluted 20 
fold into heme-deficient protein synthesis mixes supplemented with edeine 
and containing either GA (1.8 µM) or DMSO (1µ1/ml). The amount of 
luciferase renatured after incubation for 10 min at 28 °C was measured after 
10 min as described under "Materials and Methods". The rate ofluciferase 
renaturation is reported as light units renatured/10 min. 
Temperature of denaturation Additions 
DMSO GA 








HSP90 AND PROTEIN FOLDING PATHWAYS 
Introduction 
Organisms have evolved molecular chaperones to facilitate protein folding events 
occurring in the concentrated environments of the cellular cytosol and organelle interiors 
[for review see (Gething & Sambrook, 1992)]. Chaperones are thought to interact 
primarily with hydrophobic regions of protein substrates to prevent illicit interactions that 
would lead to protein aggregation [see (Ellis, 1993)]. Additionally, certain members of 
chaperone families can catalyze the isomerization of peptidyl-prolyl bonds or of disulfide 
bonds [see (Gething & Sambrook, 1992)]. Chaperones are thought to both facilitate the de 
nova folding of newly synthesized proteins and to allow renaturation of partially denatured 
proteins [see (Becker & Craig, 1994, Hartl, 1996)]. Although chaperones participate in 
both de nova folding and protein renaturation, the relationships between these two folding 
processes are poorly understood. 
The biogenesis of certain kinases appears to require one or more members of the 
90-kDa family of heat-inducible phosphoproteins (hsp90). Newly synthesized molecules of 
the viral tyrosine kinase p6osrc occur in cytoplasmic complexes with hsp90 and the p50 
cohort of hsp90 (Brugge et al., 1983, Courtneidge & Bishop, 1982). Viral p6osrc 
molecules within this complex are deficient in kinase activity and are hypophosphorylated. 
During subsequent maturation, these kinase molecules dissociate from hsp90 and p50, 
acquire greater specific activity and further posttranslational phosphorylations, and 
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associate with the plasma membrane [for review, see (Brugge, 1986)]. Hsp90 thus plays 
an essential positive role in viral p6osrc function (Xu & Lindquist, 1993). Consistent with 
hsp90's role in the biogenesis of viral p6osrc, modeling of protein biogenesis in rabbit 
reticulocyte lysate (RRL) indicates that hsp90-bound intermediates exist for most if not all 
molecules of the cellular tyrosine kinase p56lck (Hartson et al., 1996). These interactions 
are necessary for p56lck molecules to demonstrate protease-resistant conformations 
(Hartson et al., 1996). More recently, co-translational interactions between hsp90 and the 
heme-regulated eIF-2a kinase have been observed during the hsp90-dependent maturation 
of this kinase (S. Uma, S. Hartson, J.-L Chen, and R. L. Matts, in preparation). Thus, 
chaperone machinery containing hsp90 appears to be necessary for the de nova folding of 
certain kinases. 
In addition to its apparent role in de nova folding of these kinases, hsp90 also 
maintains active protein conformations. In the RRL model of chaperone function, 
reiterative interactions with chaperone machinery containing hsp90 are required to maintain 
certain steroid hormone receptors in conformations that are competent to bind hormone 
(Scherrer et al., 1990, Smith, 1993, Smith et al., 1990a). Consistent with this model, 
treatment of whole cells with the hsp90-binding drug geldanamycin causes glucocorticoid 
receptors to rapidly lose hormone binding competence and accelerates turnover of 
glucocorticoid receptor molecules (Whitesell & Cook, 1996). Hsp90 may similarly 
maintain the structure of other regulatory proteins [e.g. see (Blagosklonny et al., 1995, 
Hartson et al., 1996, Mimnaugh et al., 1996, Stancato et al., 1993, Stepanova et al., 1996, 
Wartmann & Davis, 1994)]. Also consistent with this role in maintenance of protein 
structure, the active conformation of heat-denatured firefly luciferase can be restored via the 
ATP-dependent action of hsp90 and other chaperones present in RRL (Schumacher et al., 
1994, Thulasiraman & Matts, 1996). 
Although hsp90 facilitates the efficient renaturation of firefly luciferase, physical 
interactions between hsp90 and newly synthesized molecules of luciferase have not been 
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observed (Frydman et al., 1994, Hartson & Matts, 1994). These results imply that hsp90 
may be involved in some, but not other, de novo folding pathways. In this report, we have 
utilized three chaperone antagonists, geldanamycin, clofibric acid, and denatured protein 
[reduced carboxymethylated-BSA (RCM-BSA)] to dissect the pathways for chaperone-
mediated de novo folding and for chaperone-mediated maintenance of protein function in 
RRL. Data thus obtained indicate that: (1) distinct chaperone-mediated pathways for de 
novo folding can exist for unrelated proteins; (2) efficient protein renaturation may utilize 
chaperone machinery that is not involved in de novo protein folding pathways; and (3) 
for a given protein, pathways for chaperone-mediated maintenance or renaturation may 
differ in conjunction with the degree of denaturation. We also present data demonstrating 




Purified crystalline firefly (Photinus pyralis) luciferase was obtained from Sigma. 
Plasmids bearing the full cDNA coding sequence of firefly luciferase or of p56lck were 
constructed to allow efficient synthesis of these proteins in RRL (Hartson & Matts, 1994). 
RRL for protein synthesis reactions was obtained from Promega Corporation (TNT 
nuclease-treated RRL kits). RRL used to study the maintenance of active conformations of 
purified luciferase was prepared as previously described (Matts et al., 1991). 
Geldanamycin ( obtained from the Drug Synthesis and Chemistry Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment, National Cancer Institute) was 
prepared as a 1.0 mg/ml stock in DMSO. Clofibric acid (Sigma) was prepared as a 0.15 M 
stock in water. RCM-BSA was prepared as previously described (Matts et al., 1993). 
De novo synthesis and folding in RRL. 
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Firefly luciferase and p56lck were synthesized following the manufacturer's 
suggestions. Protein synthesis was assessed by determination of [35S]Met incorporation 
into TCA-insoluble protein. The folding of p56lck was assessed as described previously 
(Hartson et al., 1996) via protease nicking assays of native [35S]kinase molecules followed 
by SOS-PAGE and autoradiography. Luciferase folding was assayed via determination of 
luciferase activity present in aliquots of protein synthesis reactions as described elsewhere 
(Thulasiraman & Matts, 1996). The specific enzymatic activity ofluciferase was calculated 
assuming an endogenous methionine content of 3.5 µM for rabbit reticulocyte lysate. The 
effects of individual chaperone antagonists were assessed in translations synchronized 
using one of two approaches described below. 
Geldanamycin and reduced carboxymethylated-bovine serum albumin (RCM-BSA) as 
antagonists of de novo protein folding. 
Although geldanamycin had no effect on protein synthesis at levels used in work 
described here, RCM-BSA inhibited re-initiation of protein synthesis via activation of the 
heme-regulated inhibitor of protein synthesis (Matts et al., 1993). Neither compound 
affected the rates of luciferase elongation during protein synthesis. Thus, to assay the 
effects of these compounds on luciferase folding, luciferase was first synthesized at 30 °C 
for 6 min in the absence of drug treatment. Following this loading of polyribosomes, a 
mixture of two inhibitors of translation initiation, edeineA (20 µM final concentration) and 
aurin tricarboxylic acid (ATA, 130 µM final concentration) were added. After addition of 
initiation inhibitors and chaperone antagonists, polyribosomes were allowed to run off and 
rates of luciferase's acquisition of activity (folding) were assayed. The chaperone 
antagonists RCM-BSA (44 µM final concentration), geldanamycin (5 µg/ml final), or the 
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appropriate drug vehicle control were added prior to onset of protein synthesis, after arrest 
of initiation of protein synthesis, or after polyribosome runoff, as indicated. 
Clofibric acid as an antagonist of luciferase de nova folding. 
Because clofibric acid inhibited polypeptide elongation during protein synthesis, 
polyribosomes programmed with luciferase message were first loaded for 10 min as 
described above and then ATA was added.(130 µM final concentration) to arrest reinitiation 
of protein synthesis. Polyribosomes were then allowed to run off for 6 min, clofibric acid 
(15 mM final concentration) was then added as indicated, and rates of luciferase folding 
after translation were assayed as described above. 
Assays of chaperone maintenance of luciferase structure in RRL. 
Luciferase stock (O.lmg/ml) was diluted 300-fold into heme-deficient protein 
synthesis mix containing DMSO (0.5 % ), geldanamycin/DMSO (5 µg/ml and 0.5 %, 
respectively), or clofibric acid (15mM). These reactions were incubated at either 37 °C or 
42 °C as indicated. Luciferase activity present in 1.5 µl of lysate was measured following 
incubation for 1 hr. For assessment of ATP-dependence, the ATP-regenerating system 
( creatine kinase and phosphocreatine) normally added to protein synthesis reactions was 
omitted. 
Assays of chaperone maintenance of p56lck structure in RRL. 
To assess maintenance of p56lck protease resistance by geldanamycin-inhibitable 
hsp90 function, [35S]p56lck was synthesized at 30 °C in the absence of geldanamycin, 
synthesis was arrested via treatment with ATA, and [35S]p56lck molecules allowed to 
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mature for 1 hr at 30 QC. Subsequently, geldanamycin and/or DMSO vehicle were added to 
5 µg/ml and 0.5% final concentrations, respectively and the reactions incubated for an 
additional hour at 30 QC. Following incubation, resistance to protease nicking was assayed 
as previously described (Hartson et al., 1996, Hartson & Matts, 1994). 
Effects of geldanamycin on the hsp90-p56lck complex. 
p56lck was synthesized for 30 min in RRL containing geldanamycin and/or DMSO 
vehicle (5 µg/ml and 0.5% final concentrations, respectively). Complexes between p56lck 
and hsp90 were co-immunoadsorbed with rabbit anti-p56lck antibodies (Amrein et al., 
1992) as previously described (Hartson et al., 1996, Hartson & Matts, 1994). 
Immunoadsorptions from 70 µl of protein synthesis reaction were washed twice with 10 
mM TrisHCl (pH=7.4), once with either 10 mM TrisHCl pH7.4 or with 10 mM TrisHCl 
pH7.4, 0.5 M NaCl, and finally with 10 mM TrisHCl pH7.4. Immunoadsorbed proteins 
were analyzed by western blotting with anti-hsp90 antiserum [rabbit 4322 antiserum at 
1:2000 (Ehrhart et al., 1988) and rabbit antibodies directed against the N-terminus of 
mouse hsp86 at 0.5 µg/ml (Affinity BioReagents)]. Immunoreactive materials (rabbit anti-
hsp90 and heavy chain of immunoadsorbing rabbit anti-p56lck antibodies) were visualized 
with alkaline phosphatase-conjugated anti-rabbit IgG as previously described (Matts et al., 
1992). 
Results 
The nature of geldanamycin-sensitive binding of hsp90 to substrates. 
The effects of geldanamycin on hsp90-substrate interactions appears to vary among 
published studies. To address these apparent discrepancies regarding the effects of 
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geldanamycin on hsp90-substrate complexes, we examined the various experimental 
protocols that have been used to assess interactions between hsp90 and substrate proteins. 
We observed that the ionic strength used for the co-immunoadsorption of hsp90 complexes 
varied among studies. 
Therefore, we examined the effect of salt concentration on the hsp90-p56lck 
complex produced in RRL in the presence or absence of geldanamycin. As previously 
described (Hartson et al., 1996, Hartson & Matts, 1994), complexes containing hsp90 
were co-immunoadsorbed by anti-p56lck antibodies in an p56lck -specific fashion (Figure 
9). These complexes could be detected following washing under either low or high ionic-
strength conditions (Figure 9, lane 3 and lane 4, respectively). However, in translation 
reactions treated with 5 µg/ml geldanamycin, interactions between hsp90 and p56lck were 
no longer detected following washing with 0.5 M NaCl (Figure 9, lane 6). In contrast, 
some interaction between hsp90 and p56lck could still be detected when hsp90-p56lck 
complexes from geldanamycin-treated translations were washed in low-salt buffer (Figure 
9, lane 5). Thus, geldanamycin disrupted the normally salt-stable interaction between 
hsp90 and p56lck, but did not prevent the detection of interactions between these proteins in 
the absence of high-ionic-strength washes. 
Geldanamycin inhibits the de novo folding of the p56kk tyrosine kinase. 
Previous work in the RRL model system has shown that the hsp90-binding drug 
geldanamycin inhibits the hsp90-dependent folding of p56lck, resulting in the failure of the 
kinase to demonstrate a protease-resistant conformation in subsequent nicking assays of 
native p56lck structure (Hartson et al., 1996). Inhibition of hsp90 function by 
geldanamycin could have either: ( 1) prevented the kinase from acquiring a protease-
resistant conformation; (2) prevented the kinase from maintaining a protease-resistant 
conformation; or (3) both 1 and 2 above. In this previous study, pulse-chase analyses of 
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p56lck biogenesis indicated that hsp90-bound intermediates existed for most if not all 
p56lck molecules synthesized in RRL (Hartson et al., 1996). Thus, we concluded that 
hsp90 participated in the de novo folding of p56lck. 
Protease nicking assays of [35S]p56lck molecules produced in RRL were used to 
confirm the involvement of hsp90 in de novo folding of p56lck. As previously reported, 
[35S]p56lck produced and matured for 1 hr in geldanamycin-treated RRL was dramatically 
hypersensitive to proteolysis relative to the kinase produced in the absence of this drug 
(Figure 10, upper panel). To confirm that this hypersensitivity reflected a role for hsp90 in 
the de novo folding of p56lck, we tested the counter hypothesis, that an ongoing 
requirement for geldanamycin-inhibitable hsp90 was necessary to maintain p56lck in a 
protease-resistant conformation. To test this counter hypothesis, [35S]p56lck was 
synthesized and allowed to mature to a protease-resistant conformation in the absence of 
geldanamycin. Following this maturation, hsp90 function was inhibited by addition of 
geldanamycin and the reaction was further incubated in the presence of geldanamycin for 1 
hr prior to proteolytic fingerprinting of [35S]p56lck. The fingerprint of the kinase thus 
produced was indistinguishable from that of the kinase produced, matured, and incubated 
in the absence of geldanamycin (Figure 10, lower panel). Thus, newly synthesized p56lck 
molecules required geldanamycin-inhibitable hsp90 function to achieve protease-resistant 
conformations, while older p56lck molecules did not demonstrate a similar requirement for 
maintenance of protease resistance. These results indicated that the counter hypothesis was 
false: the protease sensitivity of the kinase produced in the presence of geldanamycin did 
not result from inhibition of hsp90's maintenance of protease resistance. Instead, this result 
clearly demonstrated a role for geldanamycin-inhibitable hsp90-function in the de novo 
folding of p56lck. 
Geldanamycin does not inhibit the de novo folding of luciferase. 
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Previous studies have failed to demonstrate stable physical interactions between 
hsp90 and nascent or newly synthesized firefly luciferase (Frydman et al., 1994, Hartson 
& Matts, 1994). Failure to detect such interactions could have two explanations: (1) 
complexes between hsp90 and luciferase are inherently more difficult to detect than those 
formed between hsp90 and certain other proteins; or (2) hsp90 does not participate in the 
de novo folding of luciferase. To discriminate between these two possibilities, we 
examined the effect of geldanamycin on the de novo folding of luciferase into an 
enzymatically active conformation. Although luciferase synthesis began at approximately 8 
min following assembly of the protein synthesis reaction, accumulation of luciferase 
activity did not begin until approximately 16 min follow~ng assembly of the protein 
synthesis reaction (Figure 11). This lag reflected the time required for chaperone-mediated 
luciferase folding (Frydman et al., 1994). In the presence of concentrations of 
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geldanamycin that inhibit the de novo folding of p56lck, neither the rate of luciferase 
synthesis (not shown), the rate of luciferase acquisition of enzymatic activity (not shown), 
nor the specific enzymatic activity of luciferase thus produced were inhibited (Figure 11). 
This concentration of geldanamycin (5 µg/ml) is more than an order of magnitude greater 
than that which maximally inhibits the renaturation of heat-denatured luciferase 
(Thulasiraman & Matts, 1996). Thus, geldanamycin's failure to inhibit de novo folding of 
luciferase occurred at concentrations of geldanamycin which maximally inhibited hsp90 
function. Additionally, equivalent results were obtained when RRL was treated with 
geldanamycin (5 µg/ml) prior to the onset of luciferase synthesis. Thus, geldanamycin-
inhibitable hsp90-function was not necessary for the efficient de novo folding of firefly 
luciferase. 
The de novo folding of newly synthesized luciferase requires hsc70 function. 
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Geldanamycin had no effect on the folding of newly synthesized luciferase in RRL 
(Figure 11). Thus, the effects of this drug on the folding of p56lck (Figure 10) did not 
appear to reflect indirect global inhibition of chaperone function in RRL. However, this 
conclusion assumed that such assays would detect inhibition of chaperone functions 
essential to the de novo folding of luciferase. To ensure that these assays would detect such 
inhibition, titration of hsc70 function was assessed for its effects on de novo folding of 
luciferase. Hsc70 binds tightly to RCM-BSA, thus blocking or competing for the 
interaction of hsc70 with other substrates in RRL (Matts et al., 1993). Titration of hsc70 
function by the addition of RCM-BSA caused an approximately 5 min delay in the de novo 
folding of luciferase (Figure 12A), indicating that efficient de novo folding of luciferase 
required hsc70 function. 
Inhibition of hsc70 function was also examined using clofibric acid. Clofibric acid 
specifically binds to hsc70 at or near the ATP-binding site (Alvares et al., 1990). Such 
binding inhibits the interaction of hsc70 with heat-denatured luciferase.(V. Thulasiraman 
and R.L. Matts, in preparation). In control assays, clofibric acid had no direct effect on 
luciferase activity when added directly to luciferase assays or when RRL reactions 
containing luciferase were incubated at 30 °C for 10 min (not shown). However, clofibric 
acid completely inhibited the de novo folding of luciferase (Figure 12B). These results 
confirmed that: (1) assays of de novo folding of luciferase were sensitive to inhibition of 
hsc70 function; (2) de novo folding of luciferase required active chaperone machinery, as 
has been previously demonstrated (Frydman et al., 1994); and (3) the inhibition of p56lck 
folding by geldanamycin resulted from the direct inhibition of hsp90's role in folding of 
p56lck rather than a global disruption of chaperone machinery present in RRL. 
Chaperones provide ongoing maintenance of protein structure and function in rabbit 
reticulocyte lysate. 
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Under pseudo-physiological conditions, geldanamycin-inhibitable hsp90 function is 
necessary to efficiently maintain the activity of p56lck (Hartson et al., 1996). In contrast to 
inhibition of de novo folding, this failure to maintain function was not accompanied by 
gross defects in kinase structure as assessed by protease fingerprinting (Figure 1 O; 
Hartson and Matts, unpublished). To determine if cellular chaperone machinery might 
similarly support the function of luciferase at 37 ·c, the maintenance of luciferase activity at 
this temperature was assessed for: (1) ATP dependence; (2) inhibition by the hsc70-
binding drug clofibric acid; and (3) inhibition by the hsp90-binding drug geldanamycin. 
Normally, RRL is supplemented with an ATP-regenerating system (creatine kinase 
and phosphocreatine) to maintain ATP concentrations at levels necessary to support protein 
synthesis and chaperone function. However, when endogenous ATP present in RRL was 
not regenerated via this ATP regenerat_ing system, the activity of purified luciferase 
incubated in RRL declined by 43% in the course of one hr (Figure 13). Thus, the efficient 
maintenance of luciferase in an active conformation required ATP-dependent events. 
To determine if this ATP-dependent maintenance function required hsc70, the effect 
of clofibric acid on luciferase maintenance was determined. At 37 °C, the ATP-dependent 
maintenance of luciferase in an active conformation was inhibited by 96% in the presence 
of 15 mM clofibric acid (Figure 13). Thus, efficient maintenance of luciferase activity 
required clofibrate-inhibitable hsc70 function. These results indicated that thermal 
denaturation of luciferase occurred in RRL at 37 °C and that a rapid ATP-dependent and 
hsc70-dependent event maintained the activity of the luciferase under these conditions. 
The degree to which hsp90-chaperone machinery was required to maintain 
luciferase molecules in active conformations was a function of temperature. Geldanamycin 
caused minor losses in luciferase activity at 37 °C (23% inhibition; Figure 13). Thus, at 
this temperature, efficient maintenance of luciferase was somewhat dependent on 
geldanamycin-inhibitable hsp90. However, at 42 °C geldanamycin caused a 86% loss of 
the specific enzymatic activity of luciferase (Figure 14). Similar temperature-dependent 
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results have been obtained when purified luciferase is denatured at these temperatures in 
buffer and subsequently renatured in ATP-supplemented RRL (Thulasiraman & Matts, 
1996). 
Discussion 
Effects of geldanamycin on interactions between hsp90 and substrates. 
The effects of geldanamycin on hsp90-substrate interactions appears to vary among 
published studies. Geldanamycin inhibition of hsp90 function has been reported to disrupt 
hsp90's interaction with several "substrate" proteins in vivo [e.g. viral p6osrc (Whitesell et 
al., 1994), raf (Schulte et al., 1995), and pl85erbB2 (Chavany et al., 1996)]. Similar 
disruption of hsp90-substrate complexes can be modeled in the RRL model system 
(Hartson et al., 1996). In contrast, during RRL-mediated reconstitution of heteromeric 
complexes between hsp90 machinery and steroid hormone receptors, geldanamycin causes 
the accumulation of progesterone hormone receptors in intermediate complexes containing 
hsp90 and the hsp90-associated chaperones hsc70 and p60 (Johnson & Toft, 1995, Smith 
et al., 1995). Similarly, interactions between hsp90 and glucocorticoid receptor have been 
reported following treatment of whole cells with geldanamycin (Whitesell & Cook, 1996). 
Additionally, we have found that during renaturation assays in geldanamycin-treated RRL, 
heat-denatured luciferase accumulates in complexes containing hsp90, hsc70, and p60 
(Thulasiraman & Matts, 1996). 
However, the conditions under which complexes between hsp90 and its substrates 
are analyzed vary among studies. In the absence of geldanamycin, hsp90-mediated folding 
of p56lck is accompanied by a tight salt-stable interaction between hsp90 and its protein 
substrate (Figure 9). Similarly, the complex formed between hsp90 and viral p6osrc is salt-
stable [see (Brugge, 1986)]. Although geldanamycin renders this normally salt-stable 
association salt-labile, weak interactions between hsp90 and p56lck can still be detected 
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under conditions of low ionic strength (Figure 9). Thus, geldanamycin-induced disruption 
of physical associations between hsp90 and its substrate are only apparent when such 
associations are analyzed under moderate to high ionic strength conditions. In contrast to 
the normally salt-stable interaction of hsp90 with tyrosine kinases, complexes between 
hsp90 and steroid hormone receptors are reported to be salt-labile, and are thus typically 
analyzed under conditions of low ionic strength. Under these conditions, geldanamycin-
induced disruption of hsp90-binding to substrate would not be predicted to be readily 
apparent. 
The observation that normal interactions between hsp90 and tyrosine kinases are 
stable under conditions of high ionic strength suggests that hsp90 binds directly to these 
kinases via hydrophobic interactions. Thus, certain hsp90-mediated folding events may 
involve salt-stable hydrophobic binding that does not occur following geldanamycin 
treatment. However, it does not necessarily follow that all hsp90-mediated folding events 
are accompanied by similar salt-stable complexes. 
Geldanamycin-induced changes in the mode by which hsp90 binds to substrate are 
consistent with a model for geldanamycin-mediated inhibition of hsp90. Although the exact 
mechanism of geldanamycin action is poorly understood, kinetic analysis in RRL 
demonstrates that geldanamycin inhibits hsp90 noncompetitively with respect to substrate 
during renaturation of heat-denatured luciferase (Thulasiraman & Matts, 1996). Thus, 
although geldanamycin prevents the normally salt-stable interaction of hsp90 with p56lck, 
disruption of this interaction probably does not result from direct competition between 
geldanamycin and p56lck for a binding site on hsp90. Rather, we speculate that 
geldanamycin inhibits hsp90 by inhibiting the ATP-dependent switching of hsp90 to a 
hydrophobic "slow-off" conformation. Kinetic analysis of the effects of geldanamycin on 
hsp90-mediated luciferase renaturation indicates that geldanamycin either increases the 
binding affinity of hsp90 machinery for ATP or slows the rate of ATP hydrolysis 
(Thulasiraman & Matts, 1996). ATP has been shown to alter the conformations of hsp90 
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(Csermely et al., 1993) and other chaperones. For the chaperones hsc70, DnaK, and 
GroEL/ES, the ATP-bound form of the chaperone is the conformation from which 
substrates rapidly bind and rapidly dissociate; following ATP hydrolysis, the chaperones 
switch to a conformation that allows tight hydrophobic binding of the substrate [for review, 
see (Hartl, 1996) and references therein]. Additionally, inhibition of hsp90 by 
geldanamycin is correlated to the absence of the hsp90 cohort p23 from heteromeric hsp90 
chaperone machinery (Johnson & Toft, 1995, Smith et al., 1995, Thulasiraman & Matts, 
1996). Together, these observations suggest that p23 may regulate ATP hydrolysis or 
exchange during folding events mediated by hsp90 machinery (Thulasiraman & Matts, 
1996), and thus, changes in the conformation of hsp90 that allow tight hydrophobic 
binding to substrates (Figure 9). 
Following geldanamycin treatment, hsp90 interacts with p56lck via weak 
electrostatic forces (salt-labile ionic interactions). These weak interactions may be indirect. 
This speculation postulates that in the presence of geldanamycin, hsp90 is not associated 
with the substrate per se, but is instead electrostatically associated with other chaperone 
machinery directly bound to the substrate. Thus, in the presence of geldanamycin, hsp90 
might co-purify with folding intermediates due to these indirect interactions. Consistent 
with this speculation, the association of hsp90 with certain of its cohorts (e.g. 
immunophilins) does not require concomitant binding to partially folded "substrates" [for 
review, see (Pratt & Welsh, 1994a)] and many of these interactions are not inhibited by 
geldanamycin (Smith et al., 1995). 
Hsp90 and protein folding pathways. 
Regardless of the exact mechanism by which geldanamycin inhibits certain hsp90 
functions, the data presented in this report demonstrate three significant features of 
chaperone-mediated protein folding in the RRL model of the eukaryotic cytosol: (1) the 
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specific chaperone activities utilized during de novo folding pathways may differ among 
different proteins; (2) for a given protein, pathways of chaperone-mediated de novo 
folding may differ from those utilized for renaturation folding; and (3) for a given protein, 
pathways for chaperone-mediated maintenance or renaturation may differ in conjunction 
with the degree of heat denaturation. 
Our conclusion that specific chaperone activities utilized during de novo folding 
pathways may differ among different proteins is based on pharmacological characterization 
of the de novo folding pathways of the mammalian cellular tyrosine kinase p56lck and the 
firefly enzyme luciferase. Three lines of evidence indicate that hsp90 is involved in the de 
novo folding of p56lck: (1) newly synthesized molecules of p56lck interact with hsp90 
within 3 min of their synthesis at 30 °C in RRL, with the proportion of p56lck molecules 
interacting with hsp90 declining during subsequent chase incubations (Hartson et al., 
1996); (2) disruption of this normally salt-stable interaction by geldanamycin prevents the 
kinase from acquiring a protease-resistant conformation, but does not cause a loss of 
protease resistance once such resistance is acquired (Figure 10); and (3) the mechanism of 
geldanamycin inhibition of p56lck folding does not involve the global or indirect inhibition 
of other chaperone functions, since geldanamycin does not inhibit luciferase's acquisition 
of an active conformation (Figure 11). Thus, we conclude that geldanamycin-inhibitable 
hsp90 function is necessary for the de novo folding of p56lck molecules. Consistent with 
this conclusion, complexes between hsp90 and p56lck are detected in cytoplasmic, but not 
membrane, fractions of LSTRA cells (Hartson et al., 1996). Also consistent with this 
conclusion, the de novo folding of the heme-regulated eIF-2a kinase involves the co-
translational association of hsp90 with nascent kinase molecules (S. Uma, S. Hartson, J.-
J. Chen, and R.L.Matts, in preparation). However, in contrast to geldanamycin's 
inhibition of the de novo folding of p56lck, geldanamycin has no effects on the rate nor 
magnitude of the de novo folding of firefly luciferase (Figure 11). Thus, geldanamycin-
inhibitable hsp90 function is not essential for the efficient de novo folding of luciferase. 
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Together, these data indicate that the chaperone-mediated de nova folding pathways of two 
unrelated proteins differ in the involvement of geldanamycin-inhibitable hsp90 function. By 
extension, chaperone-mediated folding pathways may differ among other proteins or 
protein families. This possibility is of interest in light of the complex nature of chaperone 
machinery, including apparent differences in substrate specificity, the various homologs 
reported for individual members of conserved chaperone families, and the observation that 
many chaperones are phosphorylated with unknown consequences. 
Pharmacological characterizations presented here also indicate that for a given 
protein, pathways of de nova folding may differ from those utilized for renaturation 
folding. This conclusion is based on three lines of evidence obtained following 
geldanamycin treatment of ATP-supplemented RRL: (1) geldanamycin-inhibitable hsp90 
function is not necessary for the de nova folding of firefly luciferase (Figure 11); (2) 
geldanamycin-inhibitable hsp90 function is necessary for the efficient renaturation when 
heat-denatured luciferase is renatured in RRL, although alternative less-efficient pathways 
of folding can function to renature luciferase in the absence of geldanamycin-inhibitable 
hsp90 function (Thulasiraman & Matts, 1996); and (3) ongoing support of luciferase 
structure at heat-shock temperatures is most efficient when geldanamycin-inhibitable hsp90 
function is present (Figure 14). Thus, the renaturation of heat-denatured luciferase 
populations can occur most efficiently via a chaperone-mediated protein folding pathway 
that does not normally function during the de nova folding of this protein, namely, a 
renaturation pathway utilizing geldanamycin-inhibitable hsp90 function. Similarly, proteins 
denatured by exposure to concentrated guanidinium-HCl refold by chaperoned-mediated 
mechanisms that differ somewhat from those utilized during de nova folding (Frydman & 
Hartl, 1996). These results imply that during heat shock in vivo, denatured proteins can 
renature via chaperone-mediated processes that are distinct from those utilized during de 
nova folding. Thus, renaturation of protein structure is not necessarily the simple 
recapitulation of de nova folding. 
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Our results also indicate that at physiological temperatures, given protein 
populations may experience ongoing support of structure and function via rapid transient 
reiterative cycles of chaperone mediated folding. At 37 ·c, luciferase requires ongoing 
chaperone support, as evidenced by the loss of luciferase activity observed upon treatment 
with the hsc70 binding drug clofibric acid or by similar losses observed in ATP-deficient 
RRL (Figure 13). At this temperature, geldanamycin-inhibitable hsp90 function makes 
minor contributions to the efficient maintenance of luciferase activity. For p56lckp505 at 37 
·c (Hartson et al., 1996) or for firefly luciferase at 42 ·c (Figure 14), geldanamycin-
inhibitable hsp90 function makes major contributions to the maintenance of the active 
conformations of these proteins in RRL. These results demonstrate that an active protein 
population may require ongoing chaperone support that only becomes evident when 
chaperone machinery is inhibited. Thus, although a protein population as a whole may 
show neither defects in structure nor defects in function, individual molecules within this 
population may be experiencing chaperone-mediated folding at any given moment. We 
speculate that cryptic chaperone support becomes more evident when certain mutations 
compromise the kinetics of de novo folding or the inherent thermodynamic stability of a 
protein; this possibility may be relevant to riddles regarding differences in the detection of 
interactions between hsp90-chaperone machinery and cellular versus viral p6osrc [see 
(Brugge, 1986)] and wild-type versus mutant p53 (Blagosklonny et al., 1996, 
Blagosklonny et al., 1995, Hainaut & Milner, 1992, Sepehmia et al., 1996). 
Geldanamycin-inhibitable hsp90 function is not intrinsic to all chaperone-mediated 
folding pathways occurring in RRL for thermally denatured luciferase (Thulasiraman & 
Matts, 1996). Rather, the degree to which hsp90 is involved in the renaturation pathway of 
luciferase is dependent on the temperature at which luciferase is denatured (Figure 13 and 
14). Thus, hsp90 machinery may recognize a specific temperature-dependent protein 
folding defect or may recognize structures with significant perturbations. Regulatory 
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proteins whose function is supported by hsp90 may share with heat-denatured luciferase 
either these specific folding defects or degrees of misfolding. 
Why does p56lck require geldanamycin-inhibitable hsp90 machinery under non-heat-shock 
conditions? The obligate role for hsp90 in de nova folding of p56lck, the heme-regulated 
eIF-2a kinase, and perhaps other signal transduction proteins suggests that for these 
proteins, folding defects are inherent to their de nova folding pathways. Additionally, 
hsp90 machinery appears to supply ongoing maintenance of protein structure for these and 
other proteins (see Introduction). Thus, kinetic (de nova) and thermodynamic 
("disactivation") folding defects may have evolved to ensure that the activity of signal 
transduction proteins is not expressed inappropriately in the absence of ligands (Smith, 
1993), during biogenesis (Hartson et al., 1996), or prior to other specific stabilization 
events. 
Alternatively, kinetic and thermodynamic folding "defects" may be inherent for the 
function of p56lck and other regulatory proteins. These multi-conformational proteins 
usually have small differences between the free energies of their individual conformations 
[e.g. see (Cooper & Howell, 1993)]. These small differences may result in a nearly 
continuous free-energy spectrum of folding intermediates, with no deep energy minima. 
Theoretically, such a spectrum would slow rates of de nova folding and would decrease the 
stability of the folded proteins [for discussion, see (Baldwin, 1994) and references 
therein]. Thus, the involvement of hsp90 machinery in both de nova folding of p56lck 
(Figure 10) and in maintaining p56lck function (Hartson et al., 1996) might reflect 
specialized chaperone support for a slow-folding, inherently unstable protein with a nearly 
continuous free-energy spectrum. 
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Figure 9. Geldanamycin inhibits the salt-stable interaction of hsp90 with p56lck 
(Courtesy of Steve Hartson). 
The drug vehicle DMSO (lanes 2-4) or geldanamycin (lanes 5+6) was 
added to in vitro translation reactions that were (lanes 3-6) or were not 
(lane 2) programmed with lck template. Reactions were then incubated 
at 30 °C for 45 min, chilled on ice, and immunoadsorbed with rabbit 
anti-p56lck antibodies. Immunopellets were washed with low salt buffer 
and with one stringency wash of either low salt buffer (lanes 2,3,+5) or 
with buffer containing 0.5 M NaCl (lanes 4+6) as described in Materials 
and Methods. Aliquots of each immunoadsorption were analyzed by 
SDS-PAGE and autoradiography to assess the efficiency of 
immunoadsorption of p56lck (top panel). Bands representing [35S]p56lck 
are indicated. The balance of each immunoadsorption was analyzed by 
SDS-PAGE and western blotting with rabbit anti-(hsp90/hsp70) antisera 
to assess co-adsorption of the hsp90-p56lck complex. Additionally, 
rabbit reticulocyte lysate was applied to the gel (lane 1) to supply a 
standard for the detection of hsp90 and hsp70. Hsp90, hsp70, and the 
heavy chain of the immunoadsorbing antibody (ab he) are indicated. 
Migrations of size standards are indicated along the right side of each 
panel (kDa). 
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Figure 10. Geldanamycin prevents, but does not reverse, the acquisition of protease 
resistance by p56lck (Courtesy of Steve Hartson). 
[35S]p56lck was produced in rabbit reticulocyte lysate to which either 
DMSO or geldanamycin were added before synthesis of p56lck as indicated 
(top panel). Alternatively, p56lck was synthesized and matured in rabbit 
reticulocyte lysate lacking geldanamycin and subsequently incubated for 1 
hr in rabbit reticulocyte lysate to which either drug vehicle DMSO or 
geldanamycin had been added as indicated (lower panel). In both cases, 
translation reactions were chilled on ice and treated with the indicated . 
amounts of chymotrypsin for 6 min. Proteolyzed samples were analyzed by 
SOS-PAGE and autoradiography. The full-length lck translation product is 
indicated ( * ). Migrations and molecular masses of standards (kDa) are 
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Figure 11. Geldanamycin does not inhibit the de novo folding of luciferase. 
After 10 min of luciferase synthesis in rabbit reticulocyte lysate, inhibitors 
of translation initiation were added and polyribosomes were allowed to run 
off for another 6 min. Following this 6 min runoff, either the drug vehicle 
DMSO ( ¢) or geldanamycin ( +) was added as indicated. Aliquots were 
assayed at indicated times to determine [35S]met incorporation into acid 
precipitable protein and to determine luciferase activity. Individual points 
represent luciferase specific enzymatic activity synthesized in the absence or 
presence of geldanamycin assuming an endogenous methionine content of 
3.5 µM for rabbit reticulocyte lysate. 
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Figure 12. Antagonists of hsc70 inhibit the de novo folding of luciferase. 
Panel A: After 6 min of luciferase synthesis in rabbit reticulocyte lysate, 
inhibitors of translation initiation and either BSA ( ¢) or RCM-BSA ( +) 
were added. The specific enzymatic activity of luciferase was determined at 
the indicated times as described in Figure 11. 
Panel B: After 10 min of luciferase synthesis in rabbit reticulocyte lysate, 
inhibitors of translation initiation were added and polyribosomes were 
allowed to run off for another 6 min. At this time, either the drug vehicle 
water ( ¢) or clofibric acid ( +) was added as indicated and the specific 
enzymatic activity of luciferase was determined at the indicated times as 
described in Figure 11. 
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Figure 13. Maintenance of luciferase at 37 °C requires ongoing chaperone support. 
Purified luciferase was added to rabbit reticulocyte lysate lacking or 
containing an ATP-regenerating system, clofibric acid (CIA), DMSO 
(DMSO), or geldanamycin (GA) as indicated. Reactions were incubated for 
1 hr at 37 °C and luciferase activity assayed. Luciferase activity is expressed 
as a percentage of that recovered from control incubations in lysate 
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Figure 14. Fully folded luciferase requires ongoing chaperone support at 42 °C 
<' 
Purified luciferase was added to rabbit reticulocyte lysate containing an 
ATP-regenerating system and DMSO (DMSO), geldanamycin (GA), or 
clofibric acid (CIA) as indicated. Reactions were incubated for 1 hr at 42 °C 
and luciferase activities assayed. Luciferase activity is expressed as a 
percentage of that recovered from control incubations in lysate containing 
an ATP-regenerating system but no drugs. 
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CHAPTER IV 
HSC70 NEGATIVELY REGULATES HRI 
Introduction 
The heme-regulated translational inhibitor (HRI) is a protein kinase that specifically 
phosphorylates the 38 kDa a-subunit of eukaryotic initiation factor-2, eIF-2 (reviewed in 
(Courtneidge & Bishop, 1982, Oppermann et al., 1981, Tai et al., 1992)). The 
phosphorylation of eIF-2a in heme-deficient rabbit reticulocyte lysate (RRL) results in the 
inhibition of protein chain initiation upon sequestration of eIF-2B, the initiation factor 
responsible for catalyzing guanine nucleotide exchange which is required for the recycling 
of eIF-2 in the initiation of translation (Matts et al., 1983, Siekierka et al., 1984). The 
unavailability of eIF-2B results in the accumulation of eIF-2 in complexes with GDP and in 
the inhibition of the formation of the eIF-2•GTP•Met-tRNAi ternary complex. Since the 
amount of eIF-2B present in the lysate is much lower than the amount of eIF-2 present, 
phosphorylation of only 20-40% of the eIF-2a present is sufficient to render eIF-2B 
unavailable to catalyse GTP/GDP exchange (Matts & London, 1984). 
In addition to heme-deficiency, activation of HRI in rabbit reticulocyte lysates 
(RRL) occurs in response to a number of agents that induce the heat shock or stess 
response in whole organisms or cultured cells. These agents include: heat shock, 
sulfhydryl reagents, oxidants, glucose deficiency, heavy metal ion treatment, and ethanol 
(Bonanou-Tzedaki et al., 1978, Ernst et al., 1978, Matts et al., 1991, Wu, 1981). As HRI 
activates it becomes progressively more phosphorylated. Activation of HRI may also 
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involve sulfhydryl oxidation or sulfhydryl/disulfide bond rearrangements (Ernst et al., 
1979, Farrell et al., 1978, Gross & Rabinovitz, 1972, Kosower et al., 1972). The 
relationship between the molecular forms of HRI activated in response to heme-deficiency 
to forms of active HRI generated in hemin-supplemented lysate in response to heat or 
oxidative stress is not well understood. 
HRI activation also appears to be regulated through its interaction with the heat 
shock proteins (hsps) and hsp cohorts, hsp90, hsc70, FKBP52 and p23 in situ in RRL 
(Matts & Hurst, 1989, Matts et al., 1992, Xu et al., In preparation) The sensitivity of HRI 
to activation in response to heat and oxidative stress in hemin-supplemented RRL correlates 
inversely to the quantities of hsc70 present in lysate preparations (Matts & Hurst, 1992). 
In addition, HRI in heme-deficient RRL containing low levels of hsp70 converts more 
rapidly to an activated state that is resistant to inhibition by hemin (Matts & Hurst, 1992). 
Recently, Gross and coworkers have identified the Supernatant Factor, a purified 
component of RRL that maintains protein synthesis when added to heme-deficient lysate, 
as a hsp70 family member (Gross et al., 1994). The ability of the Supernatant Factor to 
suppress the activation of partially purified HRI in vitro supports the hypothesis that hsc70 
plays a negative role in the activation of HRI. 
In this chapter, we have examined whether purified hsc70 has the ability to 
suppress the activation of HRI in hemin-supplemented RRL that occurs in response to heat 
shock or exposure to GSSG or Hg2+. The data presented here indicate that: (i) biologically 
active pure hsc70 lowers the level of phosphorylated eIF-2a and maintains eIF-2B activity 
in heme-deficient RRL, and in hemin-supplemented RRL exposed to heat shock, RCM-
BSA, GSSG or Hg2+; (ii) hsc70 completely suppressed protein synthesis inhibition 
caused by Hg2+, but only partly reversed inhibition caused by GSSG and heat shock; (iii) 
the inability of hsc70 to fully protect protein synthesis from inhibition due to heat shock 
and GSSG was due to its inability to protect eIF-4E from heat-induced dephosphorylation, 
and its inability to protect translational elongation from GSSG-induced inhibition, 
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respectively. These results are consistent with the notion that hsc70 negatively regulates 
the activation of HRI in RRL. 
Experimental procedures 
Materials. 
Reticulocyte lysate was prepared from anemic rabbits as described (Hunt et al., 
1972), using buffered saline containing 5 mM glucose to wash the reticulocytes prior to 
their lysis (Matts et al., 1991). Nitro blue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) salicylic acid, clofibric acid, indomethacin, ibuprofen, and 7-methyl 
GTP were obtained from Sigma. Alkaline phosphatase conjugated to goat anti-rabbit IgG 
and rabbit anti-mouse IgG was obtained from ICN. L-[14C]Leucine(340 mCi/mmole) and 
[y-32P]ATP (1000-3000 Ci/mmol) were obtained from Du Pont-New England Nuclear. 
DEAE cellulose resin was from Toyohaas. eIF-2 was isolated from reticulocyte lysate 
obtained from Green Hectar as described previously (Hurst et al., 1987). 7-Methyl GTP-
Sepharose-4B was obtained from Pharmacia Biotech. Rabbit 4322 anti-hsp90/hsp70 
polyclonal antiserum (Erhart et al., 1988) was provided by Dr Stephen J. Ullrich (National 
Cancer Institute). YDJ-1 was generously provided by David Toft (Mayo Medical School, 
Rochester, MN). 
Buffers 
TB, 10 mM Tris-HCI (pH 7.5); TB/50, lOmM Tris-HCI (pH 7.5) containing 50 
mM NaCl; TBS, 10 mM Tris-HCl (pH 7.5) containing 150 mM NaCl; HE, 20 mM 
HEPES (pH 7.4), 0.5 mM EDTA; HE/50, 20 mM HEPES (pH 7.4), 0.5 mM EDTA, 50 
mM KCl, 50 mM NaF; HEM/50, 20 mM HEPES, 0.5 mM EDTA, 50 mM KCL, 50 mM 
NaF, 2 mM MgCl2, 1 mM ATP, 0.2 mM GTP; GB, 25 mM Tris-HCl (pH 7.5) containing 
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100 mM KCl, 15 mM Mg(OAc)2, and 0.2 mM EDTA; lxSDS sample buffer, 62.5 mM 
Tris-HCl (pH 6.8), 5% SDS, 90 mM dithithreitol, 5% glycerol, and 0.005% Bromophenol 
blue: alkaline phosphatase reaction buffer, 100 mM TRIS:-HCl (pH 9.5) containing 100 
mM NaCl, 100 mM Mg(OAc)2, 300 µg/ml NTB and 150 µg/ml BCIP. 
Protein synthesis and eIF-2a. phosphorylation in reticulocyte lysates 
Protein synthesis was carried out at 30 °C in standard reticulocyte lysate reaction 
mixtures with or without the addition of [14C]leucine as described (Hunt et al., 1972; Ernst 
et al., 1978). Hemin supplemented lysates contained 20 µM hemin-HCI. Protein 
synthesis was determined by measuring the incorporation of [14C]leucine into the acid-
precipitable protein at 30 °C in standard reticulocyte reaction mixtures (Hunt et al., 1972; 
Ernst et al., 1978). eIF-2a phosphorylations in 2 µl of protein synthesis mixes were 
analysed as previously described by western blotting of one-dimensional isoelectric 
focusing slab gels (Maurides et al., 1989). 
Immunoadsor.ption of BSA, RCM-BSA, and HRI from rabbit reticulocyte lysates 
Immunoadsorptions of lysate proteins with the the anti-HRI mAB For with anti-
BSA were carried out as described (Matts et al., 1993, Matts et al:, 1992). 
Analysis of eIF-4E phosphorylation 
After preincubation for 18 min at 42 °C (heat shocked) or 35 °C (control), hemin-
supplemented protein synthesis mixes were pulsed with [y-32P]ATP (0.4 mCi to 200 µI of 
protein synthesis mix) for 5 min, followed by the addition of ice cold NaF and EDTA to a 
final concentration of 50 mM and 10 mM, respectively. eIF-4E was adsorbed by the 
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addition of 30 µl of 7-methyl GTP-Sepharose to the samples (1:1 mix in HE buffer) on ice, 
followed by stirring in the cold room for 2 hr. The 7-methyl GTP-Sepharose was then 
washed sequentially with 1 ml each of HE, HEil 00, HEM, and HE/100. The bound eIF-
4E was then eluted with HE/100 buffer containing 50 µM 7-methyl GTP. Samples were 
analyzed by SOS-PAGE in 10% gels, followed by transfer of the protein onto the PVDF 
membrane and autoradiography. 
Assay for eIF-2B guanine nucleotide exchange activity 
RRLs were incubated under protein synthesizing conditions at 30 °C or 42 °C (heat 
shock) in the absence of [14C]Leu and eIF-2B activity was measured as described 
previously (Matts 1984). Briefly, at the times indicated, 50 µl of protein synthesis mix 
was mixed with 130 µl of ice cold dilution buffer ( 40 mM Tris HCl, pH7.4, 100 mM 
KCl, 50 mM KF, 2 mM Mg(OAch, 10% glycerol, 40 µM GDP), and 20 µl of preformed 
eIF-2•[3H]GDP complex. Reaction mixes were then incubated at 30 °C for 2 min. 
Exchange assays were stopped by the addition of 1 ml ice cold wash buffer, followed by 
filtration of the reaction mixture through nitrocellulose filters (HA WP 02500, Millipore) 
which rapidly binds the remaining eIF-2•[3H]GDP complex. Filters were then washed 
with an additional 15 ml of ice cold wash buffer to remove any unbound [3H]GDP. 
Polyribosome gradients 
Hemin-supplemented protein synthesis mixes (100 µl) we~e incubated in the 
presence or absence of 1.3 mM GSSG for 20 min at 30°C. These reaction mixes were 
diluted with 150 µl of ice cold GB buffer layered over a 15-40% (w/v) sucrose gradient 
and centrifuged for 1 h at 45,000 rpm in a Sorvall AH-650 rotor. The polyribosomal 
profile was analyzed using an ISCO Model 640 density gradient fractionator as described 
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previously (Matts et al., 1991). Inhibition of elongation was assayed by the determining 
the ability of agents to inhibit run-off of polyribosomes after the addition of aurin 
tricarboxylic acid (ATA), an initiation inhibitor. Specifically, hemin-supplemented protein 
synthesis mixes were supplemented with 120 µMATA and incubated in the presence or 
absence of 1.3 mM GSSG (1.3 mM) for 1.5 min at 30 °C prior to analysis as described 
above. 
Purification of hsc70 
Hsc70 was purified from the post-ribosomal supernatant of fresh rabbit reticulocyte 
lysate obtained from Green Hectar by a slight modification of the procedure described by 
Gross and co-workers for the purification of the Supernatant Factor (Gross, 1976, Gross 
et al., 1994). The inital purification of hsc70 from post-ribosomal supernatant consisted of 
acid precipitation at pH 5.4, reprecipitation at 40-80% saturated ammonium sulfate, HPLC 
chromatography on DEAE-Toyopearl from ToyoHaas, chromatography on 
phosphocellulose, followed by affinity chomatography on ATP-agarose. The hsc70 
obtained was highly pure and biologically active in reversing protein synthesis inhibition 
due to heme deficiency. Hsc70 purified in a similar manner from rabbit liver or brain is as 
pure, but is not active in reversing the protein synthesis inhibition in heme-deficient RRL. 
In agreement with the report of Gross and coworkers (Gross et al., 1994) bovine brain 
hsp70 purchased from StressGen was inactive or inhibitory to protein synthesis. 
Upon storage of aliquots of concentrated stocks of purified hsc70 at -70 °C, a 
significant amount of the protein is observed to be present in aggregates upon thawing. In 
addition, the hsc70 was observed to aggregate if the purified hsc70 was concentrated too 
extensively. These observations are consistent with reports that ATP bound to purified 
hsc70 hydrolyzes slowly, leading to the accumulation of hsc70•ADP. Most studies 
suggest that purified hsc70 occurs as a mixture of monomers, dimers and polymers in 
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ADP, while in ATP it occurs mostly as monomer molecules that readily form aggregates 
upon storage (Carlino et al., 1992, Palleros et al., 1993, Schlossman et al., 1984, Schmid 
et al., 1985, Toledo et al., 1993). Moreover polymerization of hsc70 is proportional to 
protein concentration (Gao et al., 1996). Polymerized hsc70 has either no effect or is 
inhibitory to protein synthesis in RRL (not shown). Aggregated hsc70 disaggregates when 
ATP is exchanged for bound ADP (Gao et al., 1996). To activate aggregated hsc70, hsc70 
was preincubated in hemin supplemented lysate in the presence of a creatine 
phosphate/creatine phosphokinase ATP regenerating system 10 min prior to the initiation of 
protein synthesis. Moreover, addition of low levels of YDJ-1 (yeast DnaJ homolog) to 
RRL, enhanced the ability of hsc70 to inhibit HRI activation. 
Results 
Heat shock causes a loss in the functional pool of hsc70 
Previously an inverse correlation between the degree of heat shock-induced protein 
synthesis inhibition and hsc70 levels in RRL has been observed. It was hypothesized that 
protein synthesis inhibition under heat stress occurs when heat shock-induced denatured 
proteins accumulate to a level that sequesters the available pool of functional hsc70. To test 
this hypothesis two different lysates were compared which had different resistance to heat 
stress (Fig. 15). One lysate was very sensitive to heat shock and shut off protein synthesis 
within 5 min of incubation at 42 °C (lysate 2), whereas the other lysate was more resistant 
and shut off protein synthesis after 15 min of incubation (lysate 1). These two lysates were 
compared for the availability of active hsc70 pool to bind to RCM-BSA, at 5 min and 15 
min. RCM-BSA and BSA were added to the lysates and then immunoadsorbed with anti-
BSA at the end of 5 min and 15 min. Western blot analysis showed that when the lysates 
were incubated with RCM-BSA at 30 °C the amount of hsc70 interacting with RCM-BSA 
did not vary with time, in both the sensitive and resistant lysates. But when the mixture 
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was incubated at 42 °C, there was a rapid loss of hsc70 that binds to RCM-BSA within 5 
min in the sensitive lysate, whereas in the resistant lysate this occurred only at the end of 15 
min, correlating very well with the time of protein synthesis shut off. This further indicates 
that heat shock reduces the active pool of hsc70 that can bind to substrates. 
Heat shock blocks the association of hsc70 with HRI 
It has been proposed previously that the mechanism by which denatured proteins 
activate HRI, is by binding and sequestering hsc70, and blocking the interaction of hsc70 
with HRI. To confirm if a similar mechanism occurs under heat stress, we analyzed the 
level of hsc70 interacting with HRI during heat shock. HRI was adsorbed from control 
and heat shocked hemin-supplemented lysate with anti-HRI mAbF. Western blot analysis 
indicated that hsp70 was coadsorbed with HRI from the control lysate, but not from the 
heat shocked lysate, indicating that hsp70 dissociates from HRI during heat shock (Fig. 
16). This is consistent with the observation that denatured protein has the ability to block 
the interaction of hsp70 with HRI, upon its activation in the presence of denatured proteins. 
Hsc70 partially suppressed inhibition due to RCM-BSA. 
It has been hypothesized that RCM-BSA inhibits protein synthesis by sequestering 
hsc70 from HRI, and thereby activating HRI. Consistent with this hypothesis, we 
observed that exogenously purified hsc70 when added to RCM-BSA supplementedlysate 
partially reversed inhibition in protein synthesis (Fig. 17 A). In addition, exogenously 
added hsc70 also lowered eIF-2a phosphorylation and increased eIF-2B activity in RCM-
BSA treated RRL (Table III). These results support the hypothesis that denatured proteins 
activate HRI by titrating the active pool of hsc70. 
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Effect of hsc70 on heat shock induced eIF-2a phosphorylation and eIF-4E 
dephosphorylation 
The phosphorylation state of eIF-4E correlates positively with the rate of 
translation. Both the dephosphorylation of eIF-4E and the phosphorylation of eIF-2a have 
been implicated in playing a role in translational inhibition induced by heat shock in 
cultured cells (Hershey, 1991, Pain & Clemens, 1991). To examine the mechanism of 
translational arrest in heat shocked RRL, the phosphorylation status of eIF-4E and eIF-2a 
were examined in control and heat shocked hemin-supplemented RRL by pulse-labeling 
with [y-32P]ATP. Consistent with observations made in vivo, we observed that 
translational inhibition in heat shocked lysates was accompanied by dephosphorylation of 
eIF-4E (Fig. 18) and an increase in phosphorylation of eIF-2a. 
To examine the role played by hsc70 in the regulation of translation in response to 
heat shock, the effect of purified hsc70 on protein synthesis was examined in control and 
heat shocked RRL. The addition of hsc70 to heat shocked lysate only partially restored 
protein synthesis (Fig. 17B). Examination of the phosphorylation status of eIF-2a and 
eIF-4E indicated that while hsc70 suppressed the phosphorylation of eIF2a caused by heat 
shock (Table III), hsc70 had no effect on the heat-induced dephosphorylation of eIF-4E 
(Fig. 18). Consistent with its effects on eIF-2a phosphorylation, hsc70 enhanced eIF-2B 
activity when added to heat shocked RRL (Table III). These observations suggest that 
hsc70 reverses inhibition of translation caused by the activation of HRI, but has no effect 
on the translational inhibition due to the dephosphorylation of eIF-4E. 
Hsc70 lowers eIF-2cx phosphorylation and increases eIF-2B activity in heme deficient RRL 
Hsc70 has been shown to decrease the rate at which protein synthesis shuts off in 
heme deficient RRL. However, no evidence was presented that eIF-2a phosphorylation 
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was suppressed and eIF-2B activity was maintained by the addition of hsc70 to heme-
deficient RRL. Therefore, we examined the effect of hsc70 on eIF-2a. phosphorylation 
and eIF-2B activity the hallmarks of translational regulation via eIF-2a. kinase activation. 
Addition of hsc70 to heme-deficient lysate suppressed the rate at which protein synthesis 
was inhibited (Fig. 19A), decreased the level of eIF-2a. phosphorylation and increased eIF-
2B activity (Table III). These observations are consistent with the notion that the 
interaction of hsc70 with HRI suppresses HRI activation. 
YDJ-1 enhances the ability of hsc70 to maintain protein synthesis in heme deficient RRL. 
It has been previously demonstrated that DnaJ depolymerizes hsc70. As the 
purified hsc70 was partially polymerized, we examined the effect of the yeast DnaJ 
homolog, YDJ-1 on the ability of hsc70 to suppress HRI activation in RRL. We observed 
that addition of both hsc70 and YDJ-1 together to heme deficient lysate further enhanced 
protein synthesis by 20% above the effect of hsc70 alone (Fig 20). YDJ-1 alone had small 
but significant effect on protein synthesis. 
Hsc70 enhances protein synthesis in HgCb and GSSG treated hemin-supplemented RRL 
Protein synthesis also shuts off in hemin-supplemented RRL in response to eIF-2a. 
phosphorylation caused by oxidative stress. Correlative data suggests that hsp70 protects 
translation from shut-off in response to oxidative stress generated by either treatment of 
RRL with GSSG, heavy metal ions (e.g., Hg2+) or methylene blue (Ernst et al., 1978, 
Hurst et al., 1987, Kosower et al., 1972, _Matts et al., 1991). To test this hypothesis, we 
examined the effect of hsc70 on protein synthesis in hemin-supplemented RRL treated with 
either GSSG and HgCb. Hsc70 decreased the level of eIF-2a. phosphorylation, 
maintained the eIF-2B activity (Table ill), and completely suppressed inhibition of protein 
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synthesis due to HgC!i (Fig. 19B). However, while hsc70 lowered the level of eIF-2a 
phosphorylation, and increased eIF-2B activity in GSSG-treated RRL (Table III), the 
addition of hsc70 only partially protected protein synthesis from inhibition (Fig. 21). 
GSSG inhibits both the initiation and elongation phases of translation 
Unlike Hg2+, which inhibits protein synthesis in a biphasic manner that is typical of 
inhibitors that exclusively affect initiation, GSSG inhibited the translation rate from the 
beginning of the incubation, and as incubation time progressed the rate of translation 
slowly tapered off. The effect of GSSG on the initial rate of translation suggested that 
GSSG may be inhibiting translational elongation. To test this hypothesis we examined the 
polyribosomal profile of GSSG treated hemin-supplemented RRL. Relative to untreated 
RRL (Fig 22A), the polyribosomal profile of GSSG treated RRL showed an increase in 
80S ribosomes characteristic of initiation inhibition (Fig, 22B). However, large 
polyribosomes were also present after 20 min of incubation. The maintenance of 
polyribosomes under conditions where eIF-2a phosphorylation is enhanced and eIF-2B 
activity is nearly completely inhibited suggested that GSSG was causing an inhibition of 
elongation. To examine the possibility that GSSG also inhibits elongation, the 
polyribosomal profile of control and GSSG-treated hemin-supplemented RRL was studied 
in the presence of ATA, an initiation inhibitor. In the presence of AT A, the polyribosomes 
present in untreated hemin-supplemented RRL ran-off and accumulated as inactive 80S 
monomers (Fig. 22C) within 1 min of incubation (not shown). However, in the presence 
of ATA, large polyribosomes were still present in GSSG-treated RRL after 3 min of 
incubation (Fig. 22D). The failure of the polyribosomes to run-off in the presence of an 
inhibitor of initiation indicates that GSSG, besides inhibiting protein synthesis at the 
initiation stage, is also inhibiting protein synthesis at the level of elongation. The ability of 
hsc70 to lower the phosphorylation of eIF-2a and increase the eIF-2B activity, but only 
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partially reverse protein synthesis inhibition due to GSSG, suggest that hsc70 is able to 
reverse the inhibition of initiation caused by GSSG-induced HRI activation, but that hsc70 
can not reverse GSSG-induced inhibition of elongation. 
Discussion 
The data presented in this report indicate that besides suppressing the activation of 
HRI in response to heme-deficiency in RRL, hsc70 also suppresses the activation of HRI 
in hemin-supplemented RRL that occurs in response to heat shock, or the addition of 
RCM-BSA, GSSG, or Hg2+ to RRL. The ability of hsc70 to decrease the level of eIF-2a 
phosphorylation and enhance eIF-2B activity in heme-deficient RRL and in hemin-
supplemented RRL exposed to heat shock, RCM-BSA, GSSG or Hg2+ clearly indicates 
that the ability of hsc70 to suppress HRI activation is not limited to HRI activation in 
response to heme-deficiency. While, it has been previously demonstrated that hsc70 
reversed protein synthesis inhibition under heme deficiency (Gross, 1976, Gross et al., 
1994), the ability of hsc70 to maintain protein synthesis was the only criteria used in that 
report to assess the effect of hsc70 on HRI activation. We show here that hsc70 also 
lowered the amount of phosphorylated eIF-2a and also suppressed the inhibition of eIF-2B 
GDP exchange activity, besides slowing the rate of protein synthesis inhibition during 
heme deficiency. 
Heat shock inhibits protein synthesis by causing changes in the translational 
machinery at a number of levels. Heat shock induced inhibition of protein synthesis has 
been correlated with eIF-2a phosphorylation and eIF-4E dephosphorylation in cultured 
cells. Similar to the observations made in vivo, eIF-2a phosphorylation and eIF-4E 
dephosphorylation were observed in response to heat shock in RRL. Hsc70 partially 
reversed inhibition due to heat shock. This partial protection of translation can be explained 
by the observation that, while hsc70 reduced the level of eIF-2a phosphorylation, it had no 
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effect on eIF-4E dephosphorylation. Consistent with the notion that under heat shock there 
was a loss of hsc70 bound to HRI, inhibition of protein synthesis caused by HRI activation 
correlated with loss of hsc70 that was available to bind RCM-BSA indicating that heat 
shock leads to an accumulation of denatured proteins . The denatured proteins sequestered 
hsc70 from HRI, leading to the activation of HRI. Furthermore, addition of purified hsc70 
lowered eIF-2a phosphorylation and suppressed inhibition of eIF-2B catalyzed GDP 
exchange. Moreover, with increased times of incubation hsc70 lost its ability to suppress 
inhibition of eIF-2B GDP exchange activity. The inability of hsc70 to maintain translation 
suggest that hsc70 becomes limiting as more denatured proteins are produced with time. 
This is consistent with the observation that with increasing time the amount of hsc70 
available to bind to RCM-BSA under heat shock decreases. 
Hsc70 completely reversed protein synthesis inhibition due to mercury treatment. 
Heat-shock protein 70 is a stress-induced protein and is suggested to play a protective role 
against heavy metal ion treatment. It has been previously demonstrated that lysates with 
higher level of hsc70 showed higher tolerance to heavy metal ion treatment. Consistent 
with this hypothesis we observed that addition of purified hsc70 completely reversed 
protein synthesis inhibition due to mercury. In addition, purified hsc70 lowered eIF-2a 
phosphorylation and suppressed inhibition of eIF-2B GDP exchange. 
GSSG inhibited protein synthesis both at the initiation level and at the elongation 
level. Gross et al had previously concluded that GSSG could be inhibiting protein 
synthesis by a different mechanism than heme deficiency, since hsc70 slightly suppressed 
GSSG induced inhibition of protein synthesis. We observed that hsc70 partially 
suppressed GSSG induced inhibition of protein synthesis, due to its ability to suppress the 
activation of HRI. Furthermore, hsc70 was able to completely suppress the activation of 
HRI caused by Hg2+, another sulfhydryl reactive compound that inhibits protein synthesis 
exclusively at the initiation level. Hsc70 suppressed phosphorylation of eIF-2a resulting 
from GSSG and Hg2+ treatment and also suppressed inhibition of eIF-2B GDP exchange 
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activity. The ability of hsc70 to partially revert GSSG induced inhibition of protein 
synthesis could be explained by hsc70 suppressing inhibition of initiation, but having no 
effect on inhibition at the elongation level. Consistent with this hypothesis it was shown 
previously that lysates with higher level of hsp70 were more resistant to protein synthesis 
inhibition due to oxidised glutathione and mercury. 
DnaJ may also play a role in regulating HRI activation. We observed that purified 
YDJ-1 together with hsc70 increased the rate of protein synthesis in heme deficient lysate 
by 20 % more than when only hsc70 was added. The ability of YDJ-1 to suppress HRI 
activation may be due to (i) the ability of YDJ-1 to enhance the activity of added hsc70 in 
general; and/or (ii) the ability of YDJ-1 to bind to HRI and directly enhance the interaction 
of hsc70 with HRI. Our purified hsc70 preparation contained some insoluble material 
indicating that the hsc70 was partially polymerised. Previously it has been shown that 
DnaJ helps in the depolymerisation of hsc70. Since only monomeric hsc70 is functional, 
DnaJ could be enhancing the activity of hsc70 by depolymerising hsc70. The observation 
that DnaJ alone had a rather modest effect on protein synthesis in heme deficient RRL 
suggests that YDJ-1 is not a rate-limiting activity for maintaining HRI in an inactive state in 
RRL. However, we have observed that 5 % of HRI in RRL can be immunoprecipitated 
with anti-DnaJ (data not shown). This observation suggests that DnaJ might have a direct 
effect on HRI, by directing hsc70 to HRI. Also the amount of DnaJ may become limiting 
only on the addition of exogenous hsc70 particularly if the hsc70 is polymerized, since the 
polymerised hsc70 would bind endogenous DnaJ during its depolymerization. The 
relationship between DnaJ, hsc70 and HRI activation is currently under investigation. 
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Figure 15. Heat shock causes a loss in functional hsc70 pool (Courtesy of Robin Hurst). 
A) Protein synthesis was measured in standard reaction mixtures in the 
lysate 1 (heat resistant) and lysate 2 (heat sensitive) at 30 °C (A)and 41 °C 
(F). The amount of [14C]leucine incorporated into acid precipitable protein 
in a 5 µI aliquot was determined in the times indicated in the figure. B) 
Lysates 1 and 2 were incubated at either 30 °C or 42 °C. RCM-BSA or 
BSA were added at O min or 10 min. At the end of 5 min and 15 min, 
aliquots were taken and immunoabsorbed for BSA and RCM-BSA, as 
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Figure 16. Heat shock blocks the interaction of HRI with hsc70 (Courtesy of Zouyu Xu). 
Hem.in supplemented protein synthesis mixes were incubated at 30 °C or 42 
°C for 20 min followed by apyrase treatment ( one unit of apyrase per 1 Oµl 
of protein synthesis mixes) on ice for 15 min. Proteins from 10 µl of the 
apyrase treated protein synthesis mixes were adsorbed with the non-immune 
control (C) or the anti-HRI (I) mAb Fin the presence of TBS. The adsorbed 
fractions were western blotted with the 4322 anti-hsp90/hsp70 antibody to 









Figure 17. Hsc70 partially reversed inhibition due to RCM-BSA and heat shock. 
Protein synthesis mix was preincubated with either hsc70 (0.1 mg/ml; 0, 
+) or the buffer (0) for 10 mins at 30 °C. The reaction mixes were 
transferred to iceand mixed with [14C]leucine. Protein mixes were then 
either A) supplemented with BSA (0) or RCM-BSA (lmg/ml; +, 0), and 
transferred to 30 °C; or B) transferred to 30 °C (0) or 42 °C (+, 0). The 
amount of [14C]leucine incorporated into acid precipitable protein in a 5 µl 
aliquot was determined in the times indicated in the figure. 
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Figure 18. Heat shock causes eIF-4E dephosphorylation. 
Protein synthesis mixes (200 µl) were incubated at 35 °C and 42 °C in the 
presence or absence of added hsc70 (75 µg/ml). At the end of 18 min the 
reaction mix was pulsed with 0.2 mCi of y'2P ATP and transferred to ice at 
the end of 23 min. eIF-4E was adsorbed tom 7GTP-Sepharose for 2 hrs at 4 
°C. Pellets were extensively washed and eIF-4E eluted with m7GTP. The 
pellets and the m 7 GTP eluent were then run on a 10% gel. 
Pellet m7GJP eluent 
35° I 42° 35° 
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Figure 19. Hsc70 reverses inihibition due to heme deficiency and Hg++ treatment. 
A) Protein synthesis was carried out in the presence (0) and absence ( 0 
+) of heme at 30 °C, with (0 +) or without ( 0) the addition of purified 
hsc70 (0.05 mg/ml). B) Heroin-supplemented protein synthesis mixes were 
incubated at 30 °C in the presence ( 0 +) or absence (0) of 20 µM HgCl2 
with ( +) or without ( 0) the addition of purified hsc70 (0.05 mg/ml). 
Protein synthesis was measured by following incorporation of [14C]leucine 
into acid-precipitable protein at the times indicated. 
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Figure 20. Effect of YDJ-1 and hsc70 on protein synthesis in heme deficient RRL. 
Protein synthesis mixes were carried out in the presence ( 0) or absence ( <>, 
+, X, .6.) of heme at 30 oc, with ( 0, +, .6.) or without ( <>, X) the 
addition of purified hsc70 (0.1 mg/ml) or YDJ-1 (6 µg/ml; 0, +, X). 
Protein synthesis was measured by following incorporation of [ 14qleucine 
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Figure 21. Hsc70 partially reversed protein synthesis inhibition due to GSSG. 
A) Hemin-supplemented protein synthesis mixes were incubated at 30 °C in 
the presence (0, +) or absence (0) of 1.6 mM GSSG with (0, +) or 
without ( 0) the addition of purified hsc70 (0.05 mg/ml). Protein synthesis 
was measured by following incorporation of [14C]leucine into acid-
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Figure 22. Ribosome profile of GSSG treated lysates (Courtesy of Yan Gu). 
Protein synthesizing lysates were incubated for 20 min with no addition (A) 
or with 1.3 rnM GSSG (B). Samples were diluted and centrifuged for 1 hr 
in sucrose gradients as described before. 
Protein synthesis mix supplemented with 120 µMATA were incubated in 
the presence (D) and absence (C) of 1.3 mM GSSG for 3 min at 30 °C. 
Samples were diluted with gradient buffer and supplemented with 
























Table III. Effect of hsc70 on eIF-2a phosphorylation and eIF-2B exchange under 
different stress condition. 
Heme-deficient protein synthesis mixes(experiment 1) were incubated at 30 
~C in the presence or absence of hsc70 (0.1 mg/ml). After 5 min, an 
aliquot of the reaction mix was analysed for eIF-2B activity. At the end of 
10 min, an aliquot of the reaction mix was taken for analysis of eIF-2a 
phosphorylation by IEF. With the exception of heme deficiency (experiment 
1) in all the other experiments hemin supplemented protein synthesis mixes 
with added hsc70 (0.1 mg/ml) or the buffer were preincubated for 10 min at 
30 °C to activate the hsc70, before exposure to different stress agents. After 
5 mins of incubation in the presence of HgCli, GSSG, 42 °C, or RCM-BSA 
(experiment 2, 3, 4, and 5), aliquots were taken for analysis of eIF-2a 
phosphorylation and eIF-2B activity. Experiments were repeated twice with 
similar results. 
Treatments eIF-2a Phosphorylation % inhibition of GDP 
O.Dxmm2 exchange 
Experiment 1 a Experiment 1 b 
-heme 2.475 100 
-heme + hsc70 1.588 29 
Experiment 2a Experiment 2b 
HgCh(lOµM) 0.099 64 
HgCh +hsc70 0.005 3 
Experiment 3a Experiment 3b 
GSSG (l.6mM) 0.238 106 
GSSG+hsc70 0.022 60 
Experin_ient 4a Experiment 4b 
42°c 0.387 94 
42 oc + hsc70 0.125 3 
Experiment Sa Experiment Sb 
RCM-BSA (l.S mg/ml) 0.300 56 
RCM-BSA + hsc70 0.101 1 
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CHAPTERV 
EFFECT OF HSC70 BINDING AGENTS ON PROTEIN SYNTHESIS, FOLDING, 
AND RENATURATION 
Introduction 
The hsp70 family of molecular chaperones is ubiquitous and highly conserved with 
diverse biochemical roles both under normal growth conditions and under cellular stress 
(Craig et al., 1994, Hendrick & Hartl, 1993). In cooperation with other chaperones, 
Hsp70 facilitates assembly and disassembly of proteins, protein renaturation, preventing 
aggregation of denatured proteins, and chaperones the transport and folding of newly 
translated polypeptides in the cytosol as well as within organelles. The hsp70s in 
mitochondria and the endoplasmic reticulum play an additional role by providing a driving 
force for protein translocation (Hohfeld & Hartl, 1994, Stuart et al., 1994). A link 
between the function of the hsp70 class of chaperones and cellular proteolysis has also 
been demonstrated (Craig et al., 1994). Finally, hsp70s are involved in signal transduction 
pathways in cooperation with hsp90 (Bohen & Yamamoto, 1994, Rutherford & Zuker, 
1994). 
Hsp70 recognizes short peptides (of at least seven amino acid residues) enriched in 
hydrophobic residues (Blond-Elguindi et al., 1993, Flynn et al., 1991, Takenaka et al., 
1995). Peptide binding is modulated by ATP. The ATP-bound form of hsp70 binds and 
releases peptide rapidly, whereas the ADP-bound form binds and releases peptide slowly. 
Cycling of the hsp70 homolog DnaK between these nucleotide states depends on its 
interaction with regulatory proteins such as DnaJ and GrpE of E.coli. DnaJ activates the 
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ATPase of the bacterial hsp70 homolog DnaK. Unlike hsp70, DnaJ has more affinity for 
protein substrates exhibiting secondary and tertiary structure, but exhibits very low affinity 
for polypeptides in extended conformations. The ability of DnaJ to stimulate DnaK's 
substrate binding properties correlates with DnaJ's affinity for the various protein 
substrates. Specifically, DnaJ will activate DnaK to bind to a substrate for which DnaJ has 
a high affinity, but will effectively stimulate release of DnaK from substrates for which 
DnaJ has low affinity (Cyr et al., 1994). 
GrpE functions as a nucleotide exchange factor allowing rebinding of ATP that in 
turn promotes substrate dissociation. Recently, p60 has been identified as a potential 
eukaryotic homolog of GrpE. DnaJ homologs have been identified in all compartments of 
eukaryotic cells that contain hsp70, Recently, a novel hsc70-interacting protein Hip (p48) 
has been identified in the mammalian cytosol. Hip stabilizes the ADP state of hsc70 that 
has a high affinity for protein substrates. Hip functions both as regulator of hsc70 and as a 
molecular chaperone. 
In this study we have investigated the relationship between the regulation of protein 
synthesis and the ability to fold nascent polypeptides and renature denatured proteins. 
Rabbit reticulocyte lysate (RRL) was used as the model system because of its unique 
capabilities for in vitro protein synthesis. In addition RRL contains high amounts of 
molecular chaperones that are involved in protein folding. Luciferase was used as the 
model protein to study the role of hsc70 in chaperoning protein folding and renaturation, 
because of its rapid and sensitive luminescence assay. In RRL, protein synthesis is 
regulated at the initiation level by the heme regulated inhibitor (HRI). HRI, on activation 
phosphorylates the a subunit of eIF-2 and effectively stops protein synthesis at the 
initiation level (Levin et al., 1976, Ranu & London, 1976). Previous results indicate that 
hsc70 negatively regulates HRI. Thus, drugs which inhibit hsp70 function would be 
predicted to inhibit protein synthesis. Similarly, a requirement for hsc70 in protein folding 
in the cytosol has been demonstrated (Frydman et al., 1994). Hsc70 appears to act at the 
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earlier stages of protein folding when the polypeptide backbone is still in an extended 
conformation (Beckman et al., 1990, Frydman et al., 1994). In this report different hsc70 
binding agents were used to determine the importance of hsc70 in the folding and 
renaturation of luciferase. The effects of different hsc70 binding agents on protein 
synthesis, luciferase folding and renaturation were compared. We observed that all agents 
which inhibit the folding of nascent luciferase activate HRI and inhibit protein synthesis. 
In contrast, peptide FYQLALT and geldanamycin which inhibited luciferase renaturation, 
did not inhibit either folding of nascent Juciferase or protein synthesis. These findings 
suggest that the rate of protein synthesis is coordinated with the ability to fold newly 
synthesized protein. 
Materials and methods 
Materials 
Aspirin, indomethacin, ibuprofen, clofibric acid, creatine phosphokinase (Type I), 
bovine serum albumin (acetylated), luciferin, and luciferase were obtained from Sigma. 
PepN (NIVRKK), pepF (FYQLALT), and pepSH3 (SPPTPKPRPPRPLPVAPGS) were 
obtained from Sarkeys Biotechnology Research Laboratory (OSU). L-[14C]Leucine and L-
[35S]Methionine were purchased from Du Pont-NEN. TnT coupled retictilocyte lysate and 
affinity pure anti-luciferase antibody were obtained from Promega. Geldanamycin (GA) 
was provided by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics 
Program, Division of Cancer Treatment, National Cancer Institute. The F5 anti -p60 and 
the JJ3 anti-p23 monoclonal antibodies (mAbs) were provided by David Smith (U. of 
Nebraska, Omaha) and David Toft (Mayo Medical School, Rochester, MN), respectively. 
The 4322 anti-hsp70/90 and anti-hsp90 (84/86) antiserum was provided by Stephen 
Ullrich, NCI. Anti-luciferase affinity purified polyclonal antibodies was purchased from 
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Promega. N27 anti-hsp70 mAb was purchased from StressGen. Anti-OnaJ were provided 
by William Welch (University of California, San Francisco). 
Buffers 
The buffers used were as follows: Assay buffer (AB) consisting of 25 mM Tricine-
HCl (pH 7.8), 8 mM MgS04, 0.1 mM EOTA, 33 mM OTT, 470 µM 0-luciferin, 240 µM 
coenzyme A, and 0.5 mM ATP; stability buffer (SB) consisting of 25 mM Tricine-HCl (pH 
7.8), 8 mM MgS04, 0.1 mM EOTA, 10 mg/ml bovine serum albumin, 10% glycerol, and 
1 % Triton X-100; Tris buffer (TB) consisting of 10 mM Tris-HCl (pH 7.4); Tris buffered 
saline (TBS) consisting of TB and 150 tnM NaCl; TB/500 consisting TB and 500 mM 
NaCl; and TB/50 consisting of TB and 50 mM KCl; TBS detergent buffer (TBSO) 
consisting of TBS and 1 % deoxycholate, 1 % Triton X-100. and 0.1 % SOS. 
Luciferase renaturation assay 
Firefly luciferase (0.5 mg/ml) in SB (unless otherwise specified) was denatured by 
incubation at 41° C for 10 min (Schumacher et al., 1994). After being cooled on ice, 
aliquots were diluted 20-fold into heme-deficient protein synthesis mixes (Matts et al., 
1991) containing 10 mM creatine phosphate, 20 U/ml creatine phosphokinase. Samples 
were incubated at 28°C for 10 min, luciferase activity present in 1.5 µl aliquots was 
determined by dilution into 50 µI AB. Light production was measured for 10 sec in a 
Lumac (3M) Bioluminometer. 
De novo folding of luciferase 
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Luciferase was synthesized in TNT lysate at 30°C. After 10 min, translational 
reactions were synchronised by the addition of aurintricarboxylic acid to inhibit re-
initiation. Protein synthesis reactions were then incubated for 6 min to allow 
polyribosomes to run off. Following run off, the different hsp70 binding agents were 
added to the lysates. Protein synthesis was monitored by incorporation of [35S]met into 
TCA-insoluble material. At various time points the luciferase activity present in 1.5µ1 
aliqouts was determined by dilution into 50 µI AB. Light productions was measured for 10 
sec in a Lumac (3M) Bioluminometer. 
Immunoadsot:ptions of proteins 
Affinity pure anti-luciferase antibody (1 µI) was adsorbed to 20 µl of anti-rabbit 
IgG-agarose in the presence or absence ( control) of luciferase (10 µg) for 2 hr on ice as 
described previously. Heme-deficient protein synthesis mix (30 µI), which had been 
preincubated for 10 min at 30 °C with different drugs, were added to the agarose pellet. 
The mixtures were incubated for 10 min at 30 °C with periodic mixing to prevent settling of 
the agarose. The unadsorbed proteins were separated from adsorbed proteins (pellets) by 
centrifugation. Pellets were washed with 750 µI of TB/50, three times with TBSD, and 
once with TB/50. 
eIF-2cx phosphorylation 
RRL's were incubated under protein synthesis condition at 30 °C for 10 min in the 
presence of the various drugs. Two µI of these mixes were then separated on an isoelectric 
focussing gel, western blotted and analysed for phosphorylation of eIF-2cx, as described 
previously (Maurides et al., 1989). 
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eIF-2cx GTP/GDP exchange 
RRL's were incubated under protein synthesizing conditions at 30 °C in the 
absence of [14C]Leucine as described (Hunt 1972, Ernst 1978). The rate at which 
[3H]GDP was exchanged from pre-formed eIF-2•[3H]GDP complexes were measured as 
described previously (Matts & London, 1984). At the times indicated, 50 µl of PS mix 
was mixed with 130 µl of ice cold dilution buffer ( 40 mM Tris HCl, pH7.4, 100 mM 
KCl, 50 mM KF, 2 mM Mg(OAc)2, 10% glycerol, 40 µM GDP), and 20 µl of preformed 
eIF2•[3H]GDP complex. Reactions mixes were then incubated at 30 °C for another 2 min. 
Exchange assays were stopped by the addition of 1 ml ice cold wash buffer, followed by 
filtration of the reaction mixture through nitrocellulose filters (HA WP 02500, Millipore) 
which rapidly binds the remaining eIF-2•[3H]GDP complex. Filters were washed with 15 
ml of ice cold wash buffer to remove any unbound [3H]GDP. 
Polyribosomal gradients 
Protein synthesis mixes (100 µl) were pretreated with different drugs for 20 min at 
30 °C. These reaction mixes were diluted with 150 µl of ice cold gradient buffer and 
layered over a 15-40% (w/v) sucrose gradient and centrifuged for 1 hat 45,000 rpm in a 
Sorvall AH-650 rotor. Polyribosomal profile in the gradient was analyzed as described 
previously (Matts et al., 1991). Since the drugs showed accumulation of polyribosomes, 
polyribosomal profiles were also studied in the presence of ATA, an initiation inhibitor, to 
determine if the large polyribosomes that accumulated in the presence of some of the drugs 
ran off with time. Failure to run off indicates an inhibition of the elongation phase of 
translation. Protein synthesis mixes, supplemented with various drugs and 120 µMATA, 
were incubated at 30 °C for 1.5 min. 
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Western blot analysis 
Samples were prepared for SOS-PAGE, separated in 10% gels, and transferred to 
PVDF membrane as previously described (Matts & Hurst, 1992, Matts et al., 1992). 
Hsp70 and DnaJ was detected with N-27 and anti-DnaJ respectively. 
Results 
Effect of pharmacological agents on the folding and renaturation of luciferase. 
To determine whether hsc70 could be pharmacologically inhibited in RRL, we 
examined the effect of a number of agents on two processes that are known to require 
hsc70: folding of newly synthesized protein and protein renaturation. Agents were selected 
because they had been demonstrated to interact with hsc70 in vitro, or we predicted that 
they might do so. The effect of the agents on both the folding of newly synthesized protein 
and protein renaturation was examined because previous results with the hsp90 binding 
drug geldanamycin (Chapter III) indicated that pharmacological agents exist that 
differentially inhibited the two processes. 
Clofibric acid (CIA) an hsc70 binding agent, inhibits luciferase folding and 
renaturation - CIA, a pharmacological agent that causes peroxisomal proliferation, has been 
demonstrated to be a specific hsc70 binding drug. Therefore, we examined whether the 
binding of CIA to hsc70 inhibited its function. CIA was observed to be a strong inhibitor 
of both the folding of newly synthesized luciferase and renaturation thermally denatured 
luciferase (Figure 23A and 24A). 
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Nonsteroidal anti-inflammatory drugs inhibit luciferase folding and renaturation -
Aspirin, ibuprofen, and indomethacin are nonsteroidal anti-inflammatory drugs (NSAD) 
used to treat inflammation and other chronic diseases (Wiessman 1991). NSAD's are 
inhibitors of cyclooxygenase, with the order of potency of inhibition as indomethacin > 
ibuprofen > aspirin. It has been shown previously that salicylate and indomethacin 
treatment induces DNA binding activity of heat shock factor 1 (HSFl) (Jurivich 1992, Lee 
1995). These drugs potentiate the effect of heat shock, by maintaing the HSFl in the 
activated DNA-binding state for a period twice as long as the control, resulting in enhanced 
and prolonged hsp70 mRNA transcription. Hsp70 has been suggested to negatively 
regulate HSFl DNA binding activity, and it has been proposed that one mechanism 
through which heat shock causes the activation of HSFl, is by titrating functional hsp70 
with denatured protein (Abravaya et al., 1992). This hypothesis is further supported by the 
observation that constitutive overexpression of the major inducible heat shock protein, 
hsp70, in transfected human cells reduces the extent of HSFl activation after a heat stress 
(Mosser et al., 1993). Thus, one mechanism by which NSAD agents might potentiate the 
DNA binding activity of HSF-1 is through their ability to interfere with hsc70 function. To 
test the hypothesis that NSAD agents are hsp70 inhibitors, we examined the effects of 
salicylic acid, ibuprofen and indomethacin on luciferase folding and renaturation, which are 
hsc70 dependent processes. Luciferase folding (Fig 23A) and renaturation (Fig 24A) 
processes were observed to be strongly inhibited by NSAD agents. Similar to the order of 
potency for NSAD-induced inhibition of cyclooxygenase and activation of HSF-DNA 
binding activity (Jurivich et al., 1992, Lee et al., 1995, Weissman, 1991), indomethacin 
showed a stronger inhibition than ibuprofen, which was a stronger inhibitor than salicylate 
in luciferase folding and renaturation. 
Effects of peptides and unfolded protein on luciferase folding and renaturation -
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Through the use of phage display peptide libraries, the binding specificities of 
hsp70 family members have been defined (Blond-Elguindi et al., 1993, Gragerov et al., 
1994). Hsp70 family members bind to peptides of seven amino acids in length or longer. 
The best defined specificity is that of alternating large hydrophobic amino acids. The 
peptide FYQLALT (pepF) is optimal for binding to hsc70. Recently, it has been shown 
that basic amino acids C-terminal to several hydrophobic residues, such as NIVRKK. 
(pepN), also have a very high affinity for hsc70. 
Peptides- pepSH3 and pepN strongly inhibit both luciferase folding and 
renaturation- Since hsc70 has a very high affinity for both pepN and pepF, we examined 
whether these peptides could interfere with the function of hsc70. Consistent with this 
hypothesis, we find that pepN strongly inhibits both luciferase folding (Fig 23A) and 
renaturation (Fig 24A), processes known to involve active hsc70 (Frydman et al., 1994, 
Schumacher et al., 1994). Another peptide, SPPTPKPRPPRPLPVAPGS (pepSH3) 
which like pepN, contains both hydrophobic and basic amino acids also inhibited luciferase 
folding and renaturation. PepSH3 was observed to be a slightly stronger inhibitor than 
pepN in renaturation (Table IV). However, unlike the basic peptides pepN and pepSH3 
which inhibit both luciferase folding and renaturation, the high affinity hydrophobic pepF 
had no effect on luciferase folding, but strongly inhibited luciferase renaturation. The IC50 
for luciferase renaturation by pepF was 0.3mM, which is 10 times lower than the IC50 for 
pepN (Table IV). 
RCM-BSA slowed the folding of luciferase and had selective effect on luciferase 
renaturation - The addition of RCM~BSA has been shown to bind hsc70, and block the 
interaction of hsc70 with the heme-regulated eIF-2cx kinase, and inhibit protein synthesis. 
To confirm the role of hsc70 in chaperoning the folding of nascent polypeptide chains and 
protein renaturation, we examined the effect of RCM-BSA on the folding of newly 
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synthesized luciferase and renaturation of thermally denatured luciferase. Sequestration of 
hsc70 by the addition of RCM-BSA in reticulocyte lysate significantly delayed the time 
between completion of luciferase synthesis and the acquisition of enzymatic activity (Fig 
23B). However, RCM-BSA needed to be added at much earlier times than pepN for 
RCM-BSA to have an effect on luciferase folding. In contrast to pepN, RCM-BSA added 
after the completion of luciferase synthesis did not delay the folding of luciferase. 
Similarly, RCM-BSA had no effect on the initial rate of renaturation of luciferase that had 
been denatured in the presence of TritonX-100 and glycerol, unless lysate was pre-
incubated with RCM-BSA for 20 min prior to the renaturation assay. Little or no pre-
incubation of RRL with RCM-BSA was required for RCM-BSA to inhibit the renaturation 
ofluciferase that had been denatured in the absence of TritonX-100 and glycerol (Fig 24B). 
Analysis of luciferase sedimentation velocity in glycerol gradients indicated that luciferase 
that was denatured in the absence of TritonX-100 and glycerol was present in much larger 
aggregates than luciferase denatured in the presence of these agents. 
NSAD, peptides and clofibric acid inhibit the interaction of hsp70 with the denatured 
luciferase. 
While it has been previously demonstrated that peptides and RCM-BSA inhibit the 
interaction of hsc70 with substrates, it is not known whether CIA or NSAD agents inhibit 
the interaction of hsc70 with substrates. Therefore, we examined the interaction of hsc70 
with denatured luciferase in the presence of these drugs. Hsc70 was coimmunoprecipitated 
with denatured luciferase in the presence of inhibiting concentration of different drugs in 
RRL (Fig 25). ClA and NSAD agents clearly inhibited the interaction of hsc70 with 
denatured luciferase, in a manner similar to that observed for the peptides and unfolded 
proteins. 
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Effect of the pharmacological agents and peptides on protein synthesis. 
In the last chapter, it was shown that hsc70 has a positive effect on translation, 
stimulating protein synthesis under a variety of stress conditions by negatively regulating 
HRI. Therefore, it would be predicted that pharmacological agents and peptides which 
inhibit hsp70 function may inhibit protein synthesis. Hence, we examined the effect of 
pharmacological agents and peptides on protein synthesis. 
All the drugs used. except pepF. inhibited protein synthesis- CIA, indomethacin, 
ibuprofen, and salicylate all inhibited protein synthesis. The potency of the NSAD as 
inhibitors of translation correlated with their potency in inhibiting protein folding and 
renaturation. Indomethacin was the strongest inhibitor of protein synthesis among NSAD 
agents, followed by ibuprofen, with salicylic acid being the weakest inhibitor (Table IV). 
Similar to RCM-BSA, pepN (Fig 26A) and pepSH3 inhibited protein synthesis. However, 
the hydrophobic peptide, pepF was observed to have no effect on protein synthesis (Fig 
26B). 
Polysomal profiles indicated that most of these drugs inhibited protein synthesis 
both at the initiation and elongation level - Unlike RCM-BSA which inhibited protein 
synthesis with biphasic kinetics, a characteristic of inhibition at the initiation level, all the 
other drugs examined showed more linear inhibition. This observation suggested that 
elongation rate was also being inhibited. Therefore, to examine the mechanism of 
inhibition induced by these agents, polysomal profiles were analysed. Polysomal profiles 
indicated accumulation of 80S ribosomes in the presence of all the agents except for pepF 
(Fig 27 A), indicating inhibition at the injtiation level. In addition, NSAD, CIA and pepN 
(Fig 27B) and pepSH3 also showed accumulation of the larger polyribosomes. 
Polyribosome run off experiments were performed to determine whether inhibition at the 
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elongation step was also occuring. The polyribosomes present in ibuprofen and pepF (Fig 
27C) treated lysates ran off at the end of 1.5 min, with all the polyribosomes accumulating 
the SOS ribosome complex, indicating that the polysomes observed in the absence of AT A 
were due to an incomplete inhibition of initiation. Whereas in the presence of pepSH3, 
pepN (Fig 27D), CIA, salicylic acid, and indomethacin the polyribosomes did not run off. 
A significant amount of larger polyribosomes were observed, indicating an inhibition of 
elongation. 
Effect of the pharmacological agents and peptides on eIF-2a phosphorylation and 
the guanine nucleotide exchange activity of eIF-2B- To confirm that protein synthesis is 
inhibited at the initiation level due to the phosphorylation of eIF-2a, isoelectric focussing 
was performed to examine the phosphorylation state of eIF-2a. With the exception of 
pepF which was not inhibitory to protein synthesis, all of the other agents increased the 
phosphorylation level of eIF-2a (Table V). 
NSAD, CIA, RCM-BSA and peptides, except for pepF, inhibited the eIF-2B 
GDP/GTP exchange - Exchange of bound GDP for GTP in the recycling of eIF-2 is 
catalyzed by eIF-2B. Phosphorylation of eIF-2a inhibits exchange GTP for GDP, because 
phosphorylated eIF-2 binds and sequesters eIF-2B in a poorly dissociable complex. To 
further confirm that these agents were causing eIF-2a to be phosphorylated to a level that 
was sufficient to inhibit eIF-2B activity and consequently the initiation of protein synthesis, 
the ability of RRL treated with these agents to catalyze guanine nucleotide exchange was 
determined. CIA, NSAD, pepN, pepSH3, and RCM-BSA inhibited eIF-2B catalyzed 
exchange of GDP from eIF-2 (Table VI), confirming that the phosphorylation of eIF-2 
induced by these agents was sufficient to inhibit initiation of translation. Consistent with 




We have examined the importance of hsc70 in protein synthesis, folding and 
renaturation, by using different agents that interact with hsc70. The binding of hsc70 to 
RCM-BSA, pepN, pepF, and clofibric acid has been documented previously (Alvares et 
al., 1990, Huang et al., 1994, Matts et al., 1993, Takenaka et al., 1995). Clofibric acid 
and non steroidal anti-inflammatory drugs aspirin, ibuprofen and indomethacin, completely 
inhibited the binding of hsc70 to denatured luciferase (Fig 25). In addition to inhibiting the 
interaction of hsc70 with denatured luciferase, these drugs also lowered the nonspecific 
interaction of hsc70 with control antibodies. This observation suggests that these drugs 
inhibit the binding of hsc70 to any substrate. The ability of these drugs to inhibit the 
binding of hsc70 to substrate might be through the ability of these agents to bind to the 
substrate binding site of hsc70, or through their binding to a different site (eg. the ATP 
binding site) which allosterically affects the hsc70 substrate binding site. 
The ability of the peptides to inhibit luciferase renaturation correlated with their 
hydrophobicity; the order of inhibitory potency of the peptides were pepF > pepSH3 > 
PepN. In contrast, pepF did not inhibit either de nova folding of luciferase or protein 
synthesis. Hsc70 complexed to pepF moves faster than uncomplexed hsc70, and 
uncomplexed hsc70 moves faster than hsc70 complexed to pepN in a non-denaturing gel 
(Takenaka et al., 1995). These observations indicate that these peptides are bound to hsc70 
molecules that are in different conformations, and hence may affect the function of hsc70 
differently. Moreover pepN is a weaker stimulator of the hsc70 ATPase activity compared 
to pepF (Takenaka et al., 1995). In addition, pepN has sequence similarity with HDJ-2, a 
DnaJ homolog from humans (Takenaka et al., 1995). Similarity of pepN with HDJ-2 
suggests that pepN could be binding to the DnaJ binding site on hsc70, thus preventing 
DnaJ from binding to hsc70. Interaction between DnaJ and hsp70 is important because 
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hsp70 does not bind compact protein-folding intermediates with high affinity. DnaJ 
recognizes structural features of compact protein folding intermediates and stabilizes them 
in a conformation in which binding sites for hsp70 are exposed, and thus facilitates DnaK 
binding to substrate. Therefore, it is likely that inhibition of hsc70 will have different 
consequences depending on the conformation of the inhibited hsc70. 
RCM-BSA inhibited the folding of luciferase only when added during the synthesis 
of luciferase. RCM-BSA added in the later stages of folding did not inhibit luciferase 
folding. This observation suggests that nascent proteins have higher affinity for hsc70 than 
RCM-BSA, and that RCM-BSA needs to be added earlier to successfully compete for and 
sequester the active pool of hsc70. This is consistent with the observation that RCM-BSA 
inhibits luciferase renaturation only when the lysate is preincubated with RCM-BSA prior 
to the addition of denatured luciferase. This observation again suggests that denatured 
luciferase is a better substrate for hsc70 than RCM-BSA. Less preincubation was required 
for RCM-BSA to inhibit luciferase renaturation when luciferase is denatured in the absence 
of triton and glycerol, suggesting that the luciferase that is more highly aggregated may 
titrate hsc70 faster and have an additive effect to RCM-BSA and inhibit renaturation of 
soluble denatured luciferase further. 
Affinity of hsc70 for luciferase versus RCM-BSA may reflect the affinity of DnaJ 
for the two proteins, because DnaJ stabilizes complexes between hsp70 and the substrate 
proteins for which DnaJ has high affinity. In contrast, DnaJ stimulates dissociation of 
complexes between hsp70 and the substrate polypetides for which DnaJ has low affinity. 
DnaJ binds protein substrates exhibiting secondary and tertiary structures, like denatured 
luciferase and folding intermediates of nascent luciferase, but exhibits very low affinity for 
polypeptides in extended conformation like CMLA (Cyr et al., 1994, Wawrzynow et al., 
1995). Since hsp70 can bind to polypeptides with extended conformation preincubation 
may be required because of the slow binding of hsc70 to RCM-BSA in the absence of the 
interaction of DnaJ. 
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Non steroidal anti-inflammatory drugs potentiate the heat shock response by 
inducing HSFl DNA binding activity. One potential mechanism of action for NSAD may 
be through their ability to inhibit the chaperone function, since hsc70 has been suggested to 
be the negative regulator of HSF-1. Consistent with this possibility NSAD: (i) inhibited 
the interaction of hsc70 with denaturing luciferase; (ii) inhibited folding and renaturation of 
luciferase; and (iii) inhibited protein synthesis - processes which are known to require 
hsc70. Moreover, in the presence of higher doses of NSAD and clofibric acid, we 
observed that the background level of active folded luciferase is also reduced during de 
novo folding of luciferase. This is consistent with the observation that luciferase is not 
stable above 28 °C. At temperatures above 28 °c, hsc70 is required to maintain luciferase 
in an active folded conformation. In the presence of these agents the activity of existing 
luciferase is lost as it denatures and no hsc70 is available to renature the enzyme. 
The data presented in this report indicate that chaperones which are involved in 
nascent protein folding are also intimately involved in the regulation of protein synthesis 
(Table VII). All agents tested that inhibited de novo folding of nascent luciferase also 
activated HRI and inhibited protein synthesis. However, not all agents that inhibited 
renaturation of thermally denatured luciferase inhibit de novo folding of luciferase or 
protein synthesis (Table VII). Geldanamycin (GA) an hsp90 binding drug, inhibits 
luciferase renaturation, but has no effect on protein synthesis or de novo luciferase folding 
(Thulasiraman et al., Submitted). Similarly, pepF did not inhibit the folding of nascent 
luciferase or protein synthesis. These observations are consistent with the finding that 
protein renaturation and de novo protein folding do not follow identical folding pathways 
(Frydman & Hartl, 1996, Thulasiraman et al., Submitted). This suggests that protein 
synthesis is coordinated with the ability to fold newly synthesized polypeptides. Thus 
protein synthesis becomes inhibited when the cell cannot fold the newly synthesized 
proteins. Agents that inhibit protein renaturation may also cause protein synthesis to 
become inhibited, when the amounts of denatured protein accumulates to a level that 
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sequesters sufficient amount of chaperones that then interfere with nascent protein folding. 
The ability of the protein synthesis inhibitor cycloheximide to protect cells from the toxic 
effects of heat shock (Lee et al., 1994) suggests that misfolded newly synthesized proteins 
are cytotoxic to cells. The ability of a cell to shut down protein synthesis may then be a 
critical mechanism for maintaining cell viability under adverse environmental conditions. 
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Figure 23. Effect of drugs on luciferase folding. 
After 10 min of luciferase synthesis in TnT lysate at 30 °C, protein synthesis 
was inhibited at the initiation level by the addition of ATA. Polyribosomes 
were allowed to complete the synthesis and run off of luciferase for another 
6 min. Water, 15 mM clofibric acid, 20 mM salicylic acid, 3.5 mM 
ibuprofen, 1.5 mM indomethacin, 10 mM pepSH3, 5 mM pepN, 0.5 mM 
pepF, or 5 µM geldanamycin were then added and aliquots were taken at 16 
min and 23 min for determining protein synthesis and luciferase activity. 
Amount of protein synthesis under different conditions were similar. To 
determine the effect of BSA and RCM-BSA in luciferase folding, luciferase 
was allowed to synthesize for 6 min, followed by the addition of AT A, 
edeine and BSA/RCM-BSA (44 µM). Aliquots were taken at 18 min and 
22 min for determining protein synthesis and luciferase activity. Protein 
synthesis under these two conditions were similar. 
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Figure 24. Effect of drugs on luciferase renaturation 
A) Thermally denatured luciferase (lµl of lmg/ml) was added to 20 µl of 
heme-deficient protein synthesis mixes containing either no additions or, 4 
mM pepSH3, 6 mM pepN, 0.4 mM pepF, 17 mM clofibric acid, 20 mM 
salicylic acid, 3.3 mM ibuprofen, 1.3 mM indomethacin, or 0.7 µM 
geldanamycin. After 10 min the amount of luciferase renatured was 
measured. B) Luciferase which was denatured in.the presence or absence of 
triton and glycerol was added to heme deficient protein synthesis mixes 
preincubated with RCM-BSA or BSA for 20 min or O min at 30 °C. The 
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Figure 25. Effect of the drugs on the interaction of hsc70 with luciferase. 
Luciferase was adsorbed to affinity-purified anti-luciferase antibody bound 
to GaR-agarose as described previously. The immobilized luciferase was 
incubated for 10 min at 30 °C in heme-deficient protein synthesis mixes that 
were preincubated for 10 min at 30 °c in the presence either DMSO (lane 
1), 1 mM pepF (lane 2), 69 µM BSA (lane 3), 69 µM RCM-BSA (lane 4), 
no addition (lane 5), 10 mM pepN (lane 6), 20 mM pepSH3 (lane 7), 60mM 
salicylic acid (lane 8), 10 mM ibuprofen (lane 9), 6.5 mM indomethacin 
(lane 10), or 60 mM clofibric acid (lane 11). The agarose pellets were 
washed, and analyzed by SOS-PAGE and western blotting as described 
under "Materials and Methods". The experiment was repeated two times 
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Figure 26. Effect of drugs on protein synthesis (Courtesy of Yan Gu). 
A) Protein synthesis mixes supplemented with O mM (.6.), 1.25 mM (0), 2.5 
mM (+), 3.75 mM (A), and 5mM (+) concentration of pepN, were 
incubated at 30 °C. Protein synthesis was measured by following 
incorporation of [14C]leucine into acid-precipitable protein at the times 
indicated. B) Protein synthesis mixes supplemented with no addition (0) or 
0.33mM pepF ( +) were incubated at 30 °C. Protein synthesis was measured 
by following incorporation of [35S]methionine into acid-precipitable protein 
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Figure 27. Ribosome profile of ribosomes in sucrose gradients (Courtesy of Yan Gu). 
Protein synthesizing mixes supplemented with either 0.25 mM pepF (A) or 5 
mM pepN (B) were incubated at 30 °C for 20 min. Samples were diluted and 
centrifuged for 1hr in sucrose gradients as described previously. 
Protein synthesis mixes supplemented with 120 µM AT A and with either 
0.25 mM pepF (C) or with 5 mM pepN (D) were incubated at 30 °C for 1.5 
min. Samples were diluted with gradient buffer and supplemented with 
cycloheximide (0.4 mM). Samples were centrifuged for 1 hr in sucrose 
gradients. 
A C 60s 80s 
~f ts tos 
l-polyribosome-1 l-polyribosome-1 





Table IV. IC50 for protein synthesis inhibition and luciferase renaturation for the drugs: 
Protein synthesis was carried out in the presence of varying concentrations 
of different drugs, as described for pepN in fig 26. The concentration of 
drug required to inhibit protein synthesis by 50% relative to the control 
(IC50) was estimated from plots of drug concentration vs % inhibition. 
Similarly renaturation of thermally denatured luciferase was carried out in 
the presence of varying concentrations of each drug and their IC50 was 
determined. 
.. ,,_........-
Drugs ICSO for protein ICSO for luciferase 
synthesis (mM) renaturation (mM) 
pepN 4.2 3 
pepF NA 0.3 
SH3 6 2 
ClA 8 11 
aspirin 17 23 
ibuprofen 5 3.33 
indomethacin 2.8 1.3 
Geldanamycin NA 0.0002 
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Table V. Effect of the drugs on the phosphorylation of eIF-2a. 
Protein synthesis mixes were supplemented with no addition (none), 
clofibric acid, NSAD's, pepN, pepF, SH3, RCM-BSA, and incubated at 30 C 
for 10 min. Protein synthesis mix (2µ1) was mixed with IEF buffer and run 
on IEF gels and transferred onto a membrane and western blotted for eIF-2a. 
The values in the table indicate the densitometric reading of the 
phosphorylated band of eIF-2a. 




10 mM clofibric acid 1.149 
20 mM salicylic acid 0.705 
1. 7 mM ibuprofen 0.678 
0.9 mM indomethacin 1.009 
pepF 0.087 
3.3 mMpepN 0.477 
6.6mMSH3 0.686 
22 uM RCM-BSA 0.300 
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Table VI. Inhibition of eIF-2B catalyzed GDP exchange by the drugs. 
Lysates were preincubated with no addition, or clofibric acid, NSAD's, 
pepN, pepF, or SH3 at concentrations indicated in the table, for 20 min at 30 
~C. At the end of 20 min, 50 µl of the mix was diluted with 150 µl of 
dilution buffer followed by the immediate addition of eIF-2•[3H]GDP 
complex (Matts & London 1984). The amount of [3H]GDP dissociated 
from eIF-2 in 2 min was determined as previously described. 
DRUGS Inhibit. of eIF-2B exchange 
(% of heme deficiency) 
hemin deficiency 100 
lO·mM clofibric acid 92.8 
25 mM salicylic acid 74 
7 .5 mM ibuprofen 101 
6 mM indomethacin 104 
pepF no inhibition 
pepN 65 
SH3 10 
14 µM RCM-BSA 66 
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Table VII. Overview of the effect of different drugs on protein synthesis, luciferase 
folding and renaturation: ( +) indicates inhibition and (-) indicates no effect. 
Protein Luciferase 




geldanamycin - + 
hso70 bindirn 
drug 
clofibric acid + + 
NSAD 
salicylic acid + + 
ibuprofen + + 




pepN + + 
PepF - + 
SH3 + + 
RCM-BSA + -
de nova Polysomal profile 
folding of Initiation elongation 
luciferase inhibiton inhibition 
- - -
+ + + 
+ + + 
+ + -
+ + + 
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Evidence that hsp70 regulates stress response at the transcriptional level. 
The heat shock response is characterised by the transcriptional activation of a 
number of heat shock genes and is accompanied by a shut down of normal protein 
synthesis at the level of initiation. There is selective translation of the mRNAs encoding for 
heat shock proteins. Accumulation of denatured polypeptides may be the signal that 
initiates the induction of the heat shock response (Craig, 1991, Morimoto et al., 1992, 
Sorger, 1991). Transcriptional activation of the heat shock genes occurs through the 
activation of heat shock transcription factor (HSF). Hsp70 has been proposed to bind 
HSF, maintaining it in an inactive conformation (Craig, 1991, Morimoto et al., 1992, 
Mosser et al., 1993, Sorger, 1991). Production of excess substrates for hsp70 (e.g., 
denatured proteins) would disrupt the hsp70/HSF binding equilibrium, inducing the heat 
shock response. Inactivation of the HSF would occur upon the reassociation of hsp70 
with HSF when sufficient hsp70 has been synthesized (Mosser et al., 1993). The 
hypothesis that hsp70 is a negative regulator of HSF is supported by the observation that 
constitutive overexpression of hsp70 in transfected human cells reduces the extent of HSF 
activation in response to heat stress and heavy metal ion treatment (Mosser et al., 1993). 
Moreover treatment with cycloheximide, an inhibitor of protein synthesis, before and 
during heating facilitated the dissociation of HSF-HSE complex and terminated 
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transcription activity earlier (Lee et al., 1994). It is proposed that the free pool of hsp70 is 
increased by inhibiting protein synthesis .. An increase in the level of free hsp70 will more 
effectively protect or repair thermolabile targets and consequently affect the regulation of 
heat shock response. 
Evidence that hsc70 regulates stress response at the translational level. 
Like the heat induced transcriptional effects, recovery of protein synthesis in heat 
stressed cells and the acquisition of resistance to stress-induced translational inhibition also 
correlate with the synthesis and accumulation of hsp70 within a variety of cells 
(DiDomenico et al., 1982, Laszlo, 1988, Mizzen & Welch, 1988). Moreover, HRI, which 
regulates protein synthesis at the initiation level, is associated with hsc70. Addition of 
denatured proteins and heat shock leads to the activation of HRI and dissociation of hsc70 
from HRI. This observation led to the hypothesis that hsc70 negatively regulates HRI. 
This report shows that hsp70 negatively regulates HRI, since purified hsc70 prevented 
protein synthesis inhibition in RRL exposed to heat shock, heavy metal ions, and oxidising 
agents. Heat shock causes a decrease in the functional pool of hsc70, probably by causing 
an accumulation of denatured proteins that titrates the available hsc70 and thus leading to 
the activation of HRI and HSF. The effect of hsc70 on HRI activation is similar to the 
effect of hsp70 on HSF, suggesting that hsp70 regulates stress response both at the 
transcriptional and at the translational level. 
Effect of inhibition of translation in response to stress - Protein synthesis inhibition 
in response to stress may be very useful in protecting cells from adverse physiological 
conditions. Protein synthesis inhibitors and agents that stabilize protein structure, protect 
cells from cytotoxicity of stress (Edington et al., 1989, Lee et al., 1990a, Lee & Dewey, 
1986, Lee et al., 1987, Lee et al., 1990b). It has been proposed that denatured newly 
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synthesized nascent polypeptides are extremely cytotoxic to stressed cells (Beckman et al., 
1990, Lee et al., 1990b), and that inhibition of protein synthesis is a necessary event 
required to maintain the viability of stressed cells. Consistent with this hypothesis we 
observe that all agents which inhibit nascent protein folding inhibited protein synthesis 
(Chapter V). 
Role of hsc70 in inhibiting HRI under heme deficiency - HRI is also activated 
under heme deficiency. While HRI is known to be directly regulated by binding of hemin, 
accumulation of globin chains in the absence of sufficient heme to allow assembly of 
hemoglobin might sequester hsc70 and contribute to the degree to which HRI is activated 
during heme deficiency. This notion is consistent with the observation that addition of 
cycloheximide to hemin deficient lysate prior to polyribosome run off leads to increased 
HRI activity (Ramaiah et al., 1992). Moreover, addition of purified hsc70 reverts protein 
synthesis inhibition due to heme deficiency (Chapter IV). 
Proposed mechanism of action of hsc70 in negatively regulating HRI - Hsc70 may 
affect HRI activation or activity by a number of mechanisms. Excess hsp70 might inhibit 
the folding of HRI to an active conformation. This speculation is supported by the results 
of computer simulation studies on chaperone-assisted folding (Sfatos et al., 1996). This 
model studies suggests that if the rate at which chaperones bind to folding substrate is 
faster than the rate at which the peptide folds, chaperones will retard the rate of protein 
folding. Since rate of chaperone binding is proportional to the rate constant for chaperone 
binding and the concentration of chaperone, changes in hsc70 concentration could either 
stimulate or inhibit protein folding depending on the protein target. This notion that hsc70 
can inhibit protein folding is consistent with previous reports that luciferase renaturation is 
inhibited in the presence of excess hsc70 in vitro (Schumacher et al., 1994). 
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Alternatively hsc70 may be involved in maintaining the ability of the hemin binding 
domain in a conformation competent to bind hemin. HRI is negatively regulated by 
reversible binding by hemin. In the absence of hsc70, the heme binding domain of HRI 
may denature, causing the activation of HRI as its capacity to be regulated by the binding of 
hemin is lost. This is consistent with HRI in lysates containing low levels of hsc70 being 
converted more rapidly to a heme irreversible form (Matts & Hurst, 1992). 
Inability to fold. 
Evidence is now accumulating in the literature that the etiology of a number of 
human diseases involve altered protein folding (Thomas et al., 1995). Since protein 
folding in the cell is so complex, there is a significant likelihood of defects arising in the 
process (Fig 28). Potentially, thermodynamic destabilization of the native or an 
intermediate state, alteration of the folding kinetics, prolonged or inappropriate associations 
with molecular chaperones or folding enzymes, preferential formation of off-pathway or 
toxic conformations, or folding in an improper compartment, could all lead to loss of 
functional proteins and thus, a defective phenotype. Inability of an essential protein to 
form its native structure under physiological conditions may be the basis of a variety of 
human diseases. For example, (i) development of fatal disease cystic fibrosis is caused by 
mutations of the gene encoding cystic fibrosis transmembrane conductance regulator 
(CFTR) (Denning, 1992); (ii) mutation of fibrillin leads to marfan syndrome (Wu et al., 
1995), (iii) mutation of a.-ketoacid dehydrogenase complex leads to maple syrup urine 
disease (Chuang, 1994). Besides genetic deficiency, nutritional factors also lead to 
misfolding of proteins, for example scurvy is caused due to lack of vitamin C (Eyre, 
1980). In addition, in some cases a stable fold is formed that itself is toxic to the cell, for 
example, prion proteins in scrapie (Gasset et al., 1993), and amyloid plaques in 
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Alzheimer's disease (Soto et al., 1995). Finally, sickle cell anemia and B-thalassemia are 
caused by conformers of hemoglobin, that while active, are prone to polymerization. 
Involvement of hsps in disease states. 
The elevated expression of genes encoding hsps has been detected in numerous 
disease states, including ischemia, reperfusion damage, oxidant injury, cardiac 
hypertrophy, fever, inflammation, bacterial and parasitic infection, metabolic diseases, 
neoplasia, and in sites of cell and tissue damage (Morimoto et al., 1994). The hsps 
activities are likely to exert themselves at multiple levels, by serving to detect the onset of 
physiological stress, to prevent subsequent damage resulting from the synthesis and 
accumulation of nonnative proteins, and as a key component of cellular repair processes 
following injury (Morimoto et al., 1994). Hsps, whether induced by prior exposure to 
nontoxic stress conditions or by overexpression of genes encoding hsps, have been shown 
to protect cells against a broad range of toxic conditions, including oxidative stress, tumor 
necrosis factor a, extreme temperatures, ethanol, heavy metals, and cellular damage 
following ischemia or sepsis induced injury (Angelidis et al., 1991, Jaattela et al., 1992, Li 
et al., 1992, Sanchez, 1992). 
Altered interaction of mutant proteins with molecular chaperones has been observed 
in a variety of human diseases. For example, CFTR, misfolding of which causes cystic 
fibrosis, interacts with hsp70 and altered hsp70/CFTR interaction has been observed in 
cystic fibrosis (Pind et al., 1994). Besides CFTR, p53 also interacts with hsp70. The 
mutant oncogene product p53Va1135 has a prolonged interaction with hsp70 relative to 
wild type p53 (Yehiely & Oren, 1992). Moreover, the ability of oncogenic p53 and Ras to 
induce neoplastic transformation was reduced by overproducing hsp70. Altered interaction 
with other chaperones besides hsp70 has also been observed in other human disease. For 
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example, in hereditary medium chain acyl-CoA dehydrogenase (MCAD) deficiency, the 
K304E variant of the tetrameric enzyme has altered interaction with hsp60. Expression of 
the bacterial hsp60, GroEL and its cohort, GroES, partially suppresses the inability of the 
K304E variant to fold productively in a heterologous expression system (Bross, 1993). 
Thus methods for altering chaperone levels deserve serious consideration as a means of 
combating human diseases. 
Non steroidal anti-inflammatory drugs have been shown to delay Alzheimers 
disease and cystic fibrosis (Schehr, 1994). The primary action of these drugs is by 
inhibiting inflammation (Siegel et al., 1979). Another mechanism could be through poising 
cells to respond to stress by activating HSF to bind DNA and enhancing the production of 
hsp70, by maintaining trancriptional activity of HSF in an active state for an extended 
period of time (Lee et al., 1995). Consistent with this hypothesis exposure of HeLa cells 
to NSADs and mild heat shock, led to a stronger cytoprotection towards subsequent 
exposure to very high temperatures, when compared to exposure to mild heat stress alone 
(Lee et al., 1995). The ability of NSADs to potentiate stress response may have direct 
implications for inflammation and other diseases, as the heat shock response can now be 
modulated by drugs of clinical importance under physiological relevant conditions. 
Examining the effect of pharmacological agents on protein synthesis or protein folding in 
the RRL may represent a rapid method to screen for compounds that may either be toxic or 
be beneficial pharmacologically. 
151 






i nte ractio ns 













Abravaya, K., Myers, M. P., Murphy, S. P., & Morimoto, R. I. (1992) Genes 
Development6, 1153-1164. · 
Aligue, R., Akhavan-Niak, H., & Russel, P. (1994) EMBO J. 13, 6099-6106. 
Alvares, K., Carrillo, A., Yuan, P. M., Kawano, H., Morimoto, R. I., & Reddy, J. K. 
(1990) Proc. Natl. Acad. Sci. USA 87, 5293-5297. 
Amrein, K., Flint, N., Panholzer, B., & Bum, P. (1992) Proc. Natl. Acad. Sci. USA 89, 
3343-3346. 
Anfinsen, C. B. (1973) Science 181, 223-230. 
Angelidis, C. E., Lazaridis, I., & Pagoulatos, G. N. (1991) Eur. J. Biochem. 199, 35-39. 
Baker, D., & Agard, D. A. (1994) Biochemistry 33, 7505-7509. 
Baldwin, R. L. (1994) Nature 364, 183. 
Becker, J., & Craig, E. A. (1994) Eur. J. Biochem. 219, 11-23. 
Beckman, R. P., Mizzen, L.A., & Welch, W. J. (1990) Science 248, 850-854. 
BioOrbit. (1991) The bioluminescent assay of ATP Application Note 201. 
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) Proc. Natl. Acad. 
Sci. USA 93, 8379-8383. 
Blagosklonny, M. V., Toretsky, J., & Neckers, L. (1995) Oncogene 11, 933-939. 
Blond-Elguindi, S., Cwirla, S. E., Dower, W. J., Lipshutz, R. J., Sprang, S. R., 
Sambrook, J. F., & Gething, M. J. (1993) Cell 75, 717-729. 
Bohen, S. P., Kralli, A., & Yamamoto, K. R. (1995) Science 268, 1303-1304. 
Bohen, S. P., & Yamamoto, K. R. (1993) Proc. Natl. Acad. Sci. USA 90, 11424-11428. 
· Bohen, S. P., & Yamamoto, K. R. (1994) in In the biology of heat shock proteins and 
molecular chaperones (Morimoto, R., Tissieres, A., & Georgopolous, C., Eds.) 
pp 313-334, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 
Bonanou-Tzedaki, S., Smith, K. E., Sheeran, B. A., & Arnstein, H. R. (1978) Eur. J. 
Biochem. 84, 601-610. 
154 
Bresnick, E. H., Dalman, F. C., Sanchez, E. R., & Pratt, W. B. (1989) J. Biol. Chem. 
264, 4992-4997. 
Bross, P. (1993) Biochim. Biophys. Acta 1182, 264-273. 
Brugge, J., Yonemoto, W., & Darrow, D. (1983) Mol. Cell. Biol. 3, 9-19. 
Brugge, J. S. (1986) Curr. Top. Microbial. Immunol. 123, 1-22. 
Carlino, A., Toledo, H., Skaleris, D., DeLisio, R., Weissbach, H., & Brot, N. (1992) 
Proc. Natl. Acad. Sci. USA 89, 2081-2085. 
Carver, L.A., Jackiw, V., & Bradfield, C. A. (1994) J. Biol. Chem. 269, 30109-30112. 
Chandler, J. P. (1988) , Department of Chemistry, Quantum Chemistry Program 
Exchange, Indiana University, Bloomington, IN 47401. 
Chandrashekar, G. N., Tilly, K., Woolford, C., Hendrix, R., & Georgopoulos, C. 
(1986) J. Biol. Chem. 261, 12414-12419. 
Chang, H.-C. J., & Lindquist, S. (1994) J. Biol. Chem. 269, 24983-24988. 
Chappell, T. G., Konforti, B. B., Schimdt, S. L., & Rothman, J. E. (1987) J. Biol. 
Chem. 262, 746-751. 
Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, 
L., Schnur, R., Moyer, J. D., & Neckers, L. (1996) J. Biol. Chem. 171, 4974-
4977. 
Chen, S., Prapapanich, V., Rimerman, R. A., Honore, B., & Smith, D. F. (1996) Mol. 
Endocrinol. 10 (6), 682-693. 
Chuang, D. T. e. a. (1994) J. Hum. Nutr. 125, 1766S-1772S. 
Cooper, J. A., & Howell, B. (1993) Cell 73, 1051-1054. 
Courtneidge, S. A., & Bishop, J.M. (1982) Proc. Natl. Acad. Sci. USA 79, 7117-7121. 
Craig, E. A. (1991) TIBS 16, 135-140. 
Craig, E. A., Weissman, J. S., & Horwich, A. L. (1994) Cell 78, 365-372. 
Csermely, P., Kajtar, J., Hollosi, M., Jalsovszky, J., Holly, S., Kahn, C. R., Gergely, 
P., Soti, C., Mihaly, K., & Somogyi, J. (1993) J. Biol. Chem. 268, 1901-1907. 
Cutforth, T., & Rubin, G. M. (1994) Cell 77, 1027-1036. 
Cyr, D. M., Langer, T., & Douglas, M. G. (1994) Trends Biochem .. Sci. 19, 176-181. 
Denis, M. (1988) Anal. Biochem. 173, 405-411. 
Denning, G. M. (1992) Nature 358, 761-764. 
DiDomenico, B. J., Burgarsky, G. E., & Lindquist, S. (1982) Cell 31, 593-603. 
155 
Dill, K. A. (1990) Biochemistry 29, 7133-7155. 
Edington, B. V., Whelan, S. A., & Hightower, L. E. (1989) J. Cell. Physiol. 139, 219-
228. 
Ehrhart, J.C., Duthu, A., Ullrich, S., Appella, E., & May, P. (1988) Oncogene 3, 595-
603. 
Ellis, R. J. (1993) Phil. Trans. R. Soc. Lond. B 339, 257-261. 
Ernst, V., Levin, D. H., & London, I. M. (1978) J. Chem. Biol. 253, 7163-7172. 
Ernst, V., Levin, D. H., & London, I. M. (1979) Proc. Natl. Acad. Sci. USA 76, 2118-
2122. 
Eyre, D.R. (1980) Science 207, 1315-1322. 
Farrell, P. J., Hunt, T., & Jackson, R. J. (1978) Eur. J. Biochem. 89, 517-521. 
Flaherty, K. M., DeLuca-Flaherty, C., & McKay, D. B. (1990) Nature 356, 623-628. 
Flynn, G. C., Pohl, J., Flocco, M. T., & Rothman, J.E. (1991) Nature 353, 726-730. 
Freeman, B. C., Myers, M. P., Schumacher, R., & Morimoto, R. I. (1995) EMBO J. 14, 
2281-2292. 
Frydman, J., & Hartl, F. U. (1996) Science 272, 1497-1502. 
Frydman, J., Nimmersgern, E., Erdujment-Bromage, H., Wall, J. S., Tempst, P., & 
Hartl, F. U. (1992) EMBO. J 11, 4767-4778. 
Frydman, J., Nimmesgern, E., Ohtsuka, K., & Hartl, F. U. (1994) Nature 370, 111-117. 
Gao, B., Eisenberg, E., & Greene, L. (1996) J. Biol. Chem. 28, 16792-16797. 
Gasset, M., Baldwin, M.A., Fletterick, R. J., & Prusiner, S. B. (1993) Proc. Natl. Acad. 
Sci. USA 90, 1-5. 
Georgopoulos, C. (1992) Trends in Biochem. Sci. 17, 295-299. 
Gething, M.-J., & Sambrook, J. (1992) Nature 355, 33-45. 
Gragerov, A., Li, Z., Xun, Z., Burkholder, W., & Gottesman, M. E. (1994) J. Mol. 
Biol. 235, 848-854. 
Gross, M. (1976) Biochim. Biophys. Acta 447, 445-459. 
Gross, M., & Hessefort, S. (1996) J. Biol. Chem. 271, 16833-16841. 
Gross, M., Hessefort, S., Olin, A., & Reddy, G. (1996) J. Biol. Chem. 271, 16842-
16849. 
156 
Gross, M., Olin, A., Hessefort, S., & Bender, S. (1994) J. Biol. Chem. 269, 22738-
22748. 
Gross, M., & Rabinovitz, M. (1972) Biochim. Biophys. Acta 287, 340-352. 
Hainaut, P., & Milner, J. (1992) EMBO J. 11, 3513-3520. 
Hartl, F. U. (1995) Phil. Trans. R. Soc. Lond. B 348, 107-112. 
Hartl, F. U. (1996) Nature 381, 571-580. 
Hartson, S. D., Barrett, D. J., Burn, P., & Matts, R. L. (1996) Biochemistry 35, 13451-
13459. 
Hartson, S. D., & Matts, R. L. (1994) Biochemistry 33, 8912-8920. 
Hendrick, J. P., & Hartl, F. U. (1993) Annu. Rev. Biochem. 62, 349-384. 
Hendrix, R. W. (1979) J. Mol. Biol.129, 375-392. 
Hershey, J. W. B. (1991) Annu. Rev. Biochem. 60, 717-755. 
Hohfeld, J., & Hartl, F. U. (1994) Curr. Opin. Cell Biol., 499-509. 
Hohfeld, J., Minami, Y., & Hartl, F.-U. (1995) Cell 83, 589-598. 
Hohn, T., Hohn, B., Wurtz, M., & Smith, P.R. (1979) J. Mol. Biol 129, 359-373. 
Honore, B., Leffers, H., Madsen, P., Ramussen, H. H., Vandekerckhove, J., & Celis, J. 
E. (1992)1. Biol. Chem. 267, 8485-8491. 
Huang, Q., Alvares, K., Bradfield, C. A., & Reddy, J. K. (1994) J. Biol. Chem. 269, 
8493-8497. 
Hurst, R., Schatz, J. R., & Matts, R. L. (1987) J. Biol. Chem. 262, 15939-15945. 
Hutchinson, K. A., Dittmar, K. D., Czar, M. J., & Pratt, W. P. (1994a) J. Biol. Chem. 
269, 5043-5049. 
Hutchinson, K. A., Dittmar, K. D., & Pratt, W. B. (1994b) J. Biol. Chem. 269, 27894-
27899. 
Hutchinson, K. A., Stancato, L. F., Owens-Grillo, J. K., Johnson, J. L., Krishna, P., 
Toft, D. 0., & Pratt, W. B. (1995) J. Biol. Chem. 270, 18841-18847. 
Jaattela, M., Wissing, D., Bauer, P.A., & Li, G. C. (1992) EMBO J. 11, 3507-3512. 
Jackson, R. J., Herbert, P., Cambell, E. A., & Hunt, T. (1983) Eur. J. Biochem. 131, 
313-324. 
Jacob, U., & Buchner, J. (1994) TIBS 19, 205-211. 
Jacob, U., Lilie, H., Meyer, I., & Buchner, J. (1995) J. Biol. Chem. 270, 7288-7294. 
157 
Joab, I., Radanyi, C., Renoir, M., Buchou, T., Catelli, M. G., Binart, N., Mester, J., & 
Baulieu, E. E. (1984) Nature 308, 850-853. 
Johnson, J. L., Beito, T. G., Krco, C. J., & Toft, D. 0. (1994) Mol. Cell. Biol. 14, 
1956-1963. 
Johnson, J. L., & Toft, D. 0. (1994) J. Biol. Chem. 269, 24989-24993. 
Johnson, J. L., & Toft, D. 0. (1995) Mol. Endocrinol. 9, 670-678. 
Jurivich, D. A., Sistonen, L., Kroes, R. A., & Morimoto, R. I. (1992) Science 255, 
1243-1245. 
Kosower, N. S., Vandehoff, G. A;, & Kosower, E. M. (1972) Biochim Biophys. Acta 
272, 623-637. . 
Kost, S. L., Smith, D., Sullivan, W., Welch, W. J., & Toft, D. 0. (1989) Mol. Cell. 
Biol. 9, 3829-3838. 
Koyasu, S., Nishida, E., Kadowaki, T., Matsuzaki, F., Iida, K., Harada, F., Kasuga, 
M., Sakai, H., & Yahara, I. (1986) Proc. Natl. Acad. Sci. U.S.A. 83, 8054-8058. 
Kuszewski, J., Clore, G. M., & Gronenborn, A. M. (1994) Protein Sci. 3, 1945-1952. 
Landry, S. J., Jordan, R., McMacken, R., & Gierasch, L. M. (1992) Nature 355, 455-
457. 
Langer, T. G., Pfeifer, J.M., Baumeister, W., & Hartl, F. U. (1992) EMBO. J. 11, 
4757-4765. 
Laszlo, A. (1988) Exp. Cell Res. 178, 401-414. 
Lee, B. S., Chen, J., Angelidis, C., Jurivich, D. A., & Morimoto, R. I. (1995) Proc. 
Natl. Acad. Sci. USA. 92, 7207-7211. 
Lee, Y. J., Armour, E. P., Corry, P. M., & Dewey, W. C. (1990a) Int. J. Hyperthermia 
6, 591-595. 
Lee, Y. J., & Dewey, W. C. (1986) Radiat. Res. 106, 98-110. 
Lee, Y. J., Dewey, W. C., & Li, G. C. (1987) Radiat. Res. 111, 237-253. 
Lee, Y. J., Kim, D., & Corry, P. M. (1990b) J. Cell. Physiol. 144, 401-407. 
Lee, Y. J. U., Erdos, G., Hou, Z., & Cho, J.M. (1994) J. Therm. Biol. 19, 327-333. 
Levin, D. H., Ranu, R. S., Ernst, V., & London, I. M. (1976) Proc. Natl. Acad. Sci. 
USA 73, 3112-3116. 
Lewis, V. A., Hynes, G. M., Zheng, D., Saibil, H., & Willson, K. (1992) Nature 358, 
249. 
Li, G. C., Li, L., Liu, R. Y., Rehman, M., & Lee, W. M. F. (1992) Proc. Natl. Acad. 
Sci. USA 89, 2036-2040. 
158 
Liberek, K., Marszalek, J., And, D., Geogopoulos, C., & Zylicz, M. (1991) Proc. Natl. 
Acad. Sci. USA 88, 2874-2878. 
Matts, R. L., & Hurst, R. (1989) J. Biol. Chem. 264, 15542-15547. 
Matts, R. L., & Hurst, R. (1992) J. Biol. Chem. 267, 18168-18174. 
Matts, R. L., Hurst, R., & Xu, Z. (1993) Biochemistry 32, 7323-7328. 
Matts, R. L., Levin, D. H., & London, I. M. (1983) Proc. Natl. Acad. Sci. U.S.A. 80, 
2559-2563. 
Matts, R. L., & London, I. M. (1984) J. Biol. Chem. 259, 6708-6711. 
Matts, R. L., Schatz, J. R., Hurst, R., & Kagen, R. (1991) J. Biol. Chem. 266, 12695-
12702. 
Matts, R. L., Xu, Z., Pal, J. K., & Chen, J.-J. (1992) J. Biol. Chem. 267, 18160-18167. 
Maurides, P.A., Akkaraju, G. R., & Jagus, R. (1989) Anal. Biochem. 183, 144-151. 
Melnick, J., Aviel, S., & Argon, Y. (1992) J. Biol. Chem. 267, 21303-21306. 
Melnick, J., Dul, J. L., & Argon, Y. (1994) Nature 370, 373-375. 
Mimnaugh, E.G., Chavany, C., & Neckers, L. (1996) J. Biol. Chem. 271, 22796-
22801. 
Minami, Y., Kawasaki, H., Suzuki, K., & Yahara, I. (1993) J. Biol. Chem. 268, 9604-
9610. 
Miyata, Y., & Yahara, I. (1992) J. Biol. Chem. 267, 7042-7047. 
Mizzen, L.A., & Welch, W. J. (1988) J. Cell Biol. 106, 1105-1116. 
Morimoto, R., Tissieres, A., & Georgopolous, C. (1994), Cold Spring Harbor Press, 
Plainview, NY. 
Morimoto, R. I., Sarge, K. D., & Abravaya, A. (1992) J. Biol. Chem. 267, 21987-
21990. 
Mosser, D. D., Duchaine, J., & Massie, B. (1993) Mol. Cell Biol. 13, 5427-5438. 
Nadeau, K., Das, A., & Walsh, C. T. (1993) J. Biol. Chem. 268, 1479-1487. 
Oppermann, H., Levinson, A. D., & Bishop, J.M. (1981) Proc. Nat. Acad. Sci. USA 
78, 1067-1071. 
Owens-Grillo, J. K., Czar, M. J., Hutchinson, K. A., Hoffman, K., Perdew, G. H., & 
Pratt, W. B. (1996) J. Biol. Chem. 271, 13468-13475. 
Pain, V. M., & Clemens, M. J. (1991) in Translation in eukaryotes (Trachsel, H., Ed.) 
pp. 293-324, CRC Press, Boca Raton, FL. 
159 
Palleros, D.R., Reid, K. L., Shi, L., Welch, W. J., & Fink, A. L. (1993) Nature 365, 
664-666. 
Palleros, D.R., Welch, W. J., & Fink, A. L. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 
5719-5723. 
Picard, D., Khursheed, B., Garabedian, M. J., Fortin, M. G., Lindquist, S., & 
Yamamoto, K. R. (1990) Nature 348, 166-168. 
Pind, S., Riordan, J. R., & Williams, D. B. (1994) J. Biol. Chem. 269, 12784-12788. 
Prapapanich, V., Chen, S., Nair, S. C., Rimerman, R. A., & Smith, D. F. (1996) Mol. 
Endocrinol. 10, 420-431. 
Pratt, W. B. (1992) Bioessays 14, 841-848. 
Pratt, W. B., & Welsh, M. J. (1994a) Sem. Cell Biol. 5, 83-93. 
Pratt, W. B., & Welsh, M. J. (1994b) Sem. Cell Biol. 5, 83-93. 
Puskin, A. V., Tsuprub, V. L., Solovjeva, N., A., Shubin, V. V., Evstigneeva, Z. G., & 
Kretovich, W. L. (1982) Biochim. Biophys. Acta 704, 379-384. 
Radanyi, C., Chambraud, B., & Baulieu, E. E. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 
11197-11201. 
Ramaiah, K. V. A., Dhindsa, R. S., Chen, J.-J., & London, I. M. (1992) Proc. Natl. 
Acad. Sci. USA 89, 12063-12067. 
Ranu, R. S., & London, I. M. (1976) Proc. Natl. Acad. Sci. USA 73, 4349-4363. 
Ratajczak, T., & Carreno, A. (1996) J. Biol. Chem. 271, 2961-2965. 
Ratajczak, T., Carreno, A., Mark, P. J., Warner, B. J., Simpson, R. J., Mori, R. L., & 
Housr, A. K. (1993) J. Biol. Chem. 268, 13187-13192. 
Rutherford, S. L., & Zuker, C. S. (1994) Cell 79, 1129-1132. 
Sanchez, E. R. (1992) J. Biol. Chem. 267, 17-20. 
Sanchez, E. R., Toft, D. 0., Schlesinger, M. J., & Pratt, W. B. (1985) J. Biol. Chem. 
260, 12398-12401. 
Schehr, R. S. (1994) Bio/Technology 12, 140. 
Scherrer, L. C., Dalman, F. C., Massa, E., Meshinchi, S., & Pratt, W. B. (1990) J. Biol. 
Chem. 265, 21397-21400. 
Schlossman, D. M., Schmid, S. L., Braell, W. A., & Rothman, J.E. (1984) J. Cell Biol. 
99, 723-733. 
Schmid, D., Baici, A., Gehring, H., & Christen, P. (1994) Science 263, 971-973. 
160 
Schmid, S. L., Braell, W. A., & Rothman, J.E. (1985) J. Biol. Chem. 260, 10057-
10062. 
Schreiber, S. L. (1990) Science 250, 1406-1409. 
Schulte, T. W., Blagosklonny, M. V., Ingui, C., & Neckers, L. (1995) J. Biol. Chem. 
270, 24585-24588. 
Schumacher, R. J., Hurst, R., Sullivan, W. P., McMahon, N. J., Toft, D. 0., & Matts, 
R. L. (1994) J. Biol. Chem. 269, 9493-9499. 
Sepehrnia, B., Paz, I. B., Dasgupta, G., & Momand, J. (1996) J. Biol. Chem. 271, 
15084-15090. 
Sfatos, C. D., Gutin, A. M., Abkevich, V. I., & Shakhnovich, E. I. (1996) Biochemistry 
35, 334-339. . 
Shaknovich, R., Gongliang, S., & Kohtz, D. S. (1992) Mol. Cell. Biol. 12, 5059-5068. 
Shue, G., & Kohtz, D. S. (1994) J. Biol. Chem. 269, 2707-2711. 
Siegel, M. I., McConnell, R. T., & Cuatrecasas, P. (1979) Proc. Natl. Acad. Sci. 
USA 76, 3774-3778. 
Siekierka, J., Manne, V., & Ochoa, S. (1984) Proc. Natl. Acad. Sci. U.S.A. 81, 352-
356. 
Smith, D. (1993) Mol. Endocrinol. 7, 1418-1429. 
Smith, D. F., Baggenstoss, B. A., Marion, T. N., & Rimerman, R. A. (1993a) J. Biol. 
Chem. 268, 18365-18371. 
Smith, D. F., Schowalter, D. B., Kost, S. L., & Toft, D. 0. (1990a) Mol. Endo. 4, 1704-
1711. 
Smith, D. F., Stensgard, D. B., Welch, W. J., & Toft, D. 0. (1992) J. Biol. Chem. 267, 
1350-1356. 
Smith, D. F., Sullivan, W. P., Marion, T. N., Zaitsu, K., Madden, B., McCormick, D. 
J., & Toft, D. 0. (1993b) Mol. Cell. Biol. 13, 869-876. 
Smith, D. R., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., & Rimerman, R. A. 
(1995) Mol. Cell. Biol. 15, 6804-6812. 
Smith, K. F., Faber, L. E., & Toft, D. 0. (1990b) J. Biol. Chem. 265, 3996-4003. 
Somma, M. M. D., Nuti, S., Telford, J. L., & Baldari, C. T. (1995) FEBS Lett. 363, 
101-104. 
Sorger, P. K. (1991) Cell 65, 363-366. 
Soto, C., Castano, E. M., Frangione, B., & Inestrosa, N. C. (1995) J. Biol. Chem. 270, 
3063-3067. 
161 
Stamnes, M.A., Shieh, B. H., Chuman, L., & Zuker, C. S. (1991) Cell 65, 219-227. 
Stancato, L. F., Chow, Y.-H., Hutchison, K. A., Perdew, G. H., Jove, R., & Pratt, W. 
B. (1993) J. Biol. Chem. 268, 21711-21716. 
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) Genes Development 10, 
1491-1502. 
Stuart, R. A., Cyr, D. M., Craig, U. A., & Neupert, W. (1994) TIBS 19, 87-92. 
Szabo, A., Langer, T., Schroder, H., Flanagan, J., Bukau, B., & Hartl, F. U. (1994) 
Proc. Natl. Acad. Sci. USA 91, 10345-10349. 
Tai, P.-K. K., Albers, M. W., Chang, H., Faber, L. E., & Schreiber, S. L. (1992) 
Science 256, 1315-1318. 
Takenaka, I. M., Leung, S.-M., McAndrew, S. J., Brown, J. P., & Hightower, L. E. 
(1995) J. Biol. Chem. 270, 19839-19844. 
Thomas, P. J., Qu, B.-H., & Pedersen, P. L. (1995) TIBS 20, 456-459. 
Thulasiraman, V., Hartson, S. D., Huang, W., Burn, P., & Matts, R. L. ( Submitted) 
EMBOJ. ' 
Thulasiraman, V., & Matts, R. L. (1996) Biochemistry 35, 13443-13450. 
Todd, J.M., Viitenen, P. V., & Lorimer, G. H. (1993) Biochemistry 32, 8560-8567. 
Toledo, H., Carlino, A., Vidal, V., Redfield, B., Nettleton, M. Y., Kochan, J.P., Brot, 
N., & Weissbach, H. (1993) Proc. Natl. Acad. Sci. USA 90, 2505-2508. 
Uehara, Y., Fukazawa, H., Murakami, Y., & Mizino, S. (1989) Biochem. Biophys. Res. 
Commun. 163, 803-809. 
Uehara, Y., Hori, M., Takeuchi, Y., & Umezawa, H. (1986) Mol. Cell. Biol. 6, 2198-
2206. 
Uehara, Y., Murikami, Y., Mizuno, S., & Kawai, S. (1988) Virology 164, 294-298. 
Wang, L.-M. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 4032-4036. 
Wartmann, M., & Davis, R. J. (1994) J. Biol. Chem. 269, 6695-6701. 
Wawrzynow, A., Banecki, M., Wall, D., Liberek, K., Georgopoulos, C., & Zylicz, M. 
(1995) J. Biol. Chem. 270, 19307-19311. · 
Wawrzynow, A., & Zylicz, M. (1995) J. Biol. Chem. 270, 19300-19306. 
Weissman, G. (1991) Sci. Am. 264, 84-90. 
Whitesell, L., & Cook, P. (1996) Mol. Endocrinol. 10, 705-712. 
Whitesell, L., Cook, P., & Bagatell, R. (1995) J. Cell. Biochem. 19B (Suppl), 206. 
162 
Whitesell, L., G., M. E., De Costa, B., Myers, C., & Neckers, L. M. (1994) Proc. Natl. 
Acad. Sci. U.S.A. 91, 8324-8328. 
Whitesell, L., Shifrin, S. D., Schwab, G., & Neckers, L. M. (1992) Cancer Res. 52, 
1721-1728. 
Wiech, H., Buchner, J., Zimmerman, M., Zimmerman, R., & Jacob, U. (1993) J. Biol. 
Chem. 268, 7414. 
Wiech, H., Buchner, J., Zimmermann, R., & Jakob, U. (1992) Nature 358, 169-170. 
Wu, J.M. (1981) J. Biol. Chem. 256, 4164-4167. 
Wu, Y.-S., Bevilacqua, V. L. H., & Berg, J.M. (1995) Chem. Biol. 2, 91-97. 
Xu, Y., & Lindquist, S. (1993) Proc. Natl. Acad. Sci. USA 90, 7074-7078. 
Xu, Z., Pal, J. K., Thulasiraman, V., Hahn, H. P., Chen, J.-J., & Matts, R. L. (In 
preparation). 
Yehiely, F., & Oren, M. (1992) Cell Growth Diff. 3, 803-809. 
Ziemiecki, A. (1986) Virology 151, 265-273.Abravaya, K., Myers, M. P., Murphy, S. 




Candidate for the Degree of 
Doctor of Philosophy 
Thesis: ROLE OF HEAT SHOCK PROTEINS IN PROTEIN SYNTHESIS, 
FOLDING, AND RENATURATION 
Major Field: Biochemistry and Molecular Biology 
Biographical: 
Personal Data: Born in Madras, India, March 27, 1967, the daughter of 
Rajeshwari Thulasiraman and Thulasiraman Cherukoor. 
Education: Graduated from National High School, Calcutta, India in April 1985; 
received Bachelor of Science Degree in Chemistry from Calcutta 
University, Calcutta, India in September 1988; received Master of Science 
Degree in Biochemistry, Calcutta University, Calcutta, India in April 
1991; completed requirements for the Doctor of Philosophy Degree at 
Oklahoma State University in December 1996. 
Experience: Junior Research Fellow, Epidemiology of Cervical Cancer, Indian 
Institute of Science, Calcutta, September 1991 to July 1992; Research 
Assistant, Department of Biochemistry and Molecular Biology, Oklahoma 
State University, Stillwater, Oklahoma, September 1992 to the present. 
Professional Memberships: Member of American Association for the 
Advancement of Science and Member of India Student Association. 
